Molecular regulation of adrenal androgen biosynthesis by Idkowiak, Jan
 Molecular Regulation 
of Adrenal Androgen Biosynthesis 
 
by 
Jan Idkowiak 
 
A thesis submitted to The University of Birmingham for 
the degree of 
 
DOCTOR OF PHILOSOPHY 
 
School of Clinical and Experimental Medicine 
College of Medical and Dental Sciences 
University of Birmingham 
August 2014 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“More valuable than treasures in a storehouse are the treasures 
of the body, and the treasures of the heart are the most 
valuable of all. From the time you read this letter on, strive to 
accumulate the treasures of the heart!” 
 
Nichiren Daishonin (1222-1282) 
  Abstract 
___________________________________________________________________ 
 
 III 
 
Abstract 
The biosynthesis of adrenal androgens is catalysed by steroid-modifying enzymes. 
Over the past decade, co-factors were explored to regulate these enzymes: P450 
oxidoreductase (POR) delivers electrons to the key androgen-producing cytochrome P450 
enzyme CYP17A1. In addition, sulfation of the principal androgen precursor 
dehydroepiandrosterone (DHEA) catalysed by the enzyme SULT2A1, supported by its co-
factor 3’-phosphoadenosine-5’-phosphosulfate (PAPS) synthase 2 (PAPSS2), has been 
found more recently as a gatekeeper of androgen activation. 
Here, we have further characterised children with defects of enzymes of the androgen 
pathway, namely CYP17A1 and POR. We report the first human missense mutation of 
cytochrome b5, which supports electron transfer from POR to CYP17A1. In addition, we 
have explored the molecular regulation of DHEA sulfation by in vitro and in vivo studies. 
The results from our studies provide important information on the clinical course, the 
diagnostic steroid fingerprint and underlying molecular mechanisms of conditions affecting 
androgen generation. The in vitro studies on DHEA sulfation confirm that the PAPSS2 
isoform crucially regulates SULT2A1. Our in vivo study in children with deficiencies of the 
steroid sulfatase (STS) enzyme, the counterpart of SULT2A1, suggests that STS does not 
play a major role in DHEA metabolism but is more active before puberty. 
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* Only those abbreviations are listed if they are used twice or more. Abbreviations of 
urinary steroid hormone metabolites are listed in Table 9 
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1. CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter have been published as: 
Premature adrenarche: novel lessons from early onset androgen excess. 
Idkowiak J, Lavery GG, Dhir V, Barrett TG, Stewart PM, Krone N, Arlt W. 
Eur J Endocrinol. 2011 Aug;165(2):189-207. doi: 10.1530/EJE-11-0223. 
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1.1. THE ADRENAL CORTEX AND STEROID BIOSYNTHESIS 
1.1.1. Anatomy, function and regulation of the adrenal gland 
The adrenal gland is a paired, quadrilateral-shaped organ situated in the 
retroperineum on the upper pole of each kidney. The right adrenal is more triangular-
shaped while the left adrenal has a semilunar shape. The weight of one adult adrenal 
is about 4g from autopsy specimens in cases of sudden death; hospital specimens 
are up to 50% heavier due to stress-induced proliferation (Pohorecky and Wurtman, 
1971). Macroscopically, the adrenal gland can be divided into two separate parts: the 
medulla and the cortex, with the latter comprising 90% of its total weight. Medulla and 
cortex are of different embryological origins, the medulla is derived from neural crest 
cells, the cortex develops from mesenchyme (Moore, 1988).  
 
Figure 1: Schematic depiction of the structure (left) of the adrenal gland and the zonation of the 
adrenal cortex (right).  
The adrenal medulla is the body’s main source of secreted catecholamines, 
namely epinephrine (adrenaline) and nor-epinephrine (noradrenaline). It consists of 
so-called chromaffin cells, a name derived from the characteristic brown staining 
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when exposed to chromic acid salts. Catecholamines are derived from the amino 
acid tyrosine, which is subsequently converted to epinephrines via different enzymes 
with tyrosine hydroxylase representing the rate-limiting step converting tyrosine to 
dihydroxyphenylalanine (DOPA) (Pacak et al., 2008). The acute release of these 
hormones activates immediate physical reactions in preparation for a muscular action 
(also called “flight-or-fight response”), first described by Walter Bradford Cannon 
(Cannon, 1915). The medulla is exposed to high concentrations of glucocorticoids 
produced in the adrenal cortex, and it has been shown that cortisol induces the 
enzyme phenylethanolamine-N-methyltransferase, which converts norepinephrine to 
epinephrine (Wurtman and Pohorecky, 1971). This observation revealed the 
existence of an intriguing cross-talk between these two morphologically and 
embryologically distinct compartments of the adrenal gland.   
The adrenal cortex is devoted to the production of steroid hormones. Within the 
adrenal cortex, three concentric cellular layers (or zones) can be histo-
morphologically distinguished: the outer zona glomerulosa (ZG), the zona fasciculata 
(ZF) and, adjacent to the adrenal medulla, the zona reticularis (ZR) (Figure 1). The 
morphological differences of these three zones reflect their molecular endowment as 
their cells express a specialized set of steroidogenic enzymes generating the three 
major subclasses of steroid hormones. These are mineralocorticoids produced in the 
ZG, glucocorticoids synthesized in the ZF and sex steroids generated in the ZR 
(Figure 1).  
The actions of the three subtypes of steroid hormones are complex. In brief, 
mineralocorticoids regulate salt and water balance; glucocorticoids are essential for 
glucose metabolism and stress response, but also have various immune-modulatory 
functions. Sex steroids, which are also produced in the gonads of the foetus and after 
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birth from puberty onwards, promote gender-specific sexual characteristics, including 
prenatal sexual differentiation, postnatal sexual maturation and fertility. 
Classically, they act via intracellular receptors that initiate the translational 
machinery in the nucleus, thereby affecting the transcription of various target genes 
(see section 1.1.5). 
1.1.2. Principles of steroid hormone biosynthesis and action 
All steroid hormones are derived from cholesterol and have a closely related 
structure in the form of the cyclopentanophenanthrene 4-ring. It comprises three 
cyclohexane rings (A, B and C) and a cyclopentane ring (D) (Figure 2).  
 
Figure 2: Conventional nomenclature of steroids shown by the example of cholesterol, the precursor 
for all steroid hormones. The basic structure is a cyclopentanophenanthrene 4-ring. Letters (A-D) refer 
to the rings; the carbon atoms are indicated by numbers. 
The differences in the various subclasses of steroid hormones and its 
precursors are determined 1) by the total number of carbon atoms and 2) the 
functional groups attached to the four-ring core and 3) the oxidation state of the rings. 
A lot of effort has been made in the past to correlate steroid structure with their 
physiological activities; however, when the steroid hormone receptors were cloned 
and characterized, it became clear that not the chemical structure of a steroid defines 
its activity, but rather its affinity to a certain receptor (Miller and Auchus, 2011). 
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Two major groups of enzymes are involved in steroid biosynthesis: cytochrome 
P450s (CYPs) and hydroxysteroid dehydrogenases (HSDs). The direction of the 
conversion is almost always unidirectional for the CYPs; hence, in biochemical terms, 
an accumulation of a product does not reverse the flux towards the precursors. 
However, HSD reactions are mechanistically reversible and under certain conditions 
can run in either direction in vitro; however, in vivo, each HSD drives the reaction 
predominantly either towards the direction of reduction or oxidation (Agarwal and 
Auchus, 2005). 
The human genome codes for 57 cytochrome P450s, six of them are involved 
in human steroidogenesis (Table 1); the majority of non-steroidogenic type 2 CYPs 
are hepatic enzymes involved in drug metabolism and detoxification of xenobiotics. 
The most widely accepted nomenclature is to designate the gene name (and the 
enzyme itself) with the abbreviation CYP; this is followed by a number indicating the 
gene family, then a capital letter for the subfamily and another number indicating the 
individual gene (Nelson et al., 1996). Italicizing the name of the CYP (i.e. CYP17A1) 
refers to the gene; otherwise it refers to the enzyme. The current nomenclature of the 
CYPs is under constant revision and updates are available on the P450 cytochrome 
homepage (http://drnelson.uthsc.edu/CytochromeP450.html).  
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Table 1: Molecular characteristics and functions of cytochrome P450 (CYP) involved in human 
steroidogenesis. 
CYP enzyme Type mRNA size 
(Kb) 
Protein 
size 
(aa) 
Substrate Function 
CYP11A1 1 2.0 521 Cholesterol Synthesis of 
pregnenolone 
CYP11B1 1 4.2 574 11-deoxycortisol,  
11-deoxycorticosterone 
Cortisol synthesis 
CYP11B2 1 4.2 503 11-deoxycorticosterone Aldosterone synthesis 
CYP17A1 2 1.9 508 (17OH-)progesterone, 
(17OH-)pregnenolone  
Biosynthesis of GC and 
sex steroid precursors 
CYP21A2 2 2.0 494 (17OH-)progesterone Biosynthesis of GC and 
MC precursors 
CYP19A1 2 1.5-4.5 503 Androstenedione, 
Testosterone 
Generation of 
oestrogens 
 
The common features of all CYPs are a single haeme group and a size of about 
500 amino acids, ranging from 45 to 60 kDa. The name cytochrome “P450” derives 
from the chemical properties that absorb light at 450nm when in the reduced state. 
CYPs use their haeme centre to activate molecular bound oxygen and to transfer 
electrons derived from reduced nicotinamide adenine dinucleotide phosphate 
(NADPH). A common catalytic cycle of CYPs has been elucidated in detail on the 
molecular level (Meunier et al., 2004), but the exact catalytic reactions carried out by 
the CYP enzyme can vary and largely depends on the substrate and on the enzyme 
itself. 
The diversity of catalytic reactions and also the structural properties are much 
more diverse for the hydroxysteroid dehydrogenases (HSDs). In contrast to CYPs, 
they do not contain haeme groups, but they do employ NADPH or NADP+ to oxidize 
or reduce a steroid via hybrid transfer mechanisms (Agarwal and Auchus, 2005; 
Miller and Auchus, 2011). Their molecular masses range from 35 to 45 kDa (Miller 
and Auchus, 2011). Based on their structure, HSDs can be divided in two sub-
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groups: the short-chain dehydrogenases/reductases (SDRs) and the aldo-keto 
reductases (AKRs). Table 2 provides an overview of the HSDs that are involved in 
human steroidogenesis.  
Table 2: Overview and central functional properties of key hydroxysteroid dehydrogenase (HSD) 
enzymes involved in steroid metabolism. For steroid abbreviations please refer to the abbreviation 
table at the beginning of the thesis. Adapted from (Miller and Auchus, 2011). 
HSD enzyme Co-factor Preferred 
direction 
Tissue expression 
(key tissues) 
Function 
HSD3B1 NADPH Reductase Placenta, liver, skin; 
various tissues 
Both: 
Preg ! Prog,  
17Preg ! 17OHP,  
DHEA ! d4dione HSD3B2 NADPH Reductase Adrenal cortex, gonads, placenta 
HSD11B1 NADPH Reductase Liver, adipose, muscle E ! F 
HSD11B2 NAD+ Oxidase Kidney, colon, salivary 
glands 
F ! E 
HSD17B1 NADPH Reductase Placenta, ovary E1 ! E2 
HSD17B2 NAD+ Oxidase Placenta, endometrium E2 ! E1;  
T ! d4dione;  
DHEA ! 5-diol  
HSD17B3 NADPH Reductase Testis d4dione ! T; 
5α-Androstane-3α,17βdiol ! 
DHT 
HSD17B6 
(RODH) 
NAD+ Oxidase Testes, liver, adrenal 
cortex 
androstanediol ! DHT 
HSD17B7/12 NADPH Reductase multiple E1 ! E2 
AKR1C3 
(HSD17B5) 
NADPH Reductase Ovary; multiple tissues 
(foetal) adrenals 
d4dione ! T 
AKR1C4     
SRD5A1 NADPH Reductase Various tissues: liver, 
intestine, bone, muscle, 
brain 
GC inactivation,  
Testosterone ! DHT 
SRD5A2 NADPH Reductase Prostate, testicles, skin Testosterone ! DHT 
 
Most HSDs catalyse the formation of a ketone from a secondary alcohol (or vice 
versa); the human 5α-reductases (SRD5A), which are grouped within the HSD family 
for convenience, reduce an olefinic carbon-carbon double bond to the saturated state 
(Miller and Auchus, 2011). The two human 3β-hydroxysteroid dehydrogenases 
(HSD3Bs) exhibit two catalytic reactions as the dehydrogenation is accompanied by 
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the isomerization of a carbon-carbon double bond from carbons 4 and 5 (‘delta 5’) to 
carbon 5 and 6 (‘delta 4’). In contrast to the CYP enzymes, each of the reactions 
catalyzed by HSDs can be carried out by different isozymes, which are sometimes 
structurally very different. 
1.1.3. Co-factor regulation of steroidogenesis 
For all CYPs, electrons are derived from NADPH and their transfer, crucial for 
the enzyme’s catalytic activity, is facilitated by cofactors.  
 
Figure 3: Schematic illustration of the two different routes of electron transfer for mitochondrial type 1 
and microsomal type 2 CYPs. For type 1 enzymes, electrons are transferred via adrenodoxin 
reductase (AdR) and adrenodoxin (Adx). Type 2 enzymes receive electrons via the flavoprotein P450 
oxidoreductase (POR). The crystal structures of the indicated proteins are shown in this figure: for the 
CYP enzyme, the crystal structure of CYP2D6 was chosen as a representative example. Data were 
retrieved from the pdb online protein databank; PDB IDs: FDR: 1CJC; FDX1: 3P1M; POR: 3QFS; 
CYP2D6: 2F9Q. 
Depending on the redox-cofactor system, which also determines their sub-
cellular localization, CYPs are further sub-classified into two main groups: seven 
human CYPs are expressed in the mitochondria and are termed “type 1” enzymes. 
They receive electrons via the flavoprotein adrenodoxin (Adx; also ferredoxin), which 
is in turn reduced by its co-enzyme adrenodoxin reductase (AdR; also ferredoxin 
NADPH 
NADP+ 
e- 
NADPH 
NADP+ 
e- 
e- 
e- 
e- 
AdR Adx 
POR 
CYP 
type 1 
 
inner  
mitochondrial  
membrane 
type 2 
 
endoplasmatic 
reticulum 
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reductase); the other 50 “type 2” CYPs are found in the endoplasmic reticulum (ER) 
and electron transfer from NADPH is facilitated by the single flavoprotein P450 
oxidoreductase (POR) (Figure 3). 
1.1.3.1. Adrenodoxin (Adx) and Adrenodoxin reductase (AdR) 
Adrenodoxin (Adx) and adrenodoxin reductase (AdR) are expressed in the 
mitochondrial matrix and inner mitochondrial membrane (IMM) of various tissues, in 
particular steroidogenic cells, where they support electron flux to type 1 CYPs. 
Adx is a soluble iron-sulfur protein that is only loosely attached to the IMM and 
mainly resides freely within the mitochondrial matrix. AdR is a flavoprotein attached 
to the IMM containing a flavin adenine dinucleotide (FAD) in its core domain and 
binds NADPH at its N-terminal domain, which interacts with the FAD domain when 
’activated’ by NADPH to allow electron transfer to the FAD. The FAD domain forms a 
positively charged ‘cleft’ docking to the negatively charged surface of the interaction 
domain of Adx, which is in proximity to the Fe2/S2 core of the core domain (Ziegler et 
al., 1999). There is evidence that the same surface area that docks to the AdR 
protein also interacts with the positively charged co-factor binding site of the CYPs 
(Vickery, 1997).   
1.1.3.2. P450 oxidoreductase (POR) 
POR is a membrane-bound flavoprotein that supports electron transfer from 
NADPH to all microsomal (type 2) CYPs. Only three CYPs are involved in 
steroidogenesis, namely CYP17A1, CYP21A2 and CYP19A1 (see Table 1). 
 The wide tissue distribution of the POR protein indicates that it supports many 
biological processes, including electron transfer to all major drug-metabolising CYP 
enzymes, and it has been shown that POR not only supports electron transfer to 
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CYPs, but also to other redox systems involved in crucial metabolic processes like 
squalene monooxygenase (Ono and Bloch, 1975), haeme oxygenase (Wilks et al., 
1995), fatty acid elongase (Ilan et al., 1981) and post-translational modification of 
proteins involved in the hedgehog signalling pathway (Aguilar et al., 2009). 
The structural and biochemical properties of POR have been studied 
extensively based on the rat crystal structure, which shares 94% amino acid identity 
with the human protein (Wang et al., 1997), but also the human POR protein has 
recently been crystallised (Xia et al., 2011). POR contains two derivatives of the 
nucleic acid riboflavin: a flavin adenine dinucleotide (FAD) and a flavin 
mononucleotide (FMN), which are located in major domains forming the two main 
lobes of the POR protein responsible for electron transfer. The N-terminal FMN 
domain is flexibly connected with the FAD domain by several α-helices forming the 
connecting domain, which brings the two riboflavin domains together once electrons 
are received by the C-terminal NADPH binding domain and transferred to the FAD 
moiety. A further 25 amino acid hinge region loosely connects the FMN with the 
connecting domain, suggesting a high flexibility in between these domains. NMR and 
x-ray crystallographic studies revealed drastic conformational changes during intra-
molecular electron transfer: once electrons are received by the FAD domain, the two 
lobes (FAD and FMN domains) come close together, like wings of a butterfly, and the 
electrons are passed on from the FAD to the FMN domain (Ellis et al., 2009; Miller 
and Auchus, 2011). Subsequently, negative surface charges at the FAD domain 
‘dock’ POR to positively charged basic residues of the co-factor binding site of the 
CYP protein to bring the FMN domain in close proximity to the CYP haeme centre, 
thereby passing on the electrons (Miller and Auchus, 2011). 
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The POR gene is located on chromosome 7q11.2 and consists of 16 exons, of 
which the first one is not transcribed. The coding region is 2043 base pairs long and 
encodes for the 681 amino acid protein. The human POR gene is highly polymorphic 
and sequencing analysis in over 800 subjects from different ethnicities indicate a 
variety of sequence variants, some of which have some impact on CYP-mediated 
activities and cytochrome c reduction and NADPH oxidation (Huang et al., 2008). 
There does not seem to be a hotspot for polymorphisms or mutations within the gene 
structure of POR (Huang et al., 2008; Krone et al., 2007a; 2012).   
1.1.3.3. Cytochrome b5 (CYB5A) 
Cytochrome b5 (CYB5A) is a small (~ 16kDa) membrane-bound protein that 
contains a haeme molecule as its prosthetic group. A soluble isoform lacking the C-
terminal membrane anchor is expressed in erythrocytes, the full protein containing 
the transmembrane domain and the haeme-domain is expressed in various tissues, 
but with high levels in liver, adrenals and gonads (Dharia et al., 2004; Suzuki et al., 
2000). 
CYB5A interacts with POR and CYP17A1 to further support electron flux from 
NADPH, in particular the higher demand for electrons required for its 17,20 lyase 
activity (see also section 1.1.8.1). However, the redox-potential between POR and 
CYB5A is unfavourable and hence makes it unlikely that CYB5A receives electrons 
in the context of CYP reduction, although its prosthetic group would be able to carry 
electrons. In addition, in vitro studies show that truncated CYB5A protein lacking the 
prosthetic group (apo-b5) stimulates the 17,20 lyase activity of CYP17A1 equally to 
holo-b5, suggesting that this co-factor supports allosteric interaction between POR 
and CYP17A1, rather than conducting the flux of electrons directly (Auchus et al., 
1998). 
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In a broader context, CYB5A has been shown to support other physiological 
processes like fatty acid desaturases (Guillou et al., 2004) and other P450 
monooxigenases (Schenkman and Jansson, 2003), including hepatic CYPs involved 
in steroid metabolism and drug detoxification (Yamazaki et al., 1996a; 1996b). 
Recent in vitro studies also suggest additional roles of CYB5A in steroidogenesis, in 
particular by enhancing HSD3B activity leading to an increase of androstenedione 
production (Goosen et al., 2013; 2011; Storbeck et al., 2013). 
1.1.4. The first step in human steroidogenesis  
Cholesterol is the substrate for steroid hormones. Prior to the various catalytic 
reactions generating active steroid sub-class molecules, hydrophobic cholesterol 
needs to meet its first steroidogenic enzyme CYP11A1 (also termed ‘cytochrome 
P450 side chain cleavage’, P450scc) at the inner mitochondrial membrane (IMM).  
The adrenal cortex is able to produce cholesterol de novo from acetate, but the 
majority of the cholesterol that feeds into steroid biosynthesis comes from low density 
lipoproteins (LDL) derived from dietary cholesterol (Gwynne and Strauss, 1982). The 
regulation of the intracellular cholesterol-bioavailability is complex, but largely 
orchestrated by sterol response-element binding proteins (SREBPs), a family of 
transcription factors regulating transcription of target genes involved in cholesterol 
biosynthesis (Horton et al., 2002). The steroidogenic acute regulatory protein (StAR) 
itself is responsible for carrying cholesterol from the outer (OMM) to the inner 
mitochondrial membrane (IMM). The exact molecular mechanism of how StAR 
promotes steroidogenesis and cholesterol transport are not fully elucidated; further 
interactions with other proteins are required for StAR function at the OMM (Liu et al., 
2006; Rone et al., 2009). StAR gene transcription and its activation through 
phosphorylation is rapidly induced by pituitary ACTH (Stocco et al., 2005), allowing a 
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fast flux of cholesterol molecules from the cytosol to the IMM, where it serves as the 
substrate for the first and rate-limiting P450 enzyme, CYP11A1 (Stocco and 
Sodeman, 1991). 
The biosynthesis of pregnenolone from cholesterol at the IMM is achieved by 
three subsequent and distinct catalytic reactions, all carried out by the one enzyme 
CYP11A1: (1) hydroxylation at position 22, (2) 20-hydroxylation of 22(R)-
hydrocholesterol and (3) the side chain cleavage reaction via oxidative scission of the 
C20-22 bond of 20(R),-22(R)-dihydroxycholesterol yielding pregnenolone. Each 
catalytic reaction requires two electrons, provided by NADPH via the electron donors 
Adx and AdR (Figure 3). As CYP11A1 is the key-initiating and rate-limiting step in 
human steroidogenesis, its expression marks cells or tissues as steroidogenic (Miller 
and Auchus, 2011). CYP11A1 expression is regulated by ACTH/cAMP in the adrenal 
ZF/ZR, but also in the testis and the ovary (John et al., 1986). Intracellar calcium and 
protein kinase C (PKC) regulate CYP11A1 expression in the ZG (Barrett et al., 1989). 
In addition, adrenal and gonadal steroidogenic tissues require the presence of the 
transcription factor SF1 (steroidogenic factor 1) for CYP11A1 expression (Parker and 
Schimmer, 1997).  
Once synthesized, hydrophobic pregnenolone leaves the mitochondrion without 
any active transport mechanism or carrier proteins serving as a substrate for further 
conversion in steroidogenic pathways. The fate of the pregnenolone molecule solely 
depends on the endowment of the respective adrenocortical cell type with 
steroidogenic enzymes, yielding mineralocorticoids, glucocorticoids or sex steroids 
(Figure 4). 
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Figure 4 (previous page): Overview of human adrenal steroidogenesis with key intermediate 
metabolites and steroidogenic enzymes involved. The three subclasses of steroids are colour-coded 
with green for MCs, yellow/orange for GCs and blue for androgens; the intensity of the colour indicates 
the affinity of the steroid to its receptor. The steroidogenic enzymes are shown in grey with co-factors 
in white. Arrows indicate the direction of the enzymatic reactions; dashed arrows indicate that the 
efficiency of the reaction is weak. POR: P450 oxidoreductase; Adx: adrenodoxin; AdR: Adrenodoxin 
reductase; H6PDH: Hexo-6-phosphate dehydrogenase; PAPSS2: 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) synthase 2.  
1.1.5. Principles of steroid hormone action 
Steroid hormones exert their effects mainly via targeting and activating 
intracellular receptors that act as ligand-dependent transcription factors initiating 
gene transcription. The glucocorticoid receptor (GR), the mineralocorticoid receptor 
(MR), the androgen receptor (AR) and the oestrogen receptor (ER) belong to the 
subfamily 3 of the large family of nuclear receptors (Lu et al., 2006).  
The molecular composition and the mechanism of action of nuclear receptors 
are similar and based on the arrangement of five distinct domains with different 
functions (Figure 5): the sequence of the N-terminal domain is the most variable one 
amongst the different nuclear receptors and contains the activation-function 1 (AF1) 
site initiating gene transcription independent of ligand binding. The sequence of the 
DNA-binding domain (DBD) is highly conserved amongst various subfamilies of 
nuclear receptors and contains, as a typical molecular feature, two zinc-ions each 
coordinated by four cysteine residues. The DBD recognizes hormone-responsive 
elements (HREs) within the genome, binds to DNA as homodimers and initiates gene 
transcription. A hinge region connects the DBD with the ligand-binding domain (LBD). 
A unique arrangement of eleven α-helices and four small β-strands form a highly 
selective ligand-binding pocket at its core that recognizes the steroid ligand. This 
selectivity is assured by (1) unique surface charges due to a ‘hydrogen network’ 
within the binding pocket, (2) the shape of the topology inside the binding pocket and 
(3) the relative position of the binding pocket within the LBD (Lu et al., 2006). The C-
 
Chapter 1                    General Introduction 
___________________________________________________________________ 
 
 16 
terminal domain is highly variable in sequence amongst the various nuclear 
receptors. 
 
Figure 5: Schematic representation of the structure of nuclear receptors, including steroid hormone 
receptors from the one-dimensional (1D, top) and three-dimensional (3D, bottom) perspectives. The 
crystal structures of the DNA binding domain (DBD) and ligand binding domain (LBD) are derived from 
the oestrogen receptor protein. To simplify illustration of the functional domains, the structures of the 
N-terminal domain (A/B), the hinge region (D) and the C-terminal domain (F) are not shown, but they 
are represented as red, purple and yellow dashed lines, respectively. Source: Wikipedia 
Steroid hormone receptors also have a similar mechanism of activation. If not 
activated by the steroid ligand, they are found in the cytosol bound in complexes with 
heat shock proteins (HSPs); these are chaperones preventing the receptor from 
endosomal degradation and holding them in a high affinity conformation. Upon ligand 
binding, the receptor dissociates from the HSPs, homo-dimerizes and translocates 
into the nucleus of the cell where it binds via its DBD to HREs of the genomic DNA 
initiating gene transcription. The transport of the receptor from the cytosol to the 
nucleus is facilitated by active transport mechanisms and mediated by nuclear 
targeting sequences usually found in the hinge region of the receptor (Figure 5) (Lu 
et al., 2006). 
A number of proteins have been identified that modulate gene transcription of 
steroid hormone receptors and function as either co-activators or co-suppressors. 
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Classically, co-regulators interact with the translational machinery; but in addition 
they also exert many other activities beyond the interaction with the translational 
machinery such as mRNA translation and transport and post-translational 
modification of the synthesized protein (Lonard and O'Malley, 2006). 
Beside the genomic effects of steroid hormones initiating gene transcription, 
which usually takes minutes to hours, they can also exert more rapid effects 
occurring within seconds independently of gene transcription. These non-genomic 
effects of steroid hormones are mediated via several signalling pathways ranging 
from the activation of G-protein coupled receptors (GPCRs) to the activation of 
distinct kinases like mitogen activated protein kinase (MAPK), protein kinase A (PKA) 
and protein kinase C (PKC) (Hammes and Levin, 2007). These non-genomic effects 
of steroid hormones are well documented for the rapid effects of oestrogens on 
breast cancer proliferation and in the cardiovascular system (Simoncini et al., 2000; 
Márquez and Pietras, 2001), of androgen on cell proliferation in the prostate (Kampa 
et al., 2006), and for glucocorticoids on the suppression of ACTH release (Iwasaki et 
al., 1997). 
1.1.6. Mineralocorticoids (MC) 
1.1.6.1. MC biosynthesis 
The site of mineralocorticoid biosynthesis is the ZG of the adrenal cortex, 
uniquely expressing the enzyme systems required to generate the most potent 
mineralocorticoid, aldosterone, from pregnenolone (Figure 1 and Figure 4). 
Pregnenolone can either be hydroxylated to 17α-hydroxy-pregnenolone 
(17Preg) by the 17α-hydroxylase activity of CYP17A1 or converted to progesterone 
by HSD3B2. Although the substrate binding affinity of CYP17A1 for pregnenolone is 
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much higher for CYP17A1 than for HSD3B2, CYP17A1 is virtually not expressed in 
the ZG; in contrast HSD3B2 is strongly expressed in ZG cells throughout all age 
groups (Suzuki et al., 2000). HSD3B2 has two catalytic reactions, supported by the 
two-fold oxidation of a single NADPH molecule: (1) with its dehydrogenase activity it 
oxidizes the hydroxyl group at carbon 3 to a keto group and (2) subsequently with its 
Δ4!Δ5 isomerase activity, HSD3B2 isomerases the carbon-carbon double bond 
from the position between C5/6 (‘Δ5’) to C4/5 (‘Δ4’). HSD3B2 has similar affinities to 
all Δ4 steroids, i.e. pregnenolone, 17-Preg and DHEA (Miller and Auchus, 2011).  
Progesterone generated by HSD3B2 is subsequently hydroxylated by 
CYP21A2 to form 11-deoxycorticosterone (DOC), a mineralocorticoid intermediate 
able to bind and activate the mineralocorticoid receptor. Finally, the enzyme 
aldosterone synthase, CYP11B2, produces aldosterone from DOC in the 
mitochondrion in three consecutive catalytic reactions: (1) 11β-hydroxylation of DOC 
yielding corticosterone, (2) 18-hydroxylation of corticosterone to form 18-hydroxy 
corticosterone and finally (3) the 18-methyl oxidation of corticosterone generating 
aldosterone (Miller and Auchus, 2011). CYP11B2 is predominantly expressed in the 
adrenal ZG and is closely related to its isozyme CYP11B1, which is highly expressed 
in the ZF generating cortisol from 11-deoxycortisol. CYP11B1, which is not 
expressed in the ZG, is also able to perform the first two catalytic reactions of 
CYP11B2, however, the 18-methyl oxidation generating aldosterone is unique to the 
type 2 isozyme.  
In essence, the absence of CYP17A1 17α-hydroxylase activity and the 
presence of CYP11B2 and HSD3B2 are the key molecular characteristics of the 
adrenal ZG and essential to produce mineralocorticoids. 
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1.1.6.2. MC regulation 
MCs are the key regulators of the body’s salt and water balance and blood 
pressure. As the plasma levels of most endocrine hormones are regulated via 
negative feedback mechanisms, so to the production and excretion of MCs from the 
adrenal ZG are inhibited by low intravascular potassium, high sodium concentrations 
and high blood pressure. A cascade of proteases forming the renin-angiotensin-
aldosterone system (RAAS) mediates this feedback cross-talk between the kidneys 
and the ZG of the adrenal cortex. Specialized cells within the glomeruli of the 
kidneys, as part of the juxtaglomerular apparatus, secrete the protease renin in 
response to a decrease of the glomerular filtration rate. Renin converts angiotensin to 
the inactive peptide-hormone angiotensin I. Secondly, the angiotensin converting 
enzyme (ACE), mainly expressed in the vascular endothelium of the lungs and 
kidneys, converts the deca-peptide angiotensin I to the active octa-peptide 
angiotensin II, which acts as a strong inducer of CYP11B2 expression in the ZG of 
the adrenal cortex. Beside its effects on the adrenal cortex, angiotensin II acts a 
potent vasoconstrictor targeting the smooth muscles of arteries thereby increasing 
arterial blood pressure. MC synthesis and secretion is also directly stimulated by high 
potassium levels and inhibited via direct and indirect effects by the atrial natriuretic 
peptide (ANP) (Ganguly, 1992). To a lesser extend, the ZG also responds to pituitary 
ACTH, the key stimulus for glucocorticoid synthesis in the ZF (Honda, 1976). 
1.1.6.3. MC action 
Aldosterone is the principal mineralocorticoid as it has the highest affinity to the 
mineralocorticoid receptor (MR), a classical intracellular steroid hormone receptor 
and part of the subfamily 3 of nuclear receptors (see section 1.1.5 and Figure 5). A 
MC-responsive cell is characterized by the expression of the MR. However, as the 
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MR is highly promiscuous with cortisol, the concomitant expression of the HSD11B2 
enzyme is crucial to ‘protect’ the MR from cortisol as HSD11B2 converts active 
cortisol to inactive cortisone (Kornel, 1994).  
Cells that express the MR and HSD11B2 are found in the epithelium of distal 
tubules and collecting ducts of the kidneys, where MCs play a main role in the 
regulation of salt and water homeostasis; the MR is also expressed in other epithelial 
cells like sweat and salivary glands (ductal cells) and in enterocytes of the distal 
colon. In addition, non-epithelial cells of the heart muscle, central nervous system 
(hippocampus) (Meijer, 2002), adipose tissue (Caprio et al., 2007) and blood vessels 
(Lombès et al., 1992) express the MR. Aldosterone enters freely into the cells and 
binds to the LBD of the receptor. Once activated through ligand binding, the MR 
translocates as a homodimer into the nucleus and initiates gene transcription by 
recognizing HREs, thus executing its classic genomic effects (see section 1.1.5). 
Similar to other steroid hormone receptors, a wide range of co-regulators have been 
identified to modulate gene transcription or MR-induced protein synthesis on the 
post-transcriptional level (Yang and Fuller, 2012). Their main physiological sites of 
action are the kidneys where they initiate transcription of genes involved in sodium 
reabsorption and potassium secretion. 
1.1.7. Glucocorticoids (GCs) 
1.1.7.1. GC biosynthesis 
The adrenal zona fasciculata (ZF) is the site of glucocorticoid (GC) synthesis. 
Cortisol is the principal product of this pathway having the highest affinity for the 
glucocorticoid receptor (GR). 17α-progesterone (17OHP) is the immediate precursor 
metabolite for GC synthesis and substrate of the enzyme CYP21A2. CYP17A1 17α-
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hydroxylase activity generates 17OHP directly from progesterone; it also catalyses 
the 17α-hydroxylation of pregnenolone yielding 17α-hydroxypregnenolone (17Preg), 
which serves as a substrate for the HSD3B2 enzyme to generate 17OHP. Hence, the 
presence of CYP17A1 17α-hydroxylase activity in the ZF is the rate-limiting step in 
the generation of GC precursors and biochemically distinguishes the ZF from the 
MC-producing ZG, which lacks CYP17A1. Two further catalytic reactions are 
required to produce cortisol from 17OHP: CYP21A2 catalyses hydroxylation of 
carbon 21, yielding 11-deoxycortisol, which is then hydroxylated at carbon 11 by 
CYP11B1 to generate cortisol.  
1.1.7.2. GC regulation and metabolism 
Adrenal GC secretion is regulated by the hypothalamic-pituitary-adrenal (HPA) 
axis (Figure 6). The hypothalamus is generally considered as a connector between 
the central nervous and the endocrine systems, as it regulates the secretion of 
various stimulating hormones in the pituitary gland. The paraventricular nucleus of 
the hypothalamus secretes upon central nervous influences and regulatory feedback 
mechanisms the corticotropin-releasing hormone (CRH) into the portal-vein system 
connecting the hypothalamus with the anterior lobe of the pituitary. Here, it stimulates 
corticotrophic cells and the transcription of the POMC gene coding for pre-pro-
opiomelanocortin (pre-POMC), a 285-amino acid peptide. POMC has multiple 
cleavage sites and undergoes various post-translational processes to generate a 
variety of biologically active substances, including melanocyte stimulating hormone 
(α/β-MSH), β-endorphin and the adrenocorticotrophic hormone ACTH (Pritchard et 
al., 2002). ACTH binds to its melanocortin-2 receptor (MC2R), a G-protein-coupled 
receptor predominantly expressed in the adrenal ZF and ZR. Its activation induces 
cAMP-mediated expression of genes that facilitate cholesterol import into the 
 
Chapter 1                    General Introduction 
___________________________________________________________________ 
 
 22 
mitochondrion, where it serves as substrate for CYP11A1 generating pregnenolone, 
the first step in human steroidogenesis (see 1.1.3.1). Beside the rapid increase of 
cholesterol influx, ACTH also induces gene expression of various steroidogenic 
enzymes, including CYP11A1, CYP21A2 and CYP11B1. Both actions ultimately lead 
to the initiation of adrenal glucocorticoid synthesis (Sewer and Waterman, 2003). 
The release of hypothalamic CRH and pituitary ACTH/POMC is regulated by 
cortisol itself via negative feedback (see Figure 6). However, a variety of other 
stimuli alter HPA drive and cortisol secretion, which follows a diurnal rhythm with 
higher levels during late night/early morning and a nadir around midnight. Beside the 
circadian variation of cortisol levels, a variety of other stimuli alter adrenal GC 
secretion, such as stress (both physical and emotional), mood, appetite/food intake, 
infection/pro-inflammatory cytokines. Depending on these factors, the daily GC 
secretion rates can vary drastically and increase more than five-fold above the 
normal daily production rates of 8-12 mg for cortisol (Esteban and Yergey, 1990; 
Kerrigan et al., 1993; Salem et al., 1994).  
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Figure 6: The hypothalamic-pituitary-adrenal (HPA) axis and peripheral cortisol (re)generation by 
HSD11B1.  
While the HPA axis regulates the secretion of cortisol from the ZF, the 
availability of cortisol in peripheral tissues is modulated by the enzyme 11-β 
hydroxysteroid dehydrogenase type 1 (HSD11B1) regenerating active cortisol from 
inactive cortisone (Agarwal et al., 1989; Tomlinson et al., 2004). In fact, this enzyme, 
in contrast to its type 2 isoform, acts in two directions, either as a reductase to 
regenerate cortisol, or as an oxidase to ‘inactivate’ cortisol to cortisone. However, the 
predominant direction is the reduction of cortisone, and in vitro and in vivo studies 
revealed that this activity depends on the availability of NADPH, which is provided by 
its co-enzyme hexose-6-phosphate dehydrogenase (H6PDH) (Draper et al., 2003). 
H6PDH, expressed in the lumen of the endoplasmic reticulum, generates NADPH 
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from NADP+ utilizing glucose-6-phosphate (G6P) as a substrate, which is reduced to 
6-phosphogluconate (6PGL).  
Due to the fluctuating levels of cortisol and cortisone, it is not possible to assess 
changes of activity in the HSD11B1 enzyme with simple blood sample 
measurements. However, urinary steroid profiling of cortisol and cortisone 
metabolites provide an important diagnostic tool to assess the current bio-availability 
of cortisol and cortisone ultimately reflecting the in vivo activity of HSD11B1 (Figure 
6): Both cortisol and cortisone are further metabolised by 5α- and 5β-reductases to 
their respective 5α- and 5β-reduced metabolites tetra-hydrocortisol (THF) and tetra-
hydrocortisone (THE). Subsequently, hydroxylation at carbon 6 and 20 by 20α/β 
HSDs converts these tetrahydro-metabolites to cortols and cortolones, respectively 
(Figure 6).  
In summary, the global activity of HSD11B1 determines the ratio of cortisol to 
cortisone. Hence, a change in the activity of this enzyme will affect this ratio with an 
immediate impact on the activity of the HPA axis (Figure 6). 
1.1.7.3. GC action 
The glucocorticoid receptor (GR) is expressed in virtually all cells in the body, 
underpinning the huge variety of effects GCs exert in normal human physiology and 
pathophysiology (Buckingham, 2006). From a mechanistic point of view, the GR 
functions in the same way as other nuclear receptors in the steroid receptor sub-
family. Once activated by ligand binding, it classically homo-dimerises, translocates 
to the nucleus and initiates gene transcription targeted by the recognition of HREs by 
the DBD of the receptor. The HREs are typically inverted repeats of ‘TGTTCT’ motifs 
with three base pairs in between as a spacer (‘AGAACA-XXX-TGTTCT’). Co-
activators facilitate and regulate gene expression as described in section 1.1.5. 
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Uniquely, the GR can also act as a monomer and interact with other transcription 
factors to modulate gene expression, a process called transrepression. This mode of 
GR action leads to inhibition of target gene transcription and is responsible for the 
anti-inflammatory effects of GCs. Examples of pro-inflammatory proteins, that are 
transrepressed as a consequence of the monomeric activity of the GR, are the 
transcription factors AP-1 and NF-κB (Ray and Prefontaine, 1994).  
The immediate actions of GCs can be roughly classified as metabolic and 
immunologic. The name ‘glucocorticoid’ was given based on early observations that 
they are able to increase blood sugar levels and are hence involved in glucose 
metabolism. GCs stimulate gluconeogenesis in liver and muscle by utilizing 
alternative, ‘non-sugar’ substrates like amino acids and glycerol. Simplified, the 
metabolic effects of GCs can be described as catabolic to increase the availability of 
energy substrates (carbohydrates) as required in stress or during severe 
illness/infection (Buckingham, 2006).  
Other metabolic effects of GCs include thinning of the skin due to a reduction of 
collagen synthesis, resulting in increased vulnerability and prolonged wound healing. 
In bone, GCs suppress osteoblast activity resulting in reduction of bone 
mineralization due to the prevailing catabolic activity of osteoclasts. 
GCs exert a range of immune-modulatory effects and have profound anti-
inflammatory and immunosuppressive activities. They are able to reduce the amount 
of circulating neutrophils and effectively block the synthesis of the two main 
inflammatory cytokines, prostaglandins and leukotrienes. A schematic overview of 
the various effects of GCs in the human body is shown in Figure 7. 
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Figure 7: Overview of the key actions and clinical consequences of GCs in the human body. With kind 
permission from Paul Stewart. 
1.1.8. Androgen precursors 
1.1.8.1. Biosynthesis of DHEA 
The principal precursor for all androgens in humans is dehydroepiandrosterone 
(DHEA). It is synthesized from cholesterol in the adrenal ZR and the gonads by the 
action of the two enzymes CYP11A1 and CYP17A1 (Figure 4). CYP11A1 is located 
in the mitochondrion and cleaves the cholesterol side chain, yielding pregnenolone 
(see 1.1.3.1; Figure 4). 
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The microsomal enzyme CYP17A1 is the qualitative regulator of steroid 
synthesis and exerts two distinct catalytic activities: (1) its 17α-hydroxylase activity 
catalyses the production of the glucocorticoid precursors 17OHP and 17Preg (see 
1.1.7.1). (2) The 17,20 lyase activity of CYP17A1 catalyses their subsequent 
conversion to the adrenal androgen precursors androstenedione and 
dehydroepiandrosterone (DHEA), respectively. Of note, the 17,20 lyase activity of 
CYP17A1 has approximately a 100-fold higher substrate preference for 17Preg over 
17OHP (Auchus et al., 1998). Hence, in the physiological situation, almost all 
androgen synthesis proceeds through DHEA.  
The regulation of CYP17A1 17,20 lyase activity has been of interest for many 
years as alterations in this activity can be causative for androgen deficiency as well 
as androgen excess. The availability of electrons determines whether CYP17A1 
performs only 17α-hydroxylation or whether it also performs 17,20 bond scission. 
Hence, co-factors involved in electron transfer have been considered and identified 
to regulate this activity. For both catalytic activities of microsomal CYP17A1, 
electrons are provided by the flavoprotein POR from NADPH (see Figure 3, see 
section 1.1.3). High molar ratios of POR to CYP17A1 have been shown in vitro to 
increase 17,20 lyase activity over its 17α-hydroxylase activity (Yanagibashi and Hall, 
1986). Secondly, cytochrome b5 (CYB5A) has been thought to facilitate allosteric 
interaction between POR and CYP17A1, thereby increasing the electron flux from 
POR and specifically enhancing 17,20 lyase activity (Auchus et al., 1998) (see 
section 1.1.3.3). In addition, in vitro data suggest that phosphorylation of serine and 
threonine residues of CYP17A1 facilitate 17,20 lyase activity by a cAMP-dependent 
protein kinase (Zhang et al., 1995), which has recently been identified as p38α (Tee 
and Miller, 2013). 
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While CYP11A1 and CYP17A1 are essential and theoretically sufficient to 
create the biochemical environment of the ZR, other steroidogenic enzymes also 
affect androgen synthesis. HSD3B2 converts the Δ5 steroids Preg and 17Preg to the 
Δ4 steroids Prog and 17OHP, thus crucially facilitating MC and GC synthesis (Figure 
4). 
 As it competes with CYP17A1 for substrate, decreased HSD3B2 activity will 
results in increased DHEA synthesis. Indeed, the ZR cell expresses low levels of 
HSD3B2 with CYP11A1 and CYP17A1 in abundance (Suzuki et al., 2000; Nakamura 
et al., 2009).  
1.1.8.2. Regulation of adrenal androgen secretion 
Cells of the ZR express the ACTH receptor responding with DHEA synthesis 
upon stimulation by pituitary ACTH; however, a negative feedback mechanism 
similar to the inhibitory effects of cortisol on ACTH release does not exist for DHEA 
or downstream androgens. The physiological role of androgen secretion in the 
context of central/pituitary activation is unclear, but it could be due to the immune-
modulatory effects of DHEA and DHEAS during stress and illness, in particular 
infections (Hazeldine et al., 2010; Radford et al., 2010). 
The mechanisms by which ACTH stimulates adrenal androgen synthesis are 
essentially via the same cascades that increase GC generation in the ZF, i.e. 
increased cholesterol uptake and transport to the IMM (StAR-mediated) with 
upregulation of CYP11A1 expression (see sections 1.1.5 and 1.1.7.2). In addition, in 
vitro studies show that ACTH/cAMP-stimulation of adrenal human cell lines or bovine 
primary cultures increase the expression of CYP17A1 (Miller and Auchus, 2011; 
Rodriguez et al., 1997; Sewer and Waterman, 2002; Bischof et al., 1998; Lund et al., 
1990).  
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The adrenal ZR is not present from infancy until mid-childhood. The processes 
leading to its emergence, an event called adrenarche, is not understood and remains 
one of the big riddles in steroid endocrinology (see 1.2.3).  
1.1.8.3. Adrenal androgens and androgen receptor activation 
Androgens promote their actions via the androgen receptor (AR), a member of 
the subfamily 3 of nuclear receptors. The AR gene is located on the X-chromosome 
(Xq11-12). Its structure is similar to the MR and GR (see sections 1.1.5, 1.1.6.3 and 
1.1.7.3) and consists of four domains: 1) a large NTD with an activation function 1 
(AF1), 2) the NBD followed by the 3) hinge region (HR) that contains a nuclear 
localization signal (NLS). 4) The LBD contains the activation function 2 (AF2) domain 
(Figure 8).  
 
Figure 8: Schematic illustrating the protein structure of the AR (919 aa). NTD: N-terminal domain; 
DBD: DNA-binding domain; HR: hinge-region; LBD: ligand-binding domain; AF1/2: activation function 
1 and 2; NLS: nuclear localization signal; a FQNLF-motif at the N-terminus is crucial for the interaction 
with AF2 upon ligand binding, resulting in conformational changes of the molecule. With kind 
permission from (Werner et al., 2010).  
The protein structure of the AR in relation to its function has been studied 
extensively (Moras and Gronemeyer, 1998). More than 200 co-regulators of the AR 
have been identified, that either directly interact with the AR molecules and modulate 
gene transcription, or post-translationally modify gene products of the AR by 
phosphorylation, ubiquitination, sumoylation, methylation, or others (van de Wijngaart 
et al., 2012). The co-factor binding pocket of the AR seems to be unique compared to 
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other steroid hormone receptors, as it recognizes preferentially LxxLL or FxxLF 
motifs of the protein sequence of co-regulators (van de Wijngaart et al., 2012). 
The detailed effects and actions of androgens across lifespan are described in 
detail in section 1.2 of this chapter. 
1.1.8.4. Conversion of DHEA to active androgens 
DHEA has virtually no affinity for sex steroid receptors. It is released into the 
blood stream to serve as a substrate for extra-adrenal steroidogenic enzymes 
activating DHEA to potent sex steroids, with dihydrotestosterone (DHT) and 
oestradiol (E2) having the highest affinity to the androgen and oestrogen receptors, 
respectively. This ‘activation’ of DHEA takes place in peripheral target tissues, which 
express the steroidogenic enzyme systems required for the formation of active 
hormones (Figure 9). This field of endocrinology describing intra-cellular activation 
and action of hormones derived from circulating precursors is called ‘intracrinology’, 
and peripheral adrenal androgen activation is one of the best described examples of 
this field (Labrie et al., 1988; Labrie, 2003). 
The conversion of DHEA to androstenedione is the first step of sex steroid 
activation, and this reaction is catalysed by the two isoforms of the HSD3B enzyme. 
The adrenal ZG and ZF expresse the type 2 isoform HSD3B2, which is also crucial 
for the generation of MC and GC precursors (see sections 1.1.6.1, 1.1.7.1; Figure 4). 
However, the ZR expresses HSD3B2 to a lesser extent than the two outer zones 
(Suzuki et al., 2000). Still, 50% of plasma androstenedione levels are still derived 
from the adrenal glands in pre-menopausal women (Judd et al., 1974). HSD3B2 is 
exclusively expressed in the adrenals, gonads and the placenta, while the HSD3B1 
isoform is expressed in many ‘non-steroidogenic’ tissues, including liver, skin, 
adipose, kidney and brain. Inactivating mutations in the HSD3B2 gene result in a 
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severe form of congenital adrenal hyperplasia (CAH) characterized by salt-wasting 
crisis due to MC and GC deficiencies with increased DHEA generation due to HPA 
axis activation; however, the fact that these patients develop androgen excess, 
reflects the increased peripheral activation of DHEA by the (intact) HSD3B1 enzyme. 
17β-hydroxysteroid dehydrogenases (HSD17Bs) are a large group of enzymes 
with at least 14 human isoforms known (Kong et al., 1992; Miller and Auchus, 2011). 
Like many other HSDs, they can act in two directions, either as an oxidase or a 
reductase. However, most HSD17Bs catalyse a reaction in one preferential direction. 
Six HSD17Bs are involved in steroid metabolism, in particular in the inter-conversion 
of sex steroid precursors. Their roles in sex steroid metabolism and tissue expression 
are summarized in Table 2 and illustrated in Figure 9. 
5α-reduction of testosterone yields 5α-dihydrotestosterone (DHT), the most 
potent androgen. This reaction is irreversible. Two isoforms of the enzyme 5α-
reductase (SRD5A) have been cloned and characterized (Andersson and Russell, 
1990; Andersson et al., 1991; Jenkins et al., 1992) and differ mainly regarding their 
tissue-specific distribution: the type 2 isoform (SRD5A2) is expressed in the tissues 
of the male reproductive tract, but also in foetal genital skin; SRD5A1 is widely 
expressed in peripheral tissues, but mainly in liver and skin (Luu-The et al., 1994).  
All oestrogens are derived from androgens by the activity of the enzyme P450 
aromatase (CYP19A1). CYP19A1 uses three electrons, derived from NADPH via 
POR, to oxidize and demethylate androgenic C19 steroids, yielding a C18 steroid 
with an aromatic A-ring (Miller and Auchus, 2011). Its main substrates are 
androstenedione and testosterone yielding oestrone (E1) and oestradiol (E2), 
respectively. During pregnancy, 16-hydroxy-DHEA, which is 16α-hydroxylated in the 
foetal liver, is aromatized to oestriol (E3), which reaches high levels in the maternal 
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circulation. E2 is the oestrogen with highest affinity for the oestrogen receptor (ER) 
and mediates the development of secondary female characteristics during puberty 
and the gain of fertility. CYP19A1 is mainly expressed in granulosa cells of the 
ovarian follicle and placenta, but also in adipose, the growth plate of long bones and 
the brain (Simpson et al., 1994).  
 
Figure 9: Schematic illustration of the activation of adrenal androgen precursors in peripheral target 
cells by the action of various steroidogenic enzymes. Dihydrotestosterone (DHT) is the most potent 
androgen with the highest transactivation capacity of the androgen receptor (AR); its biosynthesis is 
realised by 5α-reduction of testosterone by SRD5As. Testosterone is produced from DHEA and 
androstenedione by the action of the two HSD3B isoforms and various HSD17Bs isoforms. The 
sulfate moiety of DHEAS is hydrolysed by the enzyme steroid sulfatase (STS), yielding DHEA. Due to 
the hydrophilic properties of DHEAS, it needs active transport into the cell by OATPs. An alternative 
pathway from androstenedione to DHT without the use of testosterone is illustrated to the top and right 
part of this figure. Oestrogens are derived from androstenedione and testosterone by the action of 
CYP19A1. ER: Oestrogen receptor.  
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1.1.9. DHEA sulfation pathways and interconversion of DHEA and DHEAS 
The main product of the adrenal ZR and also the most abundant steroid 
hormone in the circulation is DHEAS, the sulfoconjugated form of DHEA. The daily 
DHEAS production in adult women of reproductive age is up to 20 mg, compared to 
3-6 mg for DHEA, 1-6 mg for androstenedione and 0.1-0.4 mg for testosterone 
(Burger, 2002).  
DHEAS is in the context of AR activation an inactive metabolite and cannot 
directly be converted to active androgens. DHEAS has strikingly different biochemical 
properties than DHEA: as a hydrophilic molecule, it is not able to cross lipid 
membranes freely as most other steroids and has to rely on active transport 
mechanisms. DHEAS is bound to plasma proteins (mainly albumin) and thus has a 
much longer plasma half-life of about 20 hours compared to 3-6 hours for DHEA. The 
sulfation of DHEA is catalysed by the enzyme DHEA sulfotransferase (SULT2A1) 
and predominantly occurs within the ZR (Falany et al., 1989; Strott, 2002). The 
enzyme steroid sulfatase (STS), which is mainly expressed in peripheral tissues, 
cleaves the sulfate moiety off the DHEAS molecule to regenerate DHEA, which can 
be converted further downstream to active sex steroids. Hence, through the counter-
actions of SULT2A1 and STS, circulating, albumin-bound DHEAS has been thought 
to represent a storage pool for amplification of sex steroid signalling in peripheral 
target tissues. However, little is known about the exact impact of the DHEA sulfation 
system and its role during childhood development. 
1.1.9.1. DHEA sulfotransferase (SULT2A1) and 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) synthases (PAPSS) 
The sulfoconjugation of substances is a major metabolic pathway in humans 
and involved in many key cellular and metabolic processes, crucial for growth and 
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development (Strott, 2002; Dawson, 2011). Sulfation is a catalytic reaction where a 
sulfate group (SO42-) is transferred to an acceptor molecule. The introduction of a 
sulfate group into a molecule results in striking alterations of the molecule’s 
biochemical properties, mainly an increase in water solubility as well as 
conformational changes.  
Sulfation reactions are catalysed by sulfotransferases (SULTs), and more than 
50 SULTs have been cloned and characterized in humans (Strott, 2002). 
Depending on their cellular localization and chemical properties, two super-
families can be distinguished: 1) soluble, cytosolic SULTs and 2) membrane-bound 
SULTs that are usually located within the Golgi apparatus (Strott, 2002). Members of 
the cytosolic group of SULTs are involved in steroid and drug metabolism, the 
membrane-associated SULTs sulfo-conjugate carbohydrates, peptides and proteins.  
SULT2A1, a member of the subfamily 2 of cytosolic SULTs, has been 
traditionally named DHEA sulfotransferase, as it utilizes DHEA as its major substrate 
(Kong et al., 1992). However, it has a broad substrate specificity and also sulfates 
other Δ4 steroids, like pregnenolone or 17-hydroxypregnenolone, but also 
testosterone, oestradiol and bile acids (Radominska et al., 1990; Falany, 1997). 
Usually, the 3α/β- or the 17β-hydroxyl-groups of these molecules undergo sulfation 
by SULT2A1. Other SULTs involved in steroid metabolism have been identified; in 
particular SULT1B1 with its two isoforms SULT1B1a and SULT1B1b is able to sulfate 
hydroxysteroids (Whitnall et al., 1993; Strott, 2002). 
SULT2A1 is robustly expressed in the cytosol of many steroidogenic tissues, in 
particular tissues involved in androgen production and metabolism, which are adrenal 
cortex, testicles, ovaries, prostate and liver but also the digestive tract (Javitt et al., 
2001). 
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The sulfate group for sulfation reactions mediated by SULTs needs to be 
‘activated’ and is delivered by an organic compound named 3’-phosphoadenosine-5’-
phosphosulfate (PAPS). In fact, PAPS serves as the universal sulfate donor for all 
sulfation reactions, and all tissues in mammals are able to produce PAPS from ATP 
and inorganic sulfate (Mulder, 2003). The generation of PAPS requires two distinct 
catalytic reactions carried out by the bi-functional enzyme PAPS synthase (PAPSS): 
First, ATP is sulfurylated yielding adenosine-5’-phosphosulfate (APS) as an 
intermediate, which is secondly further phosphorylated to form PAPS. While both 
enzymatic reactions, ATP sulfurylase and APS kinase, are located in plants, yeast 
and bacteria on different polypeptide chains, they are fused to one enzyme in 
metazoans forming the PAPSS enzyme (Strott, 2002; Mueller and Shafqat, 2013).  
Two PAPSS isoforms exist in humans, and their genes are located on two separate 
chromosomes: PAPSS1 (chromosome 4q25-26) is highly conserved amongst 
different species, including rodents, guinea pig and drosophila (Venkatachalam, 
2003; Yanagisawa et al., 1998). It has about 80% amino acid identity with the human 
PAPSS2 isoform (chromosome 10q23-56) (Strott, 2002), which was discovered in a 
search for the genetic cause of a bone malformation disorder in a large 
consanguineous pedigree with affected members suffering from distinct bone 
malformations called spondylepimatephyseal dysplasia (SEMD) (Haque et al., 1998).  
Both isoforms have a very similar structure, genomic arrangement (12 exons 
with similar intro/exon boundaries), length (614 and 624 amino acids, respectively) 
and distribution of catalytic domains with the ATP sulfurylase domain being located at 
the N-terminus and the APS kinase domain at the carboxy-terminus (Xu et al., 2000). 
Two splice variants exist for the human PAPSS2 isoform, PAPSS2a and PAPSS2b: 
PAPSS2b has an additional exon comprising 5 amino acids (‘GMALP’) within the 
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ATP sulfurylase domain (van den Boom et al., 2012; Fuda et al., 2002). However, 
there are differences between the two PAPSS isoforms in regards to their tissue 
expression: PAPSS1 is virtually ubiquitously expressed, while PAPSS2 is mainly in 
cartilage, adrenal, gonads, placenta, colon and liver (Fuda et al., 2002; Stelzer et al., 
2007). Furthermore, a different subcellular distribution of PAPSS isoforms has been 
reported. Sulfation reactions are essentially taking place within the cytoplasm for 
most substrates, including steroids; however, sulfation of oestrogens has been 
reported to occur in the nucleus for rodents and guinea pig (Mancini et al., 1992; 
Whitnall et al., 1993). Strikingly, Besset et al. reported that the human PAPSS1 
isoform is located in the nucleus whereas PAPSS2 is expressed in the cytoplasm of 
mammalian cells (Besset et al., 2000). Recently, Schröder et al. showed that the 
distribution pattern of both PAPSS isoforms is much more variable and both enyzmes 
are expressed dynamically in the cytosol and the nucleus of mammalian cells 
(Schröder et al., 2012). Interestingly, work from the same group has shown that 
PAPSS2 is less stable with a half-life of several minutes for the unfolding protein, 
whereas PAPSS1 remains structurally intact at physiological temperatures (van den 
Boom et al., 2012). In addition, Grum et al. has shown that PAPSS isoforms 
associate as hetero-dimers, suggesting the possibility of co-synergistic regulation of 
intracellular sulfation pathways (Grum et al., 2010). 
However, the functional consequences of the differences regarding their 
dynamic sub-cellular localization patterns, in vitro protein stability and dimerisation, in 
particular in the context of androgen pre-receptor metabolism, are still unknown and 
remain to be established.  
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Figure 10: Interconversion of DHEA and DHEAS. The sulfation of DHEA is catalysed by the enzyme 
DHEA sulfotransferase (SULT2A1); the opposite direction, the hydrolysis of the sulfate moiety from 
DHEAS, is performed by steroid sulfatase (STS). Both enzymes depend on co-factors: SULT2A1 
requires the activated sulfate compound PAPS, generated by the enzyme PAPS synthase (PAPSS) 
via two catalytic activities: (1) ATP is sulfurylated to APS by the ATP sulfurylase activity, (2) APS is 
further phosphorylated to form PAPS. A cysteine residue of the STS enzyme needs to be post-
translationally activated to a formylglycine (FGly) by the mono-oxigenase formylglycine-generating 
enzyme (FGE), encoded by the SUMF gene. FGly is further hydroxylated, crucial for the hydrolysis of 
the sulfate moiety catalysed by STS. 
 
1.1.9.2. Steroid sulfatase (STS) and sulfatase-modifing factors (SUMFs) 
Steroid sulfatase (STS, aka as arylsulfatase C) is a membrane-bound 
microsomal enzyme and member of a highly conserved family of arylsulfatases 
(ARS) (Reed et al., 2005). Sulfatase enzymes act in the opposite direction of 
sulfotransferases and catalyse the cleavage of the sulfate moiety from a variety of 
substrates, including conjugated steroids and other hormones, proteoglycans, post-
translationally modified proteins and aromatic compounds. 
The action of STS is implicated in the regeneration of steroids and its 
precursors from their inactive sulfo-conjugated esters, thereby enhancing their 
availability in peripheral target cells on the pre-receptor level. It hydrolyses the sulfate 
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group of 3β-hydroxysteroid sulfates, including DHEAS, pregnenolone sulfate, 17-
Preg sulfate, sulfated oestrogens, but also of cholesterol sulfate (Reed et al., 2005). 
The STS gene is localized on the short arm of the X-chromosome (Xp22.3), 
which is part of the pseudo-autosomal region escaping X-inactivation (Ballabio et al., 
1987a). It encodes a protein of 583 amino acids and has a mass of about 65kDA 
(Stein et al., 1989). 
Genetic abnormalities of the STS gene causes steroid sulfatase deficiency 
(STSD) resulting in the skin condition X-linked ichthyosis, a common inborn error of 
metabolism with a prevalence of 1:6,000 (Fernandes et al., 2010). It is characterized 
by thickening of the epidermis and large, brown scales of the skin; the 
pathomechanism is thought to be due to accumulation of cholesterol sulfate in the 
stratum corneum of the epidermis. Abnormal steroid metabolism has been reported 
in small cohorts of patients with STSD as well as elevated levels of sulfated steroids, 
like DHEAS and oestrogen sulfates (Lykkesfeldt et al., 1985a; Milone et al., 1991; 
Delfino et al., 1998). 
The molecular mechanisms underlying STS catalytic activity have been 
studied in detail and are highly conserved amongst different human sulfatase 
enzymes (Reed et al., 2005; Ghosh, 2007): a highly conserved cysteine residue 
resides in the catalytic centre of the sulfatase, which is post-translationally modified 
to form a formylglycine (FGly) residue. FGly is catalytically active and ‘attacks’ the 
sulfate moiety of substrates and is essential to hydrolyse the sulfate ester bond 
(Recksiek et al., 1998; Dierks et al., 1998; Ghosh, 2007) (Figure 10). The 
modification of the cysteine to form the FGly is mediated by the co-enzyme 
formylglycine generating enzyme (FGE), which is encoded by the gene sulfatase-
modifying factor 1 (SUMF1). Mutations in SUMF1 cause multiple sulfatase 
 
Chapter 1                    General Introduction 
___________________________________________________________________ 
 
 39 
deficiency, a rare and fatal autosomal recessive disorder characterized by absent 
activity of all sulfatase enzymes (Cosma et al., 2003; Dierks et al., 2003).  
STS is believed to be expressed in virtually all human adult and foetal tissues in 
very small amounts (Strott, 2002). Immunohistochemistry studies have demonstrated 
that STS is localized in the endoplasmic reticulum and Golgi apparatus (Willemsen et 
al., 1988). A systemic expression analysis employing semi-quantitative RT-PCR, 
immunohistochemistry and biochemical detection by activity assays detected either 
absent or very low STS expression and activity in a variety of human foetal and adult 
tissues, with low-moderate STS detection in lung, aorta, adrenal gland, thyroid, 
mammary gland, testis, prostate and endometrium (Miki et al., 2002). However, the 
richest source for STS is the syncytiotrophoblast of the human placenta. 
1.2. ADRENAL ANDROGENS DURING HUMAN PRE- AND POSTNATAL 
DEVELOPMENT 
1.2.1. The adrenal gland during foetal development 
About one month post conceptionem (pc), the human adrenal gland can be 
morphologically distinguished from the surrounding tissue and starts to express 
steroidogenic enzymes at 50-52 days pc (dpc)  (Val et al., 2006; Goto et al., 2006; 
Val and Swain, 2010). At 8 weeks pc (wpc) cortisol is produced in human foetal 
primary cultures, which are also responsive to ACTH and forskolin stimulation (Goto 
et al., 2006). The micro-architecture of the foetal adrenal cortex, however, is different 
from the postnatal situation, as only two layers are present before birth: an outer 
‘definite zone’ (DZ) and an inner larger ‘foetal zone’ (FZ), which comprises about 
75% of the entire foetal cortex of the organ (Mesiano and Jaffe, 1997). Steroidogenic 
enzymes able to synthesize cortisol de novo from cholesterol are expressed in the 
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FZ from 50-52 dpc onwards. The expression of HSD3B2 within the FZ is weak and 
decreases during further development; this is accompanied by an increased activity 
of CYP17A1 17,20 lyase, which makes the large FZ capable of producing large 
amounts of androgens (Goto et al., 2006). As SULT2A1 is strongly active in the FZ, 
DHEAS is the main product of the foetal adrenal gland (Miller and Auchus, 2011). 
Foetal DHEAS requires cleavage of the sulfate moiety to be further processed into 
sex steroids; the abundant expression of STS in the placenta therefore regenerates 
DHEA from circulatory DHEAS. Through the actions of placental STS, HSD17B1, 
HSD3B1 and CYP19A1, the placenta produces large amounts of oestrogens. As the 
placenta does not express CYP17A1, it itself is not able to produce androgens and 
relies on the foetal adrenal to generate oestrogens. Therefore, as both organs are 
linked to a common task – creating the oestrogenic environment of pregnancy – they 
are functionally connected to build the so-called ‘foetal-placental unit’. 
The exact role of oestrogens during pregnancy is unclear. Foetuses with inborn 
errors in androgen or oestrogen biosynthesis develop normally until term and 
abnormal parturition has not been reported. 
1.2.2. Sex determination and differentiation 
During foetal development, androgens play a central role in the development of 
male external genitalia. This second phase of male sexual development is called sex 
differentiation and is mechanistically distinct from the initial phase of sexual 
determination, which is mainly regulated by transcription factors and signalling 
molecules other than steroids. 
Genetically male (46,XY) and female (46,XX) foetuses do not differ 
morphologically until about 6 weeks post conceptionem (wpc), when sexual 
dimorphism occurs due to the differentiation of the bipotential gonadal anlage into 
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either testes or ovaries. In 1990, a gene on the Y-chromosome was identified as 
being responsible for the initiation of male sex determination, and called ‘sex-
determining region of the Y-chromosome’ (SRY) (Berta et al., 1990; Sinclair et al., 
1990). Since the discovery of SRY, numerous rodent and human studies have 
unravelled complex developmental pathways that mediate the determination of the 
gonadal phenotype in mammals, with the majority of these genes being discovered 
because of genetic abnormalities found in patients with disordered sexual 
development (DSD); see (Eggers and Sinclair, 2012) for an extensive review. In brief, 
the presence of SRY, which is expressed in the bipotential gonad, initiates the 
expression of the transcription factor SOX9, which stimulates in turn FGF9; both 
SOX9 and FGF9 suppress WNT4 and establish a testis-specific pathway. In ovarian 
development, WNT4 initiates canonical Wnt-signalling in the gonadal anlage, crucial 
for the establishment of the ovarian-specific pathway. 
Both mammalian steroidogenic tissues, the gonads and adrenals, are derived 
from a common embryological origin, the adreno-gonadal primordium (AGP). This 
has been suggested by histological studies as well as the detection of distinct 
steroidogenic enzymes (CYP11A1, HSD3B2, CYP19A1, CYP17A1) in both the 
gonadal and adrenal anlage during early mammalian development (Val et al., 2006; 
Val and Swain, 2010). Studies in mice implicate certain genes in the development of 
the AGP, and knock-out mice lacking these factors do not develop either gonads or 
adrenals. Steroidogenic factor-1 (SF1), a nuclear receptor from the subfamily 5 
(NR5A1), acts as a key regulator in steroidogenic cell-differentiation and function, 
with important implications for male sex differentiation (El-Khairi and Achermann, 
2012). SF1 knock-out mice are not able to maintain adrenal primordia and show a 
male-to-female sex reversal (Luo et al., 1994). Upstream of SF1, the Wilms’ tumour 
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gene 1 (WT1) has been implicated in murine SF1 transcription, modulating adrenal 
cortex differentiation (Val et al., 2007).  
In the course of male sex determination, the bipotential gonad develops into a 
testis consisting of functional Sertoli and Leydig cells. The Sertoli cells secrete the 
Muellerian inhibitory substance (MIS) at 8 wpc, inhibiting the development of the 
para-mesonephric ducts (‘Muellerian’ ducts) into uterus and vagina. At 9 wpc, 
testicular Leydig cells start to secrete testosterone (Siiteri and Wilson, 1974). 
Androgen actions are mediated by the androgen receptor (AR), which is expressed in 
the urogenital tract from 8 wpc. There are no differences in AR expression between 
male and female foetuses at this stage (Sajjad et al., 2004b; 2004a). AR activation by 
androgen action results in growth and differentiation of the male external genitalia 
and the prostate gland, respectively. From a stage of phenotypic ambiguity, 
androgens support the fusion of the two bilateral genital swellings, which forms the 
scrotum; in addition, the genital tubercle enlarges and forms the penis shaft (Werner 
et al., 2010). The critical developmental time window for the external male genitalia to 
masculinise opens between 8 and 10 wpc only  (Goto et al., 2006) (see Figure 11). 
 
Figure 11: External male genitalia at 8 wpc, showing an indifferent/ambiguous stage (panel A), which 
masculinizes under the influence of testicular androgens at 10 wpc (panel B). gs: genital swelling; uf: 
urethral fold; gt: genital tubercle. Asterisks indicate patency of the scrotal fusion. Bar: 500 µm. With 
kind permission from Goto et al., 2006. 
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1.2.3. Adrenarche 
Adrenarche refers to the developmental maturation of the adrenal gland, 
observed only in the human, chimpanzee, and gorilla (Dhom, 1973; Cutler et al., 
1978; Conley et al., 2012; Arlt et al., 2002). At adrenarche, the innermost layer of the 
human adrenal cortex, the ZR, starts to produce increasing amounts of DHEA and 
DHEAS (Rege and Rainey, 2012; Auchus and Rainey, 2004; de Peretti and Forest, 
1978; 1976). The term “adrenarche” was coined by Fuller Albright and Nathan Talbot 
in the 1940s when they linked the developmental rise in adrenal androgens to the 
appearance of pubertal and axillary hair, which they called “sexual hair” (Marshall 
and Tanner, 1969; Albright, 1947; Marshall and Tanner, 1970; Talbot et al., 1943).  
Adrenarche is a physiological mystery because it is not well understood how the 
development of the ZR is initiated or controlled [see (Arlt et al., 1999; Auchus and 
Rainey, 2004) for review] nor why adrenal androgens are significant for human pre-
pubertal development. Adrenal androgens contribute to changes in body composition 
and transient growth acceleration but without having a major impact on final height or 
subsequent developmental milestones like puberty. From the evolutionary 
perspective it has been suggested that adrenarche is a key component of ‘juvenility’, 
a period that emerges during evolution in the late Hominides and prolongs the 
transition from childhood to adolescence and adult life; juvenility may serve the 
adaptation of body composition and metabolic status to environmental conditions 
(Binder et al., 2009; Hochberg, 2010). Another interesting hypothesis refers to the 
neuro-modulatory effects of DHEAS that may help to protect more metabolically 
active regions of the cerebral cortex to support brain maturation in the developing 
pre-pubertal child (Remer et al., 2004; Campbell, 2011; Voutilainen et al., 1983; 
Sopher et al., 2011). 
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The postnatal reappearance and increase in circulating DHEAS has been 
traditionally perceived as a relatively sudden surge, physiologically occurring 
between six to eight years of age (Counts et al., 1987; de Peretti and Forest, 1976; 
Sklar et al., 1980; de Peretti and Forest, 1978). However, previous studies employing 
immunoassays for determination of serum DHEAS only identified increasing levels 
once they went above the lower limit of detection. In a recent study that applied 
highly sensitive steroid mass-spectrometry indicates that “biochemical” adrenarche 
starts with a detectable increase in DHEA and related androgenic steroids at about 
three years of age (Martin, 2004; Remer et al., 2005). In addition, histological studies 
in the 1970s from human adrenal samples taken throughout childhood, revealed that 
focal ZR cell islets are present from the age of three years onwards (Arlt, 2006; 
Dhom, 1973) (Figure 12).  
 
Figure 12: Schematic representing the morphological changes of the adrenal cortex with the rise of 
adrenal plasma androgens. DHEA and DHEAS slowly increase during mid-childhood, which correlates 
with the development of adrenal ZR cells present as focal islets in mid-childhood and then forming a 
continuous layer over a time span of several years until adolescence. Adapted from (de Peretti and 
Forest, 1976; 1978; Rege and Rainey, 2012).  
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These islets progressively form a continuous layer of ZR cells until early 
adolescence. These findings suggests that adrenarche, both as a biochemical and 
morphological phenomenon, is a long lasting developmental process rather than a 
sudden event. 
There are no sex-differences in androgen excretion in pre- and early-pubertal 
age groups (Remer et al., 2005) and consequently, these results may challenge the 
well-accepted cut-off for the definition of premature adrenarche including sex 
differences (age 8 in girls and 9 in boys), derived from Marshall and Tanner’s clinical 
observations that the appearance of pubic hair occurs about one year earlier in girls 
than in boys (Marshall and Tanner, 1969; 1970) (see section 1.3.2). The reason for 
earlier pubarche in girls might be that girls are more susceptible to peripheral 
androgen action and develop clinical signs earlier than boys.  
In normal development, the first appearance of pubic hair, i.e. pubarche, from 
the age of 8 years onwards is the direct result of the physiological rise in adrenal 
androgen production during adrenarche (Figure 12). DHEA is converted to active 
androgens in the gonads and peripheral target tissues of androgen action, including 
the skin, resulting in the development of pubic and also axillary hair. Women with 
acquired adrenal insufficiency without physiologic DHEA production suffer from a 
lack of axillary and pubic hair, which reappears after initiation of DHEA replacement 
therapy (Arlt et al., 1999). Physiologically, increasing androgen production during 
adrenarche manifests with distinct changes in body odour, oily skin and hair, followed 
by the first appearance of pubic and axillary hair. In addition, the rise in adrenal 
androgens can result in transient growth acceleration and contributes to bone 
maturation (Voutilainen et al., 1983; Remer et al., 2004). 
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 Generally, adrenarche appears to represent a developmental process 
independent of the maturation of the gonads (Sklar et al., 1980; Counts et al., 1987) 
Gonadarche, i.e. the onset of sex steroid production by the gonads, manifests with 
testicular enlargement and penile growth in boys and breast development and 
menarche in girls. Children with precocious puberty have no corresponding advance 
in the timing of adrenarche; their basal and ACTH-stimulated adrenal androgens are 
lower than in children matched for pubertal stage and only slightly higher than in age-
matched children (Wierman et al., 1986). Conversely, children with isolated 
hypogonadotropic hypogonadism and subsequent lack of spontaneous puberty were 
found to have no corresponding delay in adrenarche (Counts et al., 1987; Sklar et al., 
1980). 
1.3. ANDROGENS AND HUMAN DISEASE 
1.3.1. Monogenic causes of impaired androgen synthesis and metabolism 
Defects in steroidogenic enzymes and their co-factors can affect androgen 
production. These comprise a variety of disorders inherited in an autosomal-
recessive mode. 
 When androgen-generating enzymes or their co-factors are affected directly, 
androgen production is decreased. In contrast, disruptions in distinct pathways of 
steroidogenesis or metabolism may increase androgen generation due to 
compensatory regulatory mechanisms. 
Table 3 and Table 4 provide an overview of all known enzymatic defects of 
human steroidogenesis and co-factor mutations affecting steroid biosynthesis and 
metabolism, respectively. 
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Table 3: Overview and key clinical features of known steroidogenic disorders, where enzymes are 
affected directly. The (direct and indirect) effects on androgen metabolism are highlighted in bold. 
Gene  
(Defect) 
Key clinical features 
 
Affected 
reaction 
CYP11A1 
(CYP11A1 
deficiency) 
Sex steroid deficiency at birth (46,XY DSD) and GC 
deficiency. Only partially inactivating mutations (ie ‘non-
classical’ forms)  
Cholesterol ! 
Preg 
CYP11B1 
(11β-hydroxylase 
deficiency) 
Classical form: Isolated GC deficiency; ACTH-mediated 
androgen excess and accumulation of MC precursors. Non-
classical forms: partial GC deficiency, may presenting as 
androgen excess only. 
11-deoxycortisol 
! F 
CYP11B2  
(aldosterone 
synthase 
deficiencies) 
Isolated MC deficiency; may present at different ages with 
broad variety of symptoms.  
DOC ! B ! 
18OH-B ! Aldo 
CYP17A1 
(17α-hydroxylase 
deficiency) 
Classical form: GC and sex steroid deficiency and ACTH-
mediated MC excess. Spectrum of non-classical forms with 
predominant sex steroid deficiency and without/partial GC 
deficiency/MC excess reported. Rare: ‘isolated 17,20 lyase’ 
(= sex steroid) deficiency. 
17α-hydroxylase: 
Preg ! 17-Preg; 
Prog ! 17OHP 
17,20 lyase: 
17Preg ! DHEA 
(17OHP ! 
androstenedione) 
CYP21A2 
(21-hydroxylase 
deficiency) 
Classical form: Severe MC and GC deficiency (‘salt-wasting 
crisis’) with ACTH-mediated androgen excess (i.e. 46,XX 
DSD). ‘Simple-virilising’ forms: 46,XX DSD at birth without 
adrenal crisis. Non-classical forms: androgen excess and 
compensated GC deficiency. 
 
Prog ! DOC 
17OHP ! 11-
deoxycortisol  
CYP19A1 
(aromatase 
deficiency) 
Prenatal androgen excess due to decreased placental 
aromatisation (‘inactivation’) of foetal androgens: 46,XX DSD  
1) T ! E2 
2) A’dione! E1 
3) DHEA ! E3 
HSD3B2  
(3β-HSD type 2 
deficiency) 
Classical form: GC and MC deficiencies (salt-wasting crisis). 
Androgen excess as accumulating DHEA can be converted 
down-stream to active androgens by the HSD3B type 1 
isozyme. Non-classical form: androgen excess with 
compensated GC/MC deficiencies. 
Preg! Prog 
17Preg! 17OHP 
DHEA! A’dione 
SRD5A2  
(5α-reductase 
deficiency) 
Androgen deficiency at birth (46,XY DSD) T ! DHT 
HSD17B3 
(17β-HSD type 3 
deficiency) 
Androgen deficiency at birth (46,XY DSD) A’dione ! T 
HSD11B1 
(cortisone 
reductase 
deficiency) 
Various degrees of postnatal androgen excess, i.e. PCOS 
or premature adrenarche/pubarche. 
E ! F 
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Table 4: Overview and key clinical features of known co-factor deficiencies affecting human 
steroidogenesis and steroid metabolism. The (direct and indirect) effects on androgen metabolism are 
highlighted in bold. 
Gene (Defect) Key clinical features 
 
Affected 
reaction 
POR 
(P450 
oxidoreductase 
deficiency) 
Broad spectrum of GC deficiency. Postnatal sex steroid 
deficiency and prenatal androgen excess (DSD in both 
sexes).  
Supports all 
microsomal type 
2 CYPs 
(CYP17A1, 
21A2, 19A1) 
PAPSS2 
(apparent DHEA 
sulfotransferase 
deficiency) 
Androgen excess (premature adrenarche, PCOS-like 
phenotype) and bone malformations.  
Supports 
SULT2A1  
(DHEA ! 
DHEAS) 
H6PD 
(apparent 
cortisone 
reductase 
deficiency) 
Various degrees of androgen excess, i.e. PCOS or 
premature adrenarche/pubarche.  
Supports 
HSD11B1  
(E ! F) 
 
1.3.1.1. CYP17A1 17α-hydroxylase deficiency and isolated 17,20 lyase 
deficiency 
Inactivating mutations in the CYP17A1 gene cause 17α-hydroxylase deficiency 
(17OHD), an autosomal recessive disorder and a rare variant of CAH accounting for 
about 1% of all CAH cases (Krone and Arlt, 2009). More than 50 mutations have 
been identified so far and the vast majority of them cause impairment of both 17α-
hydroxylase and 17,20 lyase activities of CYP17A1 resulting in combined sex steroid 
and glucocorticoid deficiency (Geller et al., 1997; 1999; Miller and Auchus, 2011). 
The low glucocorticoid levels stimulate pituitary ACTH secretion resulting in adrenal 
hyperplasia with an excess of mineralocorticoid production and hypokalaemic, 
hyporeninaemic hypertension.  
A few mutations in CYP17A1 have been reported in patients who present 
without MC excess and with apparently normal GC production, indicating that the 
17α-hydroxylase activity is not impaired but only the 17,20 lyase activity is affected. 
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Hence, a selective decrease of sex steroid biosynthesis but normal GC and MC 
production is the clinical manifestation of this rare syndrome termed “isolated 17,20 
lyase deficiency” (Gupta et al., 2001). So far, there are about 25 cases of isolated 
17,20 lyase deficiency described in the literature (Yanase, 1995; Miller and Auchus, 
2011); however, in only four of them could inactivating mutations in the CYP17A1 
gene be identified as the cause of this condition (Miller and Auchus, 2011; Geller et 
al., 1997; Sherbet et al., 2003; Van Den Akker et al., 2002). Further functional 
characterizations of these mutations including in silico analysis on the protein model 
of CYP17A1 revealed novel insights into CYP17A1 function, in particular the 
regulation of 17,20 lyase activity (Geller et al., 1999): two of these mutations 
(p.R347H and p.R358Q) are located in the redox partner binding site of CYP17A1, 
that is crucial for the interaction with POR and CYB5A, and change electrostatic 
charge distribution disturbing sufficient electron flux to support 17,20 lyase activity. 
So far, only one missense mutation in the POR gene (p.G539R) has been reported to 
selectively disrupt CYP17A1 17,20 lyase activity in one family with several members 
affected (Hershkovitz et al., 2008). A CYB5A nonsense mutation resulting in early 
truncation of protein has been described in a patient with 46,XY DSD diagnosed with 
isolated 17,20 lyase deficiency (Kok et al., 2010). Hence, interaction of the three 
proteins CYP17A1, POR and CYB5A are essential for 17,20 lyase activity generating 
androgen precursors. It appears that the abundance of electrons sustained by co-
factor interaction is crucial to support CYP17A1 17,20 lyase over 17α-hydroxylase 
activity while inactivating mutations that disrupt the electron flux completely or 
interact with substrate binding, affect the efficacy of both catalytic activities (Auchus 
and Miller, 1999).  
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1.3.1.2. P450 oxidoreductase deficiency (apparent combined 21-
hydroxylase and 17-hydroxylase deficiencies) 
P450 oxidoreductase (POR) is the electron donor to all microsomal (type 2) 
CYPs, which play central roles in adrenal steroidogenesis, but are also involved in 
other metabolic processes, mainly hepatic drug metabolism (see section 1.1.3.2). 
Consequently, inactivating mutations in the POR gene, resulting in POR deficiency 
(PORD), is a multi-system disorder with manifold implications on human metabolism. 
The biochemical evidence for a syndrome with concomitant impairment of 21-
hydroxylase and 17-hydroxylase/17,20 lyase activities was initially reported in the 
1980s in patients with adrenal insufficiency and ambiguous genitalia (Peterson et al., 
1985; Augarten et al., 1992; Małunowicz et al., 1987); in addition, distinct bone 
malformations as part of the Antley-Bixler syndrome have been reported in some 
patients with a similar biochemical fingerprint  (Shackleton et al., 2004). 
In 2004, homozygous and compound heterozygous mutations in the POR gene 
were reported as the genetic basis of this syndrome (Flück et al., 2004; Arlt et al., 
2004). To date, more than 50 mutations of the POR gene have been reported in 
patients with PORD presenting with a variety of clinical and biochemical phenotypes 
(Huang et al., 2005; Fukami et al., 2006; 2009; Krone et al., 2012). 
The impact of mutant POR on human steroidogenesis, in particular apparent 
inhibition of 21-hydroxylation of GC and MC precursors by the enzyme CYP21A2, 
makes PORD a new and unique form of CAH. In contrast to 21-hydroxylase 
deficiency due to inactivating mutations in the CYP21A2 gene, the commonest form 
of CAH, the accumulating steroid precursors cannot drain downstream into the 
androgen pathway, as the catalytic activities of CYP17A1 are also impaired by 
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mutant POR. Thus, the combined apparent inhibition of these two enzymes affects 
MC and GC synthesis as well as androgen/sex steroid production.  
However, clinically apparent MC deficiency with abnormal electrolytes or 
hypotension has not yet been reported in PORD; in fact, evidence from urinary 
steroid profiling suggests that MC metabolites are indeed slightly elevated, most 
likely as a consequence of the accumulation of MC precursors due to impaired 17α-
hydroxylase activity (Krone et al., 2012). Circulating cortisol levels in PORD are often 
normal, but frequently fail to increase appropriately after ACTH stimulation, indicating 
partial adrenal insufficiency. In contrast, sex steroids are postnatally always low 
(Fukami et al., 2009; Homma et al., 2006; Krone et al., 2012), indicating that the 
17,20 lyase activity of CYP17A1 greatly depends on POR, which has also been 
consistently described by in vitro functional activity assays (Huang et al., 2005; 2008; 
Fluck et al., 2008; Dhir et al., 2007). 17OHP levels are increased and can be 
clinically used as a screening tool in suspected cases; importantly, they are not as 
high as in (classical) 21-hydroxylase deficiency (Krone et al., 2012). 
Disordered sex development (DSD) is a frequent finding in affected 46,XY 
males and can readily be explained as a consequence of prenatal androgen 
deficiency. However, 46,XX females can also present with ambiguous genitalia 
indicating prenatal androgen excess, similar to how 46,XX babies present in 
CYP21A2 deficiency. This puzzling and intriguing finding has been proposed to be 
caused by the presence of an alternative pathway towards androgen synthesis, that 
only exists prenatally and does not require testosterone as an intermediate step (Arlt 
et al., 2004). This pathway has been previously described in the tammar wallaby 
pouch young (Wilson, 2003) but its existence in the human foetus still needs to be 
conclusively proven. According to this hypothesis, 17OHP enters the alternative 
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pathway and is 5α-reduced to the intermediate 5α-pregnane-17α-ol-20-dione by the 
SRD5A1 isozyme. Further reduction at carbon 3 forms 5α-pregnane-17α-20-dione 
(also ‘5p-dione’), catalysed by HSD3As. Subsequently, 5p-dione serves as a 
substrate for the CYP17A1 17,20 lyase reaction (Figure 13) for the generation of 
androsterone. 17,20 lyase is also the key reaction to generate DHEA in the front door 
pathway (see section 1.1.8.1), and for both pathways, POR is required to deliver 
electrons from NADPH to CYP17A1 (see section 1.1.3.2); however, when 5p-diol 
(and not 17Preg) is the substrate for human CYP17A1, the catalytic efficiency is 
drastically increased and further increases 3-fold when CYB5A is added in vitro 
(Nebert and Russell, 2002; Gupta et al., 2003; Auchus, 2004). Androsterone is then 
further oxidized to androstanediol by HSD17B3 and finally its reduction at the A-ring 
via AKRCs yields DHT.  
The existence of an alternative, prenatally active androgen pathway in humans 
seems to be conclusive and explains the masculinization observed in female PORD 
foetuses. It also explains the frequent observation that pregnant mothers carrying 
affected children experience virilization during pregnancy as 5α-reduced androgens 
produced in excess via the alternative pathway cannot be inactivated by placental 
aromatase prior to entering the maternal blood stream.  
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Figure 13: Schematic illustration of the classical (front door) and suggested alternative (backdoor) 
pathway to dihydrotestosterone.  
 
Apart from abnormal steroid metabolism, the second striking and almost 
consisting finding in PORD is skeletal malformations. They are described as the 
Antley-Bixler syndrome (ABS) malformation phenotype, which can also be caused by 
mutations in the FGFR2 gene (OMIM 207410). Malformations in PORD patients 
comprise a wide spectrum including craniosynostosis, midface hypoplasia/proptosis 
with choanal stenosis, as well as limb deformities (femoral/radio/humeral bowing) 
and arachno- and camptodactyly. The underlying mechanisms of how POR is 
involved in skeletal development still remain to be fully elucidated; however, it has 
been thought that mutant POR disrupts the activity of enzymes involved in sterol 
metabolism (14α-sterol demethylase, CYP51A1; squalene epioxygenase) (Kelley et 
al., 2002). In addition CYP26 iso-enzymes, which are involved in retinoic acid 
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metabolism, also require POR-dependent electron transport (Schmidt et al., 2009). 
Lastly, impairment of heptic drug metabolism has been reported in patients with 
PORD, which is due to the effects of impaired liver CYPs involved in the 
detoxification of xenobiotics (Tomalik-Scharte et al., 2010). This includes a significant 
involvement in key drug-metabolising enzymes CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4, which metabolise more than 80% of known drugs and 
xenobiotics; some of them are also involved in the inactivation of steroid hormones 
(Nebert and Russell, 2002).   
 
Figure 14: Overview of the key metabolic pathways that are supported by POR in human physiology. 
With kind permission from (Tomalik-Scharte et al., 2010). 
The clinical presentation in PORD varies extensively with regards to GC 
deficiency, masculinization of 46,XX foetuses, maternal virilization and skeletal 
malformations (Fukami et al., 2009; Flück et al., 2004; Krone et al., 2012; Arlt et al., 
2004; Adachi et al., 2004). Genotype-phenotype analysis and in vitro functional 
studies revealed that distinct POR mutations act differently on certain CYP enzymes. 
For example, the most common mutation in the Caucasian population, p.A287P, 
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predominantly inhibits CYP17A1 but catalytic activities for CYP21A2 and CYP19A1 
are nearly fully retained (Dhir et al., 2007). In contrast, the global founder mutation 
most frequently found in the Asian population, p.R457H (Adachi et al., 2006), 
severely impairs CYP19A1 (Pandey et al., 2007) and CYP17A1 catalytic activities 
(Huang et al., 2005). Similarly, homozygous p.A287P has been consistently found in 
masculinized 46,XX females and is a predictor for moderate malformation severity; 
however, the overall genotype-phenotype prediction from larger cohorts is poor 
(Krone et al., 2012). 
1.3.1.3. CRD and ACRD (HSD11B1 and H6PDH deficiencies) 
The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is 
important for amplifying glucocorticoid signals in target tissues such as liver, adipose 
and muscle by interconverting cortisol and its metabolically inactive metabolite 
cortisone (see section 1.1.7.2). Within the endoplasmic reticulum, 11β-HSD1 oxo-
reductase activity, facilitating the regeneration of cortisol from cortisone, is dependent 
upon the maintenance of a high NADPH/NADP+ ratio and NADPH is supplied by the 
enzyme H6PDH (1.1.7.2). However, as the 11β-HSD1 enzyme is not directly affected 
the altered ER redox environment subsequent to loss of H6PDH function permits an 
increase in 11β-HSD1 dehydrogenase activity, resulting in increased inactivation of 
cortisol to cortisone. In H6PDH KO mice this leads to insensitivity to feedback 
suppression of the HPA axis and resultant ACTH-mediated adrenal hyperplasia and 
elevated circulating glucocorticoid levels.  
In humans, ‘apparent‘ cortisone reductase deficiency (ACRD) is characterized 
by decreased urinary excretion of cortisol metabolites and ACTH-driven adrenal 
androgen excess manifesting as premature adrenarche and PCOS (Draper et al., 
2003; Lavery et al., 2008; 2012). To date, approximately twelve cases have been 
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reported in the literature that have a biochemical and clinical presentation consistent 
with ACRD. In six of these cases, a complete clinical, biochemical and genetic work-
up has been published (Lavery et al., 2008; 2012). In all cases hyperandrogenaemia 
was confirmed with markedly elevated serum levels of DHEAS, androstenedione, 
and testosterone.  
Genetic analyses determined a normal sequence of the HSD11B1 gene in all 
affected individuals, but revealed inactivating mutations in the H6PD gene encoding 
H6PDH, including homozygous and compound heterozygous nonsense, missense 
and splicing mutations, which were all shown to disrupt enzymatic activity (Lavery et 
al., 2008; 2012). Thus, in ACRD, loss of H6PDH activity yields reduced 11β-HSD1 
oxo-reductase activity and a concurrent gain in 11β-HSD1 dehydrogenase activity, 
resulting in enhanced peripheral clearance of cortisol thereby reducing the negative 
feedback suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which in turn 
increases the ACTH drive and an ACTH-mediated increase in adrenal androgen 
secretion (see 1.1.7.2; Figure 6). 
In most cases serum cortisol levels were within the normal range, as might be 
expected due to the compensatory increase in HPA axis activity. However, the 
urinary levels of cortisone metabolites were grossly elevated in all affected 
individuals, resulting in characteristically decreased ratios of cortisol over cortisone 
metabolites (5αTHF+THF/THE and cortols/cortolones, see Figure 6).  
Only recently, heterozygous mutations of the HSD11B1 gene have been 
identified in two children presenting with milder forms of androgen excess (Lawson et 
al., 2011); these patients with ‘true’ cortisone reductase deficiency (CRD) showed a 
very similar biochemical fingerprint as the previous ACRD cases. 
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1.3.1.4. PAPSS2 and apparent DHEA sulfotransferase deficiency 
Noordam and co-workers have reported a case in point, a girl who presented 
with premature adrenarche manifesting with pubic hair development at the age of 6 
years (Noordam et al., 2009). She subsequently developed acne and hirsutism at 11 
years of age and secondary amenorrhoea at 13 years of age, i.e. a phenotype 
progressing from premature adrenarche to a presentation resembling PCOS. Lab 
investigations revealed increased serum androstenedione and mildly elevated 
testosterone, with her body weight progressing from overweight to the obese range. 
However, her serum DHEAS levels were undetectable throughout whereas serum 
DHEA was at the upper limit of normal, suggestive of impaired DHEA sulfation as the 
driver of androgen excess. Surprisingly, genetic analysis did not reveal any mutations 
in the SULT2A1 gene, which led to further exploration of mechanisms potentially 
impacting on DHEA sulfation. For catalytic activity SULT2A1 crucially depends on 
sulfate provision by the universal sulfate donor PAPS, which is generated by the two 
human isozymes PAPS synthase type 1 (PAPSS1) and type 2 (PAPSS2) (see 
section 1.1.9.1). Sequencing of the PAPSS2 gene in the index patient revealed 
compound heterozygous mutations: a nonsense mutation, R329X, resulting in early 
truncation of the PAPSS2 ATP sulfurylase subdomain, and a missense mutation, 
T48R, located in an area of the PAPSS2 APS kinase domain that is crucial for 
protein function. In vitro assays demonstrated complete disruption of DHEA sulfation 
by the R329X nonsense mutation while T48R maintained 5% residual activity 
(Noordam et al., 2009). Interestingly, the mother of the patient, who carried R329X 
on one allele, developed symptoms of PCOS including obesity, oligomenorrheoa and 
hirsutism at the age of 30 years, suggestive of a possible impact of milder genetic 
variation in PAPSS2 on presentation with androgen excess.  
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Of note, the patient also had short stature and showed mild signs of bone 
dysplasia that were not clinically apparent but revealed by x-ray. A severe bone 
phenotype [spondylometaphyseal dysplasia (SEMD)] has been previously reported to 
be linked with homozygous PAPSS2 mutations void of any catalytic function in a 
large consanguineous Pakistani kindred (Haque et al., 1998). An androgen 
phenotype was not reported but the researchers were only allowed to examine male 
family members and learned that affected female individuals suffered from infertility.  
These findings indicate that PAPSS2 deficiency has to be considered a multi-
system disorder, which in principle is not surprising, as sulfation is a major metabolic 
reaction occurring in multiple tissue types and organs such as liver, bone and 
cartilage and is also involved in other endocrine pathways such as neuropeptide, 
thyroid and catecholamine signalling (Strott, 2002). Importantly, PAPSS2 deficiency 
reveals DHEA sulfation as a major regulator of human androgen synthesis, with 
impaired sulfation of DHEA to DHEAS resulting in increased conversion of DHEA to 
active androgens and subsequent androgen excess, which manifests with premature 
adrenarche and PCOS.  
1.3.2. Premature adrenarche 
Premature adrenarche describes the precocious onset of adrenal androgen 
secretion, traditionally defined as occurring as early as 8 years in girls and 9 years in 
boys. It is important to note that premature adrenarche is not equivalent to premature 
pubarche, i.e. the early appearance of pubic hair only. Indeed, there is some 
inconsistency in the literature where premature pubarche is often used synonymously 
for premature adrenarche.  
A recently proposed definition of premature adrenarche is the concurrent 
presence of adrenal androgen levels increased above the age- and sex-specific 
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reference range and clinical signs of an increase in androgen action, such as adult-
type body odour, oily hair and skin and/or premature pubarche, occurring before the 
age of 8 years in girls and 9 years in boys (Utriainen et al., 2007) (Table 5). The 
definition of the exact age limits should take influences of ethnicity into account. Two 
studies in Caucasian populations found pubic hair Tanner stage 2 or above before 
the age of 8 years in girls in 0.6% and 0.8% of American and Lithuanian girls, 
respectively (Zukauskaite et al., 2005; Rosenfield et al., 2009).  By contrast, a five-
fold higher incidence of premature pubarche was reported in girls of Afro-American 
descent (Herman-Giddens et al., 1997). All these studies focused on the premature 
appearance of pubic hair only and did not report on the incidence of other signs of 
increased androgen action such as adult-type body odour or oily skin. Thus the 
overall incidence of premature adrenarche may well be higher. Generally, the 
reported prevalence of premature adrenarche is about 10-fold higher in girls than in 
boys (Rosenfield, 1994). 
Constitutional or idiopathic premature adrenarche (IPA) is most often observed, 
which is a diagnosis of exclusion. Distinct conditions manifesting with premature 
adrenarche include non-classic variants of CAH that have been diagnosed in 0-40% 
of children with premature pubarche (Utriainen et al., 2009; Armengaud et al., 2009; 
Dacou-Voutetakis and Dracopoulou, 1999; Temeck et al., 1987; del Balzo et al., 
1992; Balducci et al., 1994), depending on the pre-selection bias applied to the 
studied cohorts. Other causes potentially underlying a presentation with premature 
adrenarche are summarized in Table 5. 
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Table 5: Definition and differential diagnosis of disorders presenting with childhood androgen excess.  
Definition Causes 
Premature adrenarche = 
 
Increased adrenal androgen secretion 
above the age- and sex-specific normal 
reference range before the age of 8 years 
in girls and 9 years in boys  (= premature 
biochemical adrenarche) 
 
AND 
 
Clinical signs of androgen action before 
the age of 8 years in girls and 9 years in 
boys including 
- adult-type body odour 
- oily hair and skin, acne 
- pubic hair (= premature pubarche), 
axillary hair 
 
AND 
 
No signs of pubertal development            
(i.e. no development of secondary sexual 
characteristics including breast 
development in girls or testicular/penile 
growth in boys) 
 
Most frequent:  
 
Idiopathic (constitutional) premature adrenarche  
 
Rare: 
Defects in steroid synthesis, metabolism or action: 
Congenital adrenal hyperplasia 
- 21-hydroxylase deficiency 
- 11β-hydroxylase deficiency 
- 3β-hydroxysteroid dehydrogenase deficiency  
 
- Cushing’s disease 
- Glucocorticoid resistance  
- (Apparent) Cortisone reductase deficiency  
- Apparent DHEA sulfotransferase (PAPSS2) deficiency  
 
Other: 
- Virilizing tumours originating from adrenals or gonad 
- Exogenous testosterone treatment  
Precocious pseudo-puberty = 
 
Development of secondary sexual 
characteristics (penile growth, breast 
development, menarche) before the age of 
8 years in girls or 9 years in boys 
 
AND 
 
Low gonadotrophins before and after 
GnRH stimulation 
 
GnRH-independent; usually non-harmonic 
chronology of sexual characteristics, e.g.   
lack of bilateral testicular enlargement in 
boys (exceptions: gonadal tumours, 
familial testotoxicosis) 
 
also termed peripheral precocious puberty 
 
Rare: 
 
Defects in steroid synthesis, metabolism or action: 
Congenital adrenal hyperplasia 
- 21-hydroxylase deficiency 
- 11β-hydroxylase deficiency 
 
Other: 
- Virilizing tumours originating from adrenals or gonads  
- Exogenous sex steroid treatment 
 
- LH- or HCG-driven stimulation of adrenal androgen 
production due to 
- β-HCG-secreting tumours  
- Familial testotoxicosis (due to activating LH receptor 
(LH/CGR) mutations) 
- McCune-Albright-syndrome (due to activating Gsα 
protein (GNAS1) mutations) 
Precocious puberty = 
 
Development of secondary sexual 
characteristics (testicular/penile growth, 
breast development, menarche) before the 
age of 8 years in girls or 9 years in boys 
 
AND 
 
Increase in gonadotrophins after GnRH 
stimulation 
GnRH-dependent; usually harmonic 
chronology of sexual characteristics, e.g. 
bilaterally enlarged testicular volume in 
boys 
Most frequent: 
 
 Idiopathic (constitutional) precocious puberty  
 
Rare:  
- Central nervous system lesions, e.g. glioma, 
astrocytoma, hypothalamic hamartoma, arachnoid 
cysts 
- post-infectious (e.g. meningitis, encephalitis) 
- post-traumatic 
- Hypothyroidism 
- activating mutations in the genes encoding kisspeptin1 
(KISS1) and its receptor KISS1R (GPR54)  
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If in addition to the clinical signs and symptoms associated with premature 
adrenarche, progressive signs of pubertal development are present, such as breast 
development or menarche in girls and penile or testicular growth in boys, a diagnosis 
of precocious puberty or precocious pseudo-puberty has to be considered (Table 5). 
The clinical picture of these two distinct conditions is relatively similar. However, they 
can be distinguished by analysing the gonadotrophin response to GnRH stimulation. 
Accordingly, in precocious pseudo-puberty the gonadotrophins are low and remain 
low after GnRH stimulation. The condition is rare and most of the identified cases in 
boys are due to simple virilizing and non-classic CAH variants. In CAH, transition 
from precocious pseudo-puberty to secondary central precocious puberty has been 
observed and is thought to be due to the induction of the GnRH pulse generator by 
persistently increased sex steroids (Pescovitz et al., 1984).  
1.3.2.1. Metabolic risk in premature adrenarche  
Traditionally, idiopathic premature adrenarche (IPA) has been considered to be 
an extreme variation of normal (Silverman et al., 1952; Voutilainen et al., 1983; 
Ibanez et al., 1992). However, a series of studies in children with early onset 
androgen excess provide increasing evidence for the notion that IPA in girls may 
precede the development of the polycystic ovary syndrome (PCOS). PCOS 
manifesting during adolescence or early adulthood carries a significantly increased 
risk of developing the metabolic syndrome (Rosenfield, 2007; Ibáñez et al., 2000; 
2009; Ehrmann, 2005) and represents the leading cause of female infertility (Ibanez 
et al., 1993; Ibáñez et al., 1999; Asuncion et al., 2000). IPA and adolescent PCOS 
are linked by two similarities, early onset androgen excess and an increased 
prevalence of insulin resistance.  
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The first evidence for a link between premature androgen excess and metabolic 
syndrome emerged in 1995 from a study in American-Hispanic girls who presented 
with premature pubarche and evidence of insulin resistance (Oppenheimer et al., 
1995). Later on, Ibanez and co-workers published a series of case-control studies in 
lean Spanish (Catalonian) girls with a history of premature pubarche (PP) that 
showed evidence of insulin resistance based both on fasting insulin levels and the 
insulin response to a standard oral glucose tolerance test (oGTT) (Ibanez et al., 
1996; Ibáñez et al., 1997; 1998; 2002; Potau et al., 2003). In PP girls from North 
America, an inverse correlation between insulin sensitivity and ACTH-stimulated Δ5-
androgen precursors (17-hydroxypregnenolone, DHEA) has been found, however, 
the study population was not BMI matched (Vuguin et al., 1999). Overall, impaired 
insulin sensitivity is a consistent finding in the majority of studies. However, an 
association of PA/PP with dyslipidaemia, PCOS and neonatal growth restriction is a 
matter controversy with reported as an inconsistent finding in various study cohorts  
[see (Idkowiak et al., 2011) for an extensive review]. 
In conclusion, more research and in particular well-controlled longitudinal 
studies are required to confidently correlate early-onset androgen excess with 
metabolic risk in later life.  
1.4. AIMS AND HYPOTHESES 
The aim of this thesis is to investigate the role and the regulation of androgen 
producing enzymes of the adrenal gland in human disease states characterized by 
androgen deficiency or androgen excess. Of particular interest in this work are co-
factors or co-enzymes supporting steroid modifying enzymes, like P450 
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oxidoreductase, cytochrome b5 and PAPS synthases (see chapters 1.1.3 and 
1.1.9.1).  
This will be examined in the first part of this thesis (chapter 3-6) by clinical, 
biochemical, genetic and in vitro experimental studies of individual children 
presenting with a distinct clinical phenotype. In all studies, we will explore ex vivo 
steroid mass-spectrometry techniques to elucidate underlying conditions and 
hypothesize that they provide powerful diagnostic tools to diagnose, and differentiate 
between, distinct steroidogenic defects and co-factor deficiencies.  
Secondly, in chapter 7 we will investigate in in vitro studies the regulation of 
DHEA sulfation by the two known PAPS synthase isoforms, PAPSS1 and PAPSS2. 
As only deficient PAPSS2 has been previously shown to cause androgen excess 
(Noordam et al., 2009), we addressed the question why ubiquitously expressed 
PAPSS1 can not compensate for defect PAPSS2. We hypothesize that a different 
pattern of subcellular localization of the two isoforms explains the observed 
superiority of PAPSS2 in the context of DHEA sulfation. 
In chapter 8 of this thesis, we will further investigate the concept of DHEA 
sulfation in pre-receptor androgen metabolism. We have conducted a clinical study in 
boys and young men with a genetic defect in the steroid sulfatase (STS) enzyme. 
STS counteracts DHEA sulfation and thus works in the opposite direction of DHEA 
sulfotransferase and PAPS synthases. The aim of this study is to explore androgen 
metabolism in these individuals and we hypothesize, in line with previous 
observations (Hammer, 2005), that STS does not play a major role in the regulation 
of active androgen levels. Ultimately, we anticipate gaining a deeper understanding 
of the physiological role of STS during childhood adrenarche. 
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2. CHAPTER 2: GENERAL METHODS 
2.1. CELL CULTURE TECHNIQUES 
2.1.1. Human embryonic kidney (HEK) 293 cells  
HEK293 cells are derived from human embryonic kidneys extracted from an 
aborted foetus in the 1970s and generated by transformation with adenovirus 5 DNA 
(Graham et al., 1977). The cells were purchased from the American Type Culture 
Collection (ATCC). HEK293 cells were propagated in Minimal Essential Medium 
(Sigma, Pool, UK) supplemented with 10% foetal calf serum (FCS) (PAA, Etobicoke, 
Canada). To avoid bacterial contamination 1% penicillin/streptomycin was added to 
the medium (PAA, Etobicoke, Canada). The medium was replaced every two to three 
days and cells were passaged when reached they 90 and 100% confluence. The 
cells were discarded after reaching passage numbers more than P20. 
2.1.2. COS7 cells 
COS cells are derived from renal tissue of an African Green Monkey 
(Cercopithecus aethiops) and are fibroblast-like cells in nature. They were 
immortalized following transformation with an SV40 virus expressing the WT virus T-
antigen. Cells were available in the lab from internal collaborators and propagated in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% foetal calf 
serum and 1% penicillin/streptomycin (all: PAA, Etobicoke, Canada). The medium 
was replaced every two to three days and cells were passaged when they reached 
90 and 100% confluence. The cells were discarded after reaching passage numbers 
more than P30. 
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2.1.3. NCI-H295R cells  
The NCI-H295 cell lines were derived in 1980 from a 48-year old female patient 
with an adrenal cortical carcinoma (Gazdar et al., 1990; Rainey et al., 2004). After 
changing growth conditions with alternative serum supplements, a substrain was 
developed (NCI-H295R) growing in adherent monolayer with a population doubling 
time reduced from five to two days; different substrains were generated and 
biochemically as well as enzymatically characterized (Rainey et al., 2004). For this 
work, the NCI-H295R1 substrain was used for siRNA knock-down and 
immunofluorescence studies, as it grows conveniently in monolayers and optimised 
transfection protocols were available. The R3 substrain, which has zona reticularis-
like characteristics and grows in cell lumps, was used for fractionation studies only. 
The cells were obtained from Prof W. Rainey (Ann Arbor, Michigan, USA). The cells 
were propagated in Dulbecco’s Modified Eagle’s Medium/ Ham’s F12 medium (1:1) 
supplemented with 2% Nu-Serum, 1% ITS plus (both Collaborative Biomedical 
Products, Bedford, MA, USA), 1% penicillin/streptomycin and 0.01% gentamicin 
(both Invitrogen, Carlsbad, USA). The medium was replaced every two to three days 
and cells were passaged after growing more than 90% confluent. Only cells with a 
low passage number (P6-12) were used for experiments.  
2.1.4. Transient transfections of plasmid DNA into mammalian cells  
Transfections for enzymatic activity assays and immunofluorescence studies 
were carried out in 6-well plates (Greiner Bio-One, Stonehouse, UK). 24 hours before 
transfection cells were seeded at the appropriate concentration (cells/well as 
determined in pilot experiments; see Table 6) to reach 70-90% confluency for assays 
(10-20% for IF studies allowing the observation of single cells) prior to transfection. 
Cells were transiently transfected with 2 µg of plasmid DNA and XtremeGene HP® 
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transfection reagent (for each cell-type, an optimal amount of transfection reagent [µl] 
has been determined in preliminary experiments to reach a transfection efficiency of 
60-90%; see Table 6). The manufacturer’s protocol was followed meticulously. 
Table 6: Optimised conditions for transient transfections according to the different cell-types used for 
this work. IF: immunofluorescence. 
Cell line No. of cells to seed in a 6-well 
plate 24h prior to transfection 
Ratio transfection reagent 
(µl): plasmid DNA (µg) 
HEK 293 Assays: 75 x 104 2:2 
IF: 30 x 104 
COS7 Assays: 30 x 104 2:2 
IF: 10 x 104 
NCI-H293R Assays: 100 x 104 5:2 
IF: 20 x 104 
 
Prior to the experiment, the transfection reagent (kept at -20C) was transferred 
to room temperature, allowing equilibration to +15 C° - +25 C°. Per transfection, 2 µg 
of plasmid DNA (dissolved in ddH2O) was diluted into a total volume of 100 µl with 
serum-free cell culture medium in a 1.5 ml reaction tube. Then, the vial containing the 
transfection reagent was vortexed for 2-3 seconds at low force and the optimised 
amount (Table 6) was pipetted into the DNA containing tube, without touching the 
wall of the tube. The reaction was gently mixed and incubated for 15 minutes at RT. 
Medium from the cells was replaced with 2 ml of fresh, pre-warmed (37°C) full growth 
medium. Then, the transfection complex was added dropwise to the cells and 
subsequently the well was gently swirled for about 5 seconds for mixing. The 
expression optimum was usually between 36 and 50 hours post transfection. Cells 
were then processed as described in sections 7.2.5 and 2.5.3.4. 
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2.2. RNA AND DNA METHODS 
2.2.1. RNA extraction using TriReagent® 
For isolation of total RNA from cultured cells or tissues, TriReagent® (Sigma, 
Pool, UK) was used. The method is based on a protocol published by Chomczynski 
using the acid guanidinium thiocyanate following a phenol-chloroform extraction 
(Chomczynski and Sacchi, 1987). 
Usually, 1 ml of TriReagent® was added to one to three wells of confluent 
monolayer cells growing in six-well cell-culture plates (Greiner Bio-One, Stonehouse, 
UK). The cells were incubated for one to five minutes, which resulted in 
homogenization and lysis of the cells. Then, the homogenate was transferred into 1.5 
ml microcentrifuge tubes. Per 1 ml of TriReagent®, 0.2 ml of chloroform was added, 
mixed and incubated for 15 minutes at RT. During centrifugation (4°C; 12,000 g for 
10 minutes), the solution separated into 3 phases: an upper aqueous phase 
containing the RNA, a middle white-dense layer containing (genomic) DNA, and the 
bottom pink organic phase containing protein. The upper aqueous phase was 
carefully removed into a new tube and 0.5 ml of isopropanol was added to precipitate 
the RNA. After gentle mixing and 15 minutes incubation at RT, the solution was 
centrifuged (4°C, 15,000 g for 20 minutes) to form a solid, white pellet. The pellet was 
washed once in 70% ethanol and centrifuged again for 10 minutes (4°C for 10 
minutes). The supernatant was removed and the pellet was dried in air for not more 
than 15 minutes at RT. Finally, the pellet was resuspended in nuclease-free water, 
immediately processed (all steps on ice) or stored at -80°C. 
Prior to processing the RNA to cDNA synthesis, the integrity of the sample was 
checked by agarose gel electrophoresis containing 1:10,000 GelRed® staining for 
nucleic acids. Intact totalRNA samples should show clear bands for 18S and 28S 
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ribosomal bands after visualization under ultraviolet light, with the 28S ribosomal 
band being twice as intense as the 18S band.  
2.2.2. Quantification of RNA/DNA 
The concentration of the RNA and DNA was measured by spectrophotometry 
using a Nanodrop ND-1000 device (Thermo Scientific, Cheshire, UK). Nucleic acids 
absorb maximum light at 260 nm, which is the principle of this method to determine 
the optical density (OD) of a nucleic-acid containing solution. One OD260 unit is 
equivalent to 40 µg single stranded RNA (or 50 µg for double-stranded DNA). 
Simultaneous measurement at 280 nm indicates protein contamination of the 
sample. A ‘clean’ sample should have a 260/280 nm OD ratio between 1.8-2.0. 
2.2.3. Reverse transcriptase (RT) cDNA synthesis from RNA 
Reverse transcriptase (RT) is an enzyme derived from a recombinant Moloney 
murine leukaemia virus (rMoMuLV) that uses single stranded RNA as template in the 
presence of a primer to generate single stranded, complementary DNA (cDNA). As 
primers, hexamers were used that bind randomly to the RNA template. 
The kit MultiScribe™ Reverse Transcriptase (Life Technologies, Carlsbad, 
USA) was used for all RT reactions. 700 ng of total RNA (extracted as described 
under 2.2.1) was used as a template. In the presence of 5.5 mM MgCl2, 500 µM 
dNTPs (each), 2.5 µM random hexamers, 0.5 U/µl RNAse inhibitor and 3.125 U/µl 
RT, the RNA was incubated in the supplied reaction buffer in a final volume of 20 µl 
for 10 minutes at 25°C, with further incubation steps at 37°C (60 minutes) and 48°C 
for 30 minutes. Subsequently, the reaction was stopped and the enzyme denatured 
at 95°C for five minutes. Reactions were carried out in a thermal cycler 
(TProfessional Basic, Biometra, Goettingen, Germany). For further PCR analysis and 
processing, the reaction was 1:20 diluted with ddH2O. 
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2.2.4. Agarose gel electrophoresis 
PCR products, total RNA, but also plasmids and inserts following restriction 
digest for molecular cloning were analysed by agarose gel electrophoresis. 1% (w/v) 
SeaKam® agarose (Lonza, Amboise, France) was dissolved in Tris borate buffer 
(TBE; 89 mM Tris base, 89 mM boric acid, 2 mM EDTA). To dissolve the agarose, 
the solution needs to be heated until boiling in a microwave and gently stirred by 
shaking in a conical glass flask. Upon cooling down to 40-50°C, GelRed® Nucleic 
Acid Stain (Biotium, Hayward, CA, USA) solution was added in a 1:10,000 dilution 
and gently stirred until the dye dissolved in the liquid agarose. Then, the solution was 
poured into a gel cast and cooled down until solid. Nucleic acid solutions were loaded 
into the gel pockets in an appropriate amount (minimum estimated DNA amount: 100 
ng) and electrophoresis was carried out at 100-120V in TBE buffer for 60 minutes. As 
a loading control, HyperLadder I (Bioline, London, UK) was used. The bands were 
analysed under UV light and documented employing a gel doc system with digital 
camera (SynGene G:Box, Geneflow, UK).  
2.2.5. Ethanol precipitation of DNA 
DNA was precipitated in the presence of positive ions and abundance of 
ethanol. Generally, 1/10 volume of sodium acetate (NaAc; 3M, pH 5.2) was added to 
the DNA sample in a 1.5 ml reaction tube and gently mixed by pipetting up and down. 
Then, 3 x volume of at least 95% ethanol was added to the sample, thoroughly mixed 
and incubated for 15 minutes at RT. The DNA was pelleted by centrifugation for at 
least 30 minutes at > 14,000 g in a table-top centrifuge at 4°C (model 5451R; 
Eppendorf, Cambridge, UK). The supernatant was carefully removed with a pipette 
and then 70% ethanol was added and the tube briefly vortexed to wash the pellet. 
Following centrifugation at > 14,000 g for 10 minues, the ethanol was removed and 
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the pellet dried for 15-20 minutes at RT. Finally, the DNA was dissolved in nuclease-
free water. 
2.2.6. Extraction of DNA from agarose gels 
For DNA extraction from agarose gel, a kit (‘QIAquick gel extraction kit’) was 
used and the instructions from the protocol provided by the manufacturer were 
followed (Qiagen, Manchester, UK). After separation of the DNA by agarose gel 
electrophoresis (2.2.4), the bands were visualized under UV light and carefully 
isolated by using a fresh scalpel. The DNA/agarose fragments were transferred into 
reaction tubes and weighed. The agarose was dissolved in QG buffer at 50°C and 
subsequently loaded on a column provided with the kit. After centrifugation with a 
tabletop centrifuge (model 5451R; Eppendorf, Cambridge, UK) for one minute at 
13,000 g, the flow-through was discarded and the membrane washed by 
centrifugation with additional QG buffer to reduce agarose contamination. Then, the 
membrane was washed with PE buffer containing ethanol and completely dried by a 
final centrifugation step at full speed for one minute. Finally, to wash the DNA off the 
membrane, ddH2O or TE buffer (30-50 µl) was loaded on the membrane of the 
column, which was placed in a fresh reaction tube; after incubation for one minute, 
the column was centrifuged again at full speed for one minute and the DNA-
containing flow-through was used for subsequent experiments. 
2.2.7. Transformation of plasmids into bacteria 
A competent E.coli-based cell strain (K12 background) was used for chemical 
transformation of plasmid DNA (α-select; Bioline, London, UK). For routine sub-
cloning of plasmid DNA, bronze-efficient cells were used; for plasmid construction 
and cloning of limited amounts of plasmid DNA, gold-efficient cells were used. The 
plasmid DNA was pipetted into a pre-chilled (on ice) 1.5 ml reaction tube and the 
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bacteria, stored at -80°C, were gently thawed on ice for 10-15 minutes. Then, 20-50 
µl of bacteria where added to the DNA, gently mixed by pipetting 2-3 times up and 
down and subsequently incubated for 30 minutes on ice. Then, the bacteria were 
heat-shocked for 30 seconds at 42°C and then immediately transferred back to the 
ice. After 2 minutes incubation, the bacteria were suspended in 500 µl of LB-medium 
and incubated for 30 minutes at 37°C. Bacteria were then pelleted by gentle 
centrifugation (1,000 g for 1 minute), the supernatant was discarded and the bacteria 
dissolved in 50 µl of LB medium. With the use of a spreader, the bacteria were plated 
on pre-warmed (37°C) LB-agar plates containing the appropriate antibiotics. After 18-
24 hours incubation at 37°C, single colonies grew on the plates, which were picked 
for plasmid preparation and analysis (see next section). 
2.2.8. DNA plasmid purification from bacteria 
A kit was used for plasmid preparation from cultures of transformed DH5α E.coli 
strains (Qiagen, Manchester, UK). Depending on the amount of bacterial culture, the 
‘mini’ (up to 10 ml) or ‘midi’ (up to 150 ml) kit was used, and the instructions as stated 
in the manufacturer’s protocol were followed. The principle is based on a method for 
alkaline lysis of bacteria (Birnboim and Doly, 1979). Under alkaline conditions, the 
cytosolic plasmid is released (lysis) and following neutralization under high salt 
conditions, the DNA is selectively bound to a silica membrane, then washed and 
purified. 
All steps were carried out at RT using a tabletop centrifuge (model 5451R; 
Eppendorf, Cambridge, UK). Overnight cultures (5-10 ml) were pelleted at 5,000 g for 
10 minutes; the supernatant was discarded and the pellet re-dissolved in 250 µl 
buffer P1. Then, 250 µl NaOH-containing buffer P2 was added to initiate the cell 
lysis, and the tube was gently inverted 8-10 times to ensure homogenization of the 
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sample. Finally, 350 µl of neutralising buffer P3 was added, resulting in protein 
precipitation. The whole lysate was centrifuged at full speed (13,000 g for 10 
minutes) and the supernatant was carefully poured onto the columns containing the 
silica membrane. After centrifugation (full speed, 1 minute), the flow-through was 
discarded and the membrane was washed with 750 µl ethanol-containing PE buffer 
by centrifugation (1 minute, full-speed). Following removal of the flow-though, the 
column was centrifuged for another minute at full speed to remove residual buffer. 
Finally, 50 µl of ddH2O was added onto the membrane and incubated for one minute 
to elute the DNA. After centrifugation in a fresh reaction tube, the DNA content of the 
flow-through was quantified with spectrophotometry. 
2.2.9. Polymerase chain reaction (PCR) 
The PCR is a technique that amplifies DNA by using the enzyme DNA 
polymerase. Two pre-designed oligonucleotides (primers) anneal to distinct, 
complementary parts of the DNA, one at the 5’-position, the other one at the 3’-
position of the desired fragment to be amplified. Then, the polymerase, traditionally 
derived from thermus aquaticus, hence called Taq polymerase, extends the DNA 
downstream (5’!3’) from the primer, generating a new DNA strand. This strand 
serves as a template for the generation of further DNA strands in subsequent cycles 
of the reaction, yielding an exponential amplification of DNA fragments. 
The standard Taq polymerase was purchased from Bioline (London, UK); for 
PCR-based cloning, a mixture of two polymerases, Taq- and Tgo-polymerase, were 
used, as the latter one, derived from thermococcus gorgonarius, possesses a 
pronounced 3’!5’ exonuclease activity. This ‘proofreading’ ability of the enzyme 
reduces the error rate from 1.3 x 105 (Taq) to 4.9 x 107 (Tgo) resulting in a high 
fidelity of DNA synthesis (Keohavong and Thilly, 1989). The enzymes were 
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purchased from Roche as part of the Expand High Fidelity PCR System™ (Roche, 
Basel, Switzerland). 
All reactions were carried out in a 25 µl total reaction volume. The following 
components were added (final concentration): reaction buffer (1x), MgCl2 (1.5-4 mM), 
forward and reverse primer (0.4 µM), dNTPs (200 µM each) (Bioline, London, UK), 
DNA polymerase (0.05 U/µl), 10-15 ng of DNA template.  
Reactions were carried out in 200 µl reaction tubes (Sigma, Pool, UK) in a 
thermal cycler (TProfessional Basic gradient, Biometra, Goettingen, Germany). After 
one initial denaturation step (95°C, 5 minutes), 32-35 cycles followed with 1) 95°C for 
1 minute (denaturation), 2) 60°C for 30 seconds (primer annealing) and 3) 72°C 
between 30 seconds and 2 minutes (elongation). After the last cycle, a final 
elongation step of 5 minutes at 72°C was performed. The duration of cycle step 3) 
depends on the length of the DNA fragment to be amplified; it was calculated based 
on the capacity of the polymerase, which is about 1000 bp per minute. Fragments 
were analysed by agarose gel electrophoresis (2.2.4). 
2.2.10. Real-time quantitative (RTQ) PCR 
RTQ-PCR is an enhancement of the PCR and measures the amplification of 
DNA strands at each cycle, i.e. in real time. Essentially, it has the same components 
of a standard PCR; its principle relies on the 5’!3’-exonuclease activity of the 
polymerase and the presence of a 20-60 bp oligonucleotide probe that binds to the 
DNA template in-between the primer pairs. This probe has a fluorophore at its 5’ end 
and a quencher at its 3’ end, that silences the emission of fluorescence when both 
quencher and probe are in close proximity, as in intact oligonucleotides. During 
amplification, the probe binds to the synthesized DNA strands and gets degraded by 
the 5’!3’-exonuclease activity of the enzyme, which removes the quencher from the 
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fluorophore. Then, the probe is able to emit fluorescent light when excited and the 
amount of fluorescence detected in the sample directly correlates with the amplified 
DNA in the sample, but it also correlates to the amount of DNA template that was 
initially added into the PCR reaction.  
During the initial RTQ-PCR cycles, the DNA is amplified exponentially, until the 
amplification is saturated, mainly as a consequence of the consumption of the dNTPs 
or exhaustion of the enzyme. To compare the amount of DNA in a sample, a 
threshold needs to be determined when the DNA is amplified exponentially; the 
threshold allows the calculation of threshold cycles (Ct) for each target, which 
essentially correspond to the amount of template added to the sample or the mRNA-
expression in a sample, whose RNA was extracted and transcribed into cDNA by RT 
reaction. Importantly, the lower the Ct values are, the higher the gene of interest is 
expressed. To determine the relative expression of a gene, the Ct values of a 
constantly expressed housekeeping gene (i.e. 18S) can be subtracted from the gene-
specific Ct values; these resulting delta Ct (dCt) values correct for equal sample 
loading and were used for calculations. 
All assays (a pre-mix of gene-specific primers and probes) and the Taq 
polymerase mastermix were purchased from Applied Biosystems (Quarrington, UK). 
The RTQ-PCR reactions were carried out in a 7500 ABI qPCR machine (Applied 
Biosystems, Quarrington, UK) and the data were analysed with the product-specific 
software. The total reaction volume was 10 µl, consisting of 5 µl mastermix, 0.5 µl 
TaqMan gene expression assays and 4.5 µl of cDNA sample (see 2.2.3; 7.8 ng 
mRNA-equivalent cDNA). Reactions were carried out in duplicate and 18S was used 
as a housekeeping gene. All TaqMan assay probes were labelled with 6-
carboxyfluorescein (FAM), the 18S probe with the VIC® fluorophore. 
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2.2.11. Sequencing analysis 
DNA sequencing analysis was performed after obtaining informed consent and 
assent from patients and their parents with approval of the local institutional review 
board committees. 
After genomic DNA extraction from peripheral leukocytes utilizing a blood and 
cell culture DNA kit (Qiagen, Hilden, Germany), the mutation analysis was performed 
by PCR of the respective gene with primer pairs covering the whole coding region, 
including the intron-exon boundaries (Table 7). The PCR conditions are described in 
section 2.2.9. The PCR fragments were checked for integrity and correct size (Table 
7) by agarose gel electrophoresis (section 2.2.4) and subsequently purified with the 
QIAquick PCR purification kit, following the manufacturer’s protocol (Qiagen, Hilden, 
Germany). 5-10 ng of purified DNA template with 3.2 pmol of primer (the same as 
used for PCR amplification; see Table 7) was processed for electrophoresis on an 
automated ABI PRISM 310 Sequencer and analysed with the ABI SeqScape 1.1 
software (Applied Biosystems Inc., Weiterstadt, Germany). Sequencing analysis was 
performed using Lasergene® software (DNASTAR Inc., Madison, USA) and mutation 
numbering was carried out referring to the NCBI reference sequences: POR: 
NG_008930.1 (genomic) and NP_000932 (protein); CYP17A1: NG_007955.1 
(genomic) and NP_000093 (protein); CYB5A: NG_023211.1 (genomic), 
NP_683725.1 (protein). For DNA numbering, the nucleotide designated +1 was the A 
of the ATG start codon. 
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Table 7: Primer sequences, annealing temperatures (Tm) and expected fragment sizes following PCR 
amplification of the exons of CYP17A1, POR and CYB5A from genomic DNA.  
Name Sequence  
(5’-3’) 
Tm  
(C) 
Fragment size 
(bp) 
CYP17A1 
CY17A1 - 1F TCTAGGCTCAGAGAGAGGTG 65.1 650 
CY17A1 - 1R GGGCTCCAGGAGAATCTTTC 63.9 
CY17A1 - 2F GGTGTGAGATTCCTACGCC 61.1 676 
CY17A1 - 3R TCTACAGAACCTGAAGGCAG 57.8 
CY17A1 - 4F GGTGGAGTAGGAACTTCCAS 60.1 316 
CY17A1 - 4R TGTGCCAGGTTCTCTGCTT 66.6 
CY17A1 - 5F CCTGCCCAGACTTGCTCTAC 63.9 935 
CY17A1 - 6R CTGACTTTAGGTTGGCCAGCA 66.3 
CY17A1 - 7F AGCTGTTCAGACAGAAGCGC 64.6 1259 
CY17A1 - 8R GGCATTGCCACAAGCTGAAA 68.3 
POR 
POR - 1F AGT GAC CAT TTC CTG CAG 58.7 368 
POR - 1R ACT GCT TGG AGT GGT GAC AG 63.0 
POR - 2F ATG ACA CCT GCC TCC CAC 63.8 159 
POR - 2R GAC TTG ATT ACA TGC CCA TCG 64.1 
POR - 3F GTG GCT GAG GTC TGT GGC 64.9 241 
POR - 3R TAC AGA CCT GCT CCC TGT CC 64.3 
POR - 4F TTG AAC AGG CTC AGT CAT GG 63.9 236 
POR - 4R TGG AGT CCC CAG GGA GG 66.5 
POR - 5F CCA CTG GTC AGG TCG AGG 64.6 232 
POR - 5R CAC GGC CCC TGC CTA AG 66.8 
POR - 6F ACA GTC CTG AGC TTT GGG G 64.2 303 
POR - 6R CTT CTA ACC TTG CTG CGA CC 63.7 
POR - 7F TGT AGT CCA ACC CCT CCC TC 65.2 218 
POR - 7R AGT GGC CAT AGA GCC GTC TG 66.6 
POR - 8F GTG CTT TGT GCA ACC AGA AG 63.5 515 
POR - 9R GCC TAA GCA GAA GCT CAA CC 63.0 
POR - 10F GAG CAT AGG CCT TGT TTC CA 64.0 544 
POR - 11R CTT GCA CTC TGC CTG CTG T 64.6 
POR - 12F CTG CAG AAC GGG ACT TGG 64.6 649 
POR - 13R AAG GGT GGT GCT GTG AGG 63.9 
POR - 14F AGC AGT CCC ACA AGG TGA GA 64.9 583 
POR - 15R GGC TGA GGA GGA TGC AC 62.1 
CYB5A 
CYB5A - 1F GCTCTGCTCCACCCCGAC 65.0 246 
CYB5A - 1R CAGTGAACCCCCAAACCC 65.3 
CYB5A - 2F TGGTTAAATAAATTTCTGGCCG 62.4 276 
CYB5A - 2R GACTAGGGTAAGGTCATCTGATAGC 62.0 
CYB5A - 3F AAGTCAGCATTTTGGAAGTGG 62.9 175 
CYB5A - 3R CCCTCTGCCTTCAGTTTGAC 63.7 
CYB5A - 4F AAGTTCAGATTCCCTTGAAC 62.0 144 
CYB5A - 4R CAAACCTGGACCCATGACC 64.3 
CYB5A - 5F AGTCCACCACAGTGCACATC 63.9 199 
CYB5A - 5R GCAATGGCTTCTTTTCTCCC 64.3 
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2.3. PROTEIN METHODS 
2.3.1. Protein preparations 
Protein for Western blot analysis was either derived from whole cell lysates of 
mammalian adherent cell lines or from purified yeast microsomes (see sections 3.2.4 
and 6.2.6). 
Adherent cells were usually grown until confluency in 6-well plates; cells from 
one or two wells (combined) were used for protein extraction. All steps were 
performed on ice with PBS containing proteinase inhibitor (Complete™ Protease 
Inhibitor Cocktail, Roche, Basel, Switzerland). After washing (2x in PBS) the cells to 
reduce contamination with cell culture medium and serum, the adherent monolayer 
was gently detached with a scraper in 0.5 ml PBS/well and loose cells transferred 
into 1.5 ml reaction tubes. To release the protein and disrupt the cell membrane, the 
homogenate was sonicated (three times for 15 seconds, medium power) with a 
Bioruptor® Professional sonicator (Diagenode, Liege, Belgium). The cell lysate was 
subsequently centrifuged with a tabletop centrifuge (4°C) at 10,000 g for 10 minutes 
and the supernatant containing the protein transferred into a fresh reaction tube.   
2.3.2. Protein quantification 
Protein extracts were quantified with a colourimetric assay (Bio-Rad Protein 
Assay, Bio-Rad, Hemel Hempstead, UK), which is based on the Lowry method 
(Lowry et al., 1951). The reaction of the protein with 1) an alkaline copper tartrate 
solution and 2) folin reagent, which reduces the protein-copper complexes, results in 
a characteristic blue-coloured staining with maximum absorbance at 750 nm. The 
measurements were carried out on a 96-well microtiter plate. The protein 
concentration was derived from a standard curve, which was generated by a 
calibration series of known protein concentrations. 
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According to the manufacturer’s protocol, 5 µl of protein standard (0, 0.5, 1, 2, 
5, 8 and 10 mg/ml bovine serum albumin) or sample was added to each well (all 
reactions in duplicate). Then, 25 µl of solution A (containing Cu2+-tartrate) followed by 
200 µl Solution B (Folin reagent) were added to the protein sample. After 10-15 
minutes incubation, the absorbance was measured at OD690nm on a Victor3 1420 
multilabel counter (Perkin Elmer, Bucks, UK).  
2.3.3. Western blot 
Western blotting is a technique to semi-quantify protein, i.e. to measure the 
relative content of a distinct protein in a heterogeneous protein extract. After the 
separation of proteins according to their size by denaturing SDS polyacrylamide gel 
electrophoresis (PAGE), the proteins are transferred onto a membrane, which 
consisted of nitrocellulose in this thesis. To detect and visualize the protein, indirect 
immunostaining with a primary antibody, targeted against the protein of interest, and 
a secondary antibody, which is labelled with a dye or enzyme (horseradish 
peroxidase [HPE], in this thesis) is performed. Incubation of the membrane with 
chemiluminescent agents result in light generation by HPE, which can be recorded 
by photographic film. To compare the protein content between different samples, the 
membrane can be co-stained with an antibody against a housekeeping protein to 
demonstrate that the amount of protein loaded has been kept constant.  
Solutions for Western blot: 
• Loading buffer (4x): 50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% 14.7 
M β-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue.  
• Running buffer (20x): NuPAGE MOPS SDS (Invitrogen).  
• Transfer buffer (10x stock): 30.3 g Tris base, 144 g glycine in 1 litre of distilled 
water, adjusted using 5M HCL to pH 8.3.  
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• Transfer buffer (working solution): for 1 litre, 100 ml 10x stock solution + 200 
ml 100% methanol + 700 ml H2O  
• Washing solution: 0.1% Tween 20 (Sigma, Pool, UK) in PBS.  
• Blocking solution: 5% non-fat resuspended dried milk in washing  solution.  
All Western blot equipment was purchased from Invitrogen (Carlsbad, USA), 
unless stated otherwise.  
Between 10 – 20 µg of protein were loaded per lane on a pre-cast NuPAGE® 
10% SDS Bis-Tris gel and samples were run for 60 min at 200V in the XCell 
SureLock® Mini Cell Running Chamber in NuPAGE® MOPS running buffer. 
Subsequently, the protein-containing PAGE was transferred to a Hybond ECL 
nitrocellulose membrane (GE Healthcare), either immersed in transfer buffer at 30V 
for one hour in a transfer module, or by employing the iBLOT® DryBlotting system. To 
confirm the successful transfer of the protein, the nitrocellulose membrane was 
incubated with 1 ml of Ponceau S solution (Sigma, Pool, UK) for one minute at RT. 
Then, to block unspecific antigen binding, membranes were incubated with 10% 
(m/v) skimmed milk powder in phosphate-buffered saline containing 0.05% Tween 20 
(PBST) (Sigma, Pool, UK) for one hour at room temperature on an orbital shaker. 
Subsequently, membranes were incubated with a primary antibody (concentrations 
varied between 1:200 and 1:1000 in 10% milk/PBST) overnight at 4°C. After washing 
with PBST (3 times for 10 mins), membranes were incubated with an IgG antibody 
conjugated with horseradish peroxidase (1:1000 in 10% milk/PBST) targeted against 
the species of the primary antibody for about one hour at room temperature. After 
washing with PBST, the protein bands were briefly incubated in enhanced 
chemiluminescence reagent (ECL, GE Healthcare, Bucks, UK) and exposed to a 
photographic film (Perkin Elmer, Surrey, UK) in a dark room for 30 seconds to 1 hour. 
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Films were developed in a Compact X4 automatic film processor (Xograph Imaging 
Systems, Gloucestershire, UK). 
2.4. MOLECULAR CLONING AND SITE-DIRECTED MUTAGENESIS 
To assess steroidogenic enzyme activities, different in vitro systems have been 
used to express either wild type or mutant enzymes. The functionality of these 
proteins was investigated by steroid conversion assays (see section 2.5). 
In this work, human steroidogenic enzymes were either generated and 
subsequently isolated in baker’s yeast (saccharomyces cerevisiae) or expressed in 
mammalian non-steroidogenic cell lines.  
2.4.1. Expression vectors 
2.4.1.1. pDE2 and V10 yeast expression vectors 
For co-expression of POR with the respective CYP proteins (i.e. CYP21A1, 
CYP17A1 and CYP19A1) in saccharomyces cerevisiae, yeast expression vectors 
V10 and pDE2 (Hadfield et al., 1987; Pompon et al., 1996) containing the enzymes’ 
cDNA were employed [kindly donated by Prof Walter Miller (University of California, 
San Francisco, USA)].  
2.4.1.2. pcDNA™6/V5-6xHis mammalian expression vector 
The pcDNA™6/V5-6xHis expression vector was employed for cloning human 
CYP17A1 cDNA before subcloning the WT and mutant variants (generated by site-
directed mutagenesis) into the pIRES vector. The vector contains a V5-tag 
downstream of the multiple cloning sites, which is attached to the CYP17A1 cDNA 
during subcloning into pIRES in order to perform accurate Western blot analysis. 
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2.4.1.3. pIRES™ mammalian expression vector 
The mammalian expression vector pIRES (Clontech, Mountain View, USA) was 
used for in vitro functional assays in HEK293 cells. It contains two cloning sites (A + 
B) downstream of a single CMV promotor, which are separated by an internal 
ribosome entry site (IRES) sequence derived from the encephalomycarditis virus. 
The IRES cassette allows ribosomal binding and initiation of translation from an 
additional internal site of the mRNA, which is usually only permitted at its 5’-cap. 
Hence, it allows the translation of two open reading frames (ORFs) from one mRNA 
and consequently equal expression of two proteins of interest. 
The pIRES vector was employed to express a steroidogenic enzyme with a co-
factor, i.e. CYP17A1 and CYB5A (see chapters 5 and 6) and SULT2A1 with PAPS 
synthase isoforms (see section 7.2).  
2.4.2. Molecular cloning 
Molecular cloning in this context means the targeted insertion of the CDS of a 
distinct protein into an expression vector. This is facilitated by the use of restriction 
endonucleases. For most expression vectors, a designated ‘multiple cloning site’ 
(MCS) downstream of the promotor contains a variety of restriction sites for enzymes 
to cut. The CDS can be enzymatically ligated into the linearized vector at this site, if it 
contains the same nucleotide overhang(s) at its ends. If both vector and insert were 
digested with the same two enzymes, there is only one possible orientation of the 
insert/CDS (‘directional cloning’). 
2.4.2.1. Restriction digest 
Restriction endonucleases are usually enzymes derived from bacteria that 
recognize nucleotide motifs (restriction sites) within double-stranded DNA molecules 
and cut the DNA. They evolved as defence mechanisms to protect the cell from viral 
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DNA. Most enzymes cut the DNA at restriction sites (type I enzymes); others cut the 
DNA a short distance away from the respective nucleotide motif. Each enzyme has a 
specific restriction site and a specific way of cutting the DNA, creating either blunt or 
sticky ends (Figure 15). 
 
Figure 15: Two examples of restriction endonucleases. EcoRI (left) performs a sticky end digest and 
SmaI (right) a blunt end digest. The enzyme-specific recognized motifs are shown with the exact 
course of the cut indicated by the green line. 
 
The protocols for restriction digests are similar for different enzymes: a specific 
buffer assuring optimum activity for the enzyme is crucial. The amount of the enzyme 
added and the length of the incubation varied, depending on the particular 
circumstances like the type of enzyme, amount of DNA, single/multiple cutting. The 
enzymes are delivered in unit per volume. By definition, one unit is the amount of 
enzyme necessary to digest 1 µg of λ DNA at 25°C in one hour in a total reaction 
volume of 50 µl. Some enzymes exhibit unspecific digestion outside the restriction 
sites (“star activity”), which makes it necessary to restrict the incubation time to a 
minimum. Double digests of DNA simultaneously with two different enzymes are 
possible, if the enzymes work well in the same reaction buffer. 
For this work, all restriction enzymes were purchased from New England 
BioLabs (Ipswich, MA, USA).  
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For the digest of 1 µg of plasmid DNA with the restriction enzyme EcoRI (single 
cut), the following exemplary protocol has been used: 
 Reaction Buffer (10x)   5 µl 
 Template DNA (1 µg)   x µl 
 ddH2O      x µl to a final volume of 50 µl 
 then add EcoRI (20,000 units/ml)  1-2 µl 
Incubation for 60 minutes at 37°C, followed by heat inactivation of the enzyme 
for 5 minutes at 65°C. Subsequently, the digested DNA was analysed to check the 
completion of the digest by agarose gel electrophoresis (section 2.2.4) and then 
further processed for cloning after purification by ethanol precipitation (section 2.2.5). 
2.4.2.2. Cloning with T4 DNA ligase 
T4 DNA ligase is a bacteriophage-derived enzyme that catalyses the formation 
of phosphodiester linkages of adjacent nucleotides of double-stranded DNA 
molecules in an ATP-dependent fashion. The enzyme was purchased from Promega 
(Madison, USA).  
The DNA insert was PCR-amplified with special hybrid primers that contain the 
gene-specific sequence at their 3’-ends and the restriction sites required for ligation 
into the vector at their 5’-end. By using these primers during a standard PCR with 
High-Fidelity®Taq/Pfo polymerases (section 2.2.9) the generated DNA contained the 
restriction sites at both ends. Following separation by agarose gel electrophoresis 
(section 2.2.4) and extraction from the gel (section 2.2.6), the purified DNA was 
digested with the appropriate restriction enzymes (section 2.4.2.1). The purified and 
digested insert and vector DNA were quantified to calculate the amount of vector and 
insert for the ligation reaction.  
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Usually, a 3:1 molar ratio of insert:vector was used for all ligation reactions and 
the amounts of DNA calculated by using the following formula: 
!"!!"#$%&!!!!"!!"#$!!"!!!!!!"#$%&!"!!"#$!!"!!!!!!!"#$%& !!! !! != !"!!"!!"#$%&  
The standard protocol used to ligate a 1.5 kB insert into a 5 kB vector (50 ng) 
with a 3:1 molar ratio of vector to insert is as follows: 
 Ligase Buffer (10 x)    1 µl 
 Vector DNA (50 ng)    x µl 
 Insert DNA (75 ng)    x µl 
 T4 DNA Ligase (10 U)   1 µl     
 ddH2O      x µl to a final volume of 10 µl 
The mixture was incubated either in the fridge (4°C) overnight or at RT (20°C) for 4-6 
hours. The ligation reaction as a whole, without purification necessary, was 
transformed into DH5α bacteria as described in section 2.2.7. Single colonies were 
picked and grown in small scale to prepare plasmid DNA, which was analysed by 
either direct sequencing or restriction digest. 
2.4.2.3. Cloning with the In-Fusion™ kit 
In-Fusion™ (Clontech, Mountain View, USA) is a PCR-based cloning method 
that works without the use of the ligase enzyme and is useful to clone either multiple 
DNA-fragments into one single vector or to facilitate cloning that is difficult with the 
traditional ligase-based technique.  
First, PCR fragments are generated with gene-specific primers that have 15 bp 
extensions homologous to the ends of the linearized vector. The purified fragments 
are then fused into the vector by the In-Fusion™ enzyme that creates single-
stranded regions at the end of insert and vector. Finally, the generated constructs are 
transformed into bacteria for selected amplification.  
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The primer sequences were designed based on the manufacturer’s 
specification with the help of an online tool provided by Clontech 
(http://bioinfo.clontech.com/infusion/) and purchased from Sigma (Pool, UK). The 
PCR was performed under standard conditions with the High-Fidelity Taq/Pfo 
polymerase (see section 2.2.9). Plasmids were linearized by restriction digest 
(section 2.4.2.1), and both linearized plasmids and PCR products were run on an 
agarose gel (section 2.2.4), purified by extraction from the gel (section 2.2.6) and 
quantified (section 2.2.2). 
 
Figure 16: Overview of the In-Fusion™ cloning method (from the manufacturer’s protocol). 
For a standard cloning procedure with linearized vector and column-purified 
insert, the following reagents were combined in a 200 µl PCR-reaction tube: 
 Reaction Buffer (5x)    2 µl 
 Linearized Vector DNA (100 ng)  x µl 
 Insert DNA (50 ng)    x µl 
 In-Fusion™ Enzyme   1 µl     
 ddH2O      x µl to a final volume of 10 µl 
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Then, the mixture was incubated for 15 minutes at 37°C, followed by another 
incubation step for 15 minutes at 50°C. Then, the mixture was kept on ice and 
brought to a volume of 50 µl with TE-buffer (pH 8). 2.5 µl of this mixture were added 
to 50 µl of gold-efficient DH5α cells for transformation as described in section 2.2.7. 
Single colonies grown on LB-agar plates with an appropriate antibiotic drug were 
selected for restriction digest and subsequently Sanger sequenced to check the 
integrity of the insert and to exclude mutations caused by faulty amplification of the 
polymerase. 
2.4.3. Site-directed mutagenesis 
Site-directed mutagenesis (SDM) modifies expression vectors to change the 
structure of a protein and further investigate the relationship between 
structure/mutation and functional abilities of the protein. 
It is a PCR-based technique, where the entire vector DNA is amplified with 
primers introducing the desired mutation into the coding sequence of the protein. For 
all SDMs, the Quick-Change® II XL Site-Directed Mutagenesis kit was used (Agilent 
Technologies, Santa Clara, USA). The procedure is divided into three parts: 1) PCR 
amplification of the plasmid, 2) digestion of the plasmid template and 3) 
transformation of the modified plasmid into bacteria. 
The primers were designed based on guidelines provided in the manufacturer’s 
protocol: the desired length for the mutagenic oligos is 25-45 base pairs with a 
melting temperature (Tm) > 75°C. The following formula has been used to calculate 
the Tm of the primers: 
 Tm = 81.5 + 0.41(%GC) – 675/(number of nucleotides)  – % mismatch  
The desired mutation should be in the middle of the oligos, with equal amounts of 
nucleotides (10-15) on both sides; the GC content should be between 40% and 60%. 
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 The digest of the parental template plasmid was performed with the 
endonuclease Dpn I (target sequence: 5’-Gm6ATC-3’), which selectively digests 
methylated and hemi-methylated DNA, thereby selectively targeting the bacterial-
derived template but not the PCR-amplified plasmid DNA. 
The following components have been added into a 200 µl PCR-tube: 
 Reaction Buffer (10 x)   5 µl 
 Template DNA (10 ng)   x µl 
 Oligo Primer 1 (125 ng)   x µl 
 Oligo Primer 2 (125 ng)   x µl 
 dNTP Mix     1 µl 
 QuickSolution    3 µl 
 ddH2O      x µl to a final volume of 50 µl 
 Then: PfuUltra HF DNA polymerase 1 µl  
The following settings were used for all SDMs in a GeneAmp 9700 thermal cycler 
(Applied Biosystems, Foster City, USA): 
Step Temperature Length Cycles 
1) 95°C 1 minute 1 cycle 
2) 95°C 50 seconds 
18 cycles  60°C 30 seconds 
 68°C 10 minutes 
3) 68°C 7 minutes 1 cycle 
After amplification, 1 µl (10 U/µl) of the Dpn I enzyme was added, gently mixed 
by pipetting up and down and then incubated for 60 minutes at 37°C to digest the 
non-mutated, supercoiled DNA. After digestion, the DNA was precipitated with 500 µl 
100% ethanol in a 1.5 ml reaction tube for 2 hours at -20°C. After centrifugation (60 
minutes, 13,200 g at 4°C in a 5415R Eppendorf centrifuge), the supernatant was 
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carefully removed and the pellet washed once in 70% ethanol. After a further 15 
minutes of centrifugation (same settings as above), the supernatant was removed 
and the pellet was dried at RT for 15 minutes. Finally, the dry pellet was re-
suspended in 10 µl of ddH2O.  
For the transformation, XL10-Gold ultracompetent cells were thawed on ice and 
an aliquot of 45 µl was transferred into a 1.5 ml reaction tube. 2 µl β-mercaptoethanol 
(provided with the cells) were added to the bacteria, gently swirled and incubated for 
10 minutes on ice (with intermittent swirling every 2 minutes). Then, the bacteria 
were added to the DNA, gently homogenized by swirling the tube and incubated on 
ice for 30 minutes. The plasmid DNA was transformed by heat-shocking the cells at 
42°C for 30 seconds, followed by 2 minutes incubation on ice. Then, 200 µl of LB 
medium was added and the bacteria were incubated for 30 minutes at 37°C. Finally, 
the bacteria were plated on LB-agar plates containing the appropriate antibiotic for 
selection and incubated overnight at 37°C until single colonies grew. 2-3 single 
colonies were picked, grown in 5 ml of LB medium (+ antibiotic) at 37°C, with 
shaking, overnight to prepare the plasmid DNA (see section 2.2.8). Finally, the whole 
coding sequence was analysed by direct sequencing (see 2.2.11). 
2.5. ENZYMATIC ACTIVITY ASSAYS 
2.5.1. Principle 
The catalytic enzyme activity of intact cells expressing steroidogenic enzymes 
(and co-factors, if necessary) or purified proteins can be assessed by incubating the 
cells/protein with steroid precursors and measuring the product generated after 
incubation. By correlating the amount of substrate to the amount of product, the 
activity of the enzyme can be determined. Steroids are extracted from the incubation 
medium by using an organic solvent.  
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In this thesis, two different methods were used to quantify substrate conversion 
rates: 1) indirect quantification of substrate conversion rates after co-incubation of 
radiolabelled substrates, followed by steroid separation by thin-layer chromatography 
(TLC) and quantification on a bioscanner; 2) direct quantification of steroids with 
liquid-chromatography/tandem mass-spectrometry (LC/MSMS). 
For TLC, the assay was performed in the presence of a known concentration of 
steroid substrate and a small molar quantity of tritiated (3H) steroid substrate. The 
radiolabelled steroid is converted to the respective product (in the same fashion as 
the nonlabelled steroid), and co-migrates in the optimised mobile phase during TLC.  
For the LC/MSMS method, the direct quantification of the substrates and 
precursors after extraction is employed to calculate subtrate conversion rates. The 
addition of non-radioactively labelled (deuterated) steroids prior to extraction, which 
usually run about two mass transitions behind the original compound, rectifies for 
loss of steroids during the extraction procedure. 
2.5.2. Calculation of steroid conversion and enzyme kinetics 
To calculate enzyme conversion rates following incubation and steroid 
extraction, the amount of steroid product and substrate can either be quantified as 
total counts with a radio-detector (TLC) or as total mass (LC/MSMS). Then, 
conversion rates can be deduced based on substrate concentration (µmol), protein 
content (µg/mg) and incubation time (h) as molar conversion per mg protein per hour. 
However, the optimised incubation time at a given substrate concentration and 
amount of protein has to be determined in pilot experiments in order to assess the 
enzyme’s linear phase. The linear phase is the initial period of an enzymatic reaction 
when it produces the product at a certain rate. When the reaction continues and 
substrate is consumed, this rate slows down. Therefore, to assess the activity of an 
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enzyme, assays were carried out during the initial step of the reaction, which is – by 
definition – up to 40% of substrate conversion.  
As steroidogenic P450 cytochrome enzymes perform single-substrate reactions, 
they follow the Michaelis-Menten kinetic model of enzymatic reactions. This model 
describes how the activities of distinct enzymes vary and is illustrated in Figure 17: 
with increasing amounts of substrate (x-axis) the reaction rate or velocity (v) of the 
enzyme increases (y-axis). This is a linear relationship at low substrate 
concentrations. However, at higher amounts of substrate the curve becomes 
asymptotic as the enzyme’s capacity to convert the substrate is saturated until its 
maximum velocity (Vmax) is reached. 
 
 Figure 17: Michaelis-Menten curve of a single-substrate reaction. 
The Michaelis-Menten constant Km is an experimentally derived number and 
defines the substrate concentration at which the enzyme operates at ½ Vmax. 
Michaelis-Menten curves, as shown in Figure 17, are calculated from experiments 
where the enzyme is incubated with different concentrations of substrate. The 
catalytic efficiency of the enzyme is defined as Vmax/Km and frequently used to 
compare the activity of a mutant protein to WT.  
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The linear (or double reciprocal) Lineweaver-Burk plot is commonly used to 
illustrate kinetic data (Figure 18). This plot is generated by taking the reciprocal of 
both axes from the Michaelis-Menten plot. Important information can be obtained 
directly from this graph, in particular when comparing enzyme activities (WT/mutant) 
in one plot: the gradient of the straight line reflects Km/Vmax and is steeper when the 
catalytic efficiency is reduced. The intercepts of the axes and the line reflect the 
reciprocals of Vmax (y-axis) and Km (x-axis). 
  
Figure 18: An example of a Lineweaver-Burk plot, the common way to illustrate kinetic data.  
For all kinetic experiments, the software ‘EnzFitter’ (BioSoft; version 2.0.9.1) 
was used to obtain fitted curves and kinetic parameters. 
2.5.3. Yeast activity assays 
Yeast cells (from baker’s yeast; saccharomyces cerevisae) are a robust 
eukaryotic system to yield large amounts of purified protein. They grow fast and are 
relatively simple to transform with expression vectors encoding human steroidogenic 
enzymes. Double-transformations are possible if the impact of mutant co-factor 
proteins on CYP enzymatic activities is assessed. 
For this work, the W303B wild type strain (JC 104, Matα/ leu+/his+ / trp 1-1/ ura 
3-1/ ade 2-1) was used to generate protein for assessing the catalytic activities of 
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three steroidogenic CYPs, i.e. CYP17A1, CYP21A2 and CYP19A1 in the presence of 
a mutant POR protein. The functional assays were performed with purified yeast 
microsomes employing TLC. 
2.5.3.1. General procedures for yeast 
Solutions: 
YPD medium (whole nutrient medium) 
For 500 ml: 
- 5 g yeast extract (Fisher Biotech) 
- 10 g peptone (Sigma, Pool, UK) 
- (10 g agar; 2% [Fisher Biotech]; for plates only) 
- 475 ml dH2O 
The solution was autoclaved and 25 ml glucose (Sigma, Pool, UK) 40% in ddH2O 
(sterile filtered) were added. 
SD medium (selective media for vector-transformed yeast) 
For 500 ml: 
- 0.85 g Yeast Nitrogen Base (YNB; Difco)       
- 2.5 g NH4SO4 (Sigma, Pool UK)     
- 470 ml dH2O     
- (for plates: 10 g agar; 2%) 
The solution was autoclaved and 25 ml glucose (Sigma, Pool, UK) 40% in ddH2O 
(sterile filtered) were added. Amino acids (final concentration: 20 mg/l) were added 
after cooling down to hand-warmth. 
Amino acids (all purchased from Sigma, Pool, UK) 
Stock solution: 2 g/l (200 mg/100 ml) in dH2O.  
All amino acid solutions have been sterile filtered; adenine to be kept at RT, 
tryptophan to be stored at 4°C (fridge) and light protected (wrapped with aluminium 
foil), Uracil to be kept at 4°C (fridge). 
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2.5.3.2. Transformation of yeast cells  
The W303B yeast strain was transformed by a lithium-acetate method (Delfino 
et al., 1998; Auchus et al., 1998). The selection process after transformation of the 
plasmid DNA is based on the ability of the successfully transformed yeast clones to 
produce essential amino acids. The W303B strain cannot produce the amino acids 
adenine, uracil and tryptophan (ade-/trp-/ura-). The yeast expression vectors 
containing the protein of interest also carry coding sequences generating essential 
amino acids and thus can serve as a selection tool when transformed cells are 
incubated in minimum selective medium.  
Solutions: (All reagents were purchased from Sigma [Pool, UK]) 
10 x Tris-EDTA (TE) stock 
(100 mM Tris, 10 mM EDTA) 
12.1 g Tris-base were dissolved in 400 ml of dH2O. 
Then, 1.68 g EDTA-disodium was added and adjusted 
to pH 7.5 by adding 1M HCL. Finally, dH2O was added 
to top up the final volume to 500 ml. 
1 x TE 
(100 mM Tris, 10 mM EDTA) 
For 10 ml, add 1ml of 10xTE and 9 ml of dH2O. 
Tris-EDTA (TE) /LiAc For 1 ml, add 100 µl of 1M LiAc, 100 µl 10xTE and 800 
µl of dH2O. 
PEG/LiAc For 1 ml, add 800 µl 50% PEG 3350, 100 µl 10xTE 
and 100 µl 1M LiAc. 
Sorbitol/TE For 10 ml, add 2.5 ml of 4M sorbitol, 1 ml 10xTE and 
6.5 ml dH2O. 
10-15 ml YPD medium was inoculated with a pipette tip of W303B yeast and left 
on the bench to grow at RT in a 50 ml tube with a loosened lid to assure oxygenation 
of the culture. After 2-3 days, a white-brown pellet of yeast cells formed at the bottom 
of the tube. The evening before transformation, a dilution series (1:1000; 1:1500; 
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1:2000) in YPD medium was prepared and left on the bench top overnight; the next 
morning, cultures were incubated at 30°C in an orbital incubator (220 rpm) for 3-5 
hours. To obtain yeast in the linear range of growth, ideal for transformation, the OD 
at 600 nm needed to be between 0.3 and 0.5. OD measurements were carried out 
with a Unicam Helios gamma photometer (Life Technologies, Carlsbad, USA). 1 ml 
of the optimum density yeast cultures were transferred into a 1.5 ml reaction tube 
and centrifuged at 12,000xg (RT) on a bench top centrifuge. Then, the supernatant 
was removed and the pellet carefully resuspended in 100 µl TE/LiAc. Then, 700 µl of 
freshly prepared PEG/LiAc was added to each transformation. Subsequently, 5 µl of 
herring sperm DNA (after denaturation at 95°C for 5 min) was added and the tube 
was inverted gently several times for homogenization. Finally, 1-2 µg of plasmid DNA 
(in less than 10 µl of total volume) was added and, again, the tube was gently 
inverted to assure distribution of the DNA within the mixture. After 30 minutes 
incubation at 30°C, the yeast was heat-shocked at 42°C for 15 minutes (waterbath). 
Then the transformed yeast cells were centrifuged for 5 mins (12,000xg), the 
supernatant removed and the pellet was resuspended in 200 µl Sorbitol/TE buffer by 
pipetting and vortexing (medium velocity). After another 5 mins centrifugation 
(12,000xg), the supernatant was removed and the pellet resuspended in 100 µl TE 
buffer by pipetting. Then, the yeast cells were immediately plated on appropriate 
selection plates and incubated at 30°C for 3-4 days until single colonies formed. 
For double transformation to yield microsomes containing the CYP proteins and 
the WT/mutant POR protein, W303B yeast cells were first transformed with the V10 
(ura+) plasmid containing the CDS of human CYP21A2, CYP17A1 and CYP19A1, 
respectively. Transformed yeast cells were plated on SD-Agar plates containing 20 
mg/l adenine and tryptophan. Selected yeast clones were subsequently grown in 
liquid SD (ade+/trp+) medium and the second transformation was performed with the 
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pYdE2 plasmid (trp+) containing the WT and mutant POR sequence, respectively. 
The selection was then carried out on SD (ade+) medium agar plates. Single 
colonies were then selected to grow in large scale cultures for microsome 
preparations. 
2.5.3.3. Microsome preparation 
Solutions: (All ingredients were purchased from Sigma [Pool, UK], unless stated 
otherwise.) 
Te-K 
(50 mM Tris pH 8.0, 1 mM 
EDTA, 0.1 mM KCl) 
 
For 100 ml, add 0.2 ml 0.5M EDTA (pH 8.0) to 5 ml 
TrisHCl, 3.3 ml 3M KCl and 91.5 ml dH2O 
TES-B 
(50 mM Tris pH8.0, 1 mM 
EDTA, 0.6 M sorbitol) 
 
For 100 ml, add 0.2 ml 0.5M EDTA (pH 8.0) to 5 ml 
TrisHCl, 15 ml 4M sorbitol and 80 ml dH2O 
TE-G 
(50 mM Tris pH 8.0, 1 mM 
EDTA, 20 % glycerol [v/v]) 
 
For 100 ml, add 0.2 ml 0.5M EDTA (pH 8.0) to 5 ml 
TrisHCl, 25 ml 80% glycerol and 70 ml dH2O 
 
Stock solutions: 
 
4M Sorbitol 54 g sorbitol in 75 ml dH2O, sterile filtered 
0.5M EDTA, pH 8.0 97.5 g EDTA-Na2 in 500 ml dH2O; adjust to pH 8.0 
with 1M NaOH 
1M Tris-base, pH 8.0 121 g Tris-base dissolved in 1l dH2O; adjust pH to 8.0 
with 1M HCl 
3M KCl 22.5 g KCl in 100 ml dH2O, autoclaved 
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Pre-cultures of transformed yeast clones were grown in 15 ml selective medium 
for 2-3 days. This assures viability of the cells, and allows the synchronization of the 
various clones (i.e. wild type/mutant protein).  
5 ml of the saturated pre-cultures were diluted in 300 ml selective SD medium 
and cultures were incubated in a large orbital incubator at 30°C for 15-20 hours to 
grow to a density of 1 or higher at OD600. Then, the saturated cultures were 
centrifuged 5 minutes at 6,000 rpm (Avanti J-20XP with a JLA 16.2500 rotor). The 
supernatant was subsequently discarded and the pellet resuspended in 5 ml TE-K 
buffer by carefully pipetting up and down. The solution was transferred to 50 ml 
reaction tubes with screwed lid, left at RT for 5 minutes and then spun down (5 mins 
at 4,000 g; BOSRAG64 rotor; Harrier 18/80 MSE centrifuge, Jepson Bolton, Watford, 
UK). The pellet was re-dissolved in 2 ml TES-B (containing proteinase inhibitor 
cocktail; one tablet in 15 ml [Roche, Basel, Switzerland]) and acid-washed glass-
beads (Sigma, Pool, UK) were added up to the top of the fluid level in a 50 ml 
reaction tube. All subsequent steps were performed on ice. For breaking-down the 
yeast cell membranes, the tubes were briskly shaken and vortexed at high speed. 
Seven cycles of one minute shaking (30 seconds shaking and 30 seconds vortexing) 
and 30 seconds incubation on ice were performed. Subsequently, the supernatant 
was transferred into 50 ml polycarbonate screw-top centrifuge tubes. The remaining 
glass beads were washed twice with 2 ml TES-B, which was also transferred and 
added to the centrifuge tubes. To separate the cell debris, the tubes were then 
centrifuged for 10 minutes at 9,000 RCF (4°C) in a Beckman J26XP centrifuge with a 
JA25.5 rotor (Beckman Coulter, High Wycombe, UK). Subsequently, the 
supernatants were transferred into polycarbonate ultracentrifuge tubes, placed into a 
perfectly balanced pre-chilled Ti-70 rotor of an LE-80K ultracentrifuge and spun down 
at 32,000 rpm (100,000 g) for 90 minutes at 4°C. After centrifugation the supernatant 
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was discarded and the pellet resuspended in 250/500 µl of TE-G. The pellet was first 
homogenized with 19G needles and then with 25G needles, using a 2 ml syringe. 
The protein content of the solution was measured with the BioRad method (section 
2.3.2); 10-20µl aliquots were made and immediately transferred to -80°C for storage. 
2.5.3.4. Activity assays 
Yeast microsomes stored at -80°C were gently thawed on ice and transferred 
into a 50 mM potassium phosphate reaction buffer (pH 7.4) [1M potassium 
phosphate stock solution = 80.2 ml 1M K2HPO4 + 19.8 ml 1M KH2PO4] in 13 x 100 
mm borosilicate glass tubes (Thermofisher, Loughborough, UK). The reaction volume 
was 196 µl, including steroid substrate at the appropriate concentration, tritiated 
steroid substrates (normally 3 µl of a 1:10 dilution from the stock) and CYB5A protein 
for CYP17A1 17,20 lyase reaction only. The reaction was initiated by adding 4 µl of 
100 mM NADPH. The enzymatic reaction was carried out at 37°C and was 
terminated by adding 5 ml of dichloromethane. Then, steroids were extracted as 
described in section 2.5.5. 
2.5.4. Activity assays in mammalian cells 
2.5.5. Steroid extraction 
A liquid-liquid extraction with the inorganic solvent dichloromethane (DCM) or 
methyl tert-butyl ether (MTBE) was used to release steroids from the reaction buffer 
and protein following steroid conversion assays. 5 ml of DCM (2 ml of MTBE) was 
added to the reaction buffer or cell culture supernatant in a 10 ml borosilicate glass 
tube (Appleton Woods, Birmingham, UK). The tubes were sealed with plastic caps 
and the tube was vortexed vigorously for 30 seconds at highest velocity. Then, the 
tubes were centrifuged at 500 g for 10 minutes. Buffer and protein form a thin layer 
on the top of the DCM solvent; this layer was carefully removed with glass pipettes 
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and the samples were evaporated for 30-40 minutes under constant airflow at 60°C. 
When MTBE extraction was performed, the buffer/protein layer was at the bottom of 
the tube, overlaid by the solvent. Here, the samples were frozen at -20°C for 60 
minutes. Then the MTBE supernatant was carefully transferred by pouring into a 
fresh glass tube and evaporated as above. 
2.5.6. Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) for separation of extracted steroids was 
performed on PE SIL G/UV silica gel plates (Whatman, Maidstone, UK). The steroids 
extracted as decribed in section 2.5.5 were eluted in 70 µl of DCM by vigorous 
vortexing for 15-30 seconds. The solvent was then transferred dropwise with a glass 
pipette onto points marked on the silica gel plate. For the separation of the steroids, 
the plate was vertically transferred with the steroids at its bottom, into a tank 
containing a mixture of anorganic solvents. The separation of the respective steroids 
depends on the assay and requires different conditions concerning the exact mixture 
of solvents and the running time. They are summarized in Table 8. 
Table 8: Overview of solvent systems for the separation of steroids by TLC. 
Steroid 
precursor 
Steroid 
product 
Enzyme activity Solvent Running 
time 
Prog 17OHP CYP17A1  
(17α-hydroxylase) 
3:1 chloroform/ethyl acetate 45 min 17 Preg DHEA CYP17A1  (17,20 lyase) 
Prog DOC CYP21A2 
(21-hydroxylase) 
A’dione E1 CYP19A1 
(aromatase) 
12:1 dichloromethane/acetone 45 min 
DHEA DHEAS SULT2A1 
(DHEA 
sulfotransferase) 
8:2:4:2:1 chloroform/methanol/acetone/ 
acetic acid/water 
120 min 
 
 Following separation, the plates were dried for 1-2 hours at room temperature 
and radio-counts were quantified with a Bioscan 2000 image analyzer (Lablogic, 
Sheffield, UK).  
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2.6. STEROID HORMONE MEASUREMENT BY RADIOIMMUNOASSAYS 
Most serum steroid hormone measurements of individual case reports in this 
thesis were performed by collaborators across the world (chapters 3, 4, 5 and 6). The 
steroid assays applied for the diagnostic work-up are radio-immunoassays (RIAs) 
and were performed in the routine hospital clinical chemistry department. These are 
all certified laboratories with approved age-specific reference ranges for each 
individual assays, which are stated in the respective chapters of this thesis. 
2.7. STEROID HORMONE MEASUREMENT BY STEROID MASS 
SPECTROMETRY 
2.7.1. Principles 
Mass spectrometry (MS) identifies and quantifies steroids in a sample according 
their mass-to-charge ratio (m/z). This requires a series of subsequent physical-
chemical steps: (1) ionization of the steroids molecules in a gaseous phase, (2) 
separation of the ionized molecules according to their m/z ratio and (3) detecting the 
ions and quantifying the relative abundance of each m/z ratio. These reactions are 
carried out within the three major components of a mass-spectrometer (see Figure 
19): The ionization source, the mass analyser and the detector. 
Prior to steroid detection and quantification by MS, steroids need to be 
extracted from the respective sample. As steroids are polar molecules, they move 
easily from an aqueous to an organic phase and liquid-liquid extractions with organic 
solvents is commonly applied for this purpose. Then, to allow the determination of 
several steroids in a single experiment, chromatography is usually coupled to MS 
analysis. In this thesis, either liquid chromatography (LC) or gas chromatography 
(GC) has been applied. Both methods have their own strengths and disadvantages 
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(see (Krone et al., 2010) for a recent and detailed review). LC/MS is suited for the 
rapid and highly sensitive analysis of individual steroids from a small sample volume. 
It therefore is considered as the gold standard for steroid measurements from serum, 
replacing conventional radioimmunoassays (RIAs), which are often unspecific due to 
cross-reactivity of the employed antibodies. 
 
Figure 19: Schematic illustration of the key procedures involved in steroid mass spectrometry 
analysis. The upper panel shows the technical components and the bottom panel illustrates the 
biochemical and physical processes occurring to a mixture of analytes carried out by these 
components: the different analytes (illustrated by grey symbols) are separated by chromatography 
(liquid: LC or gas: GC) before they enter the mass spectrometer (grey-shaded box). The ionization 
source produces gaseous ions of the molecules. Then, the analyser resolves the ions according to 
their mass-to-charge ratio (m/z). Finally, the detector counts the relative abundance of each ionic 
species. A computer ‘translates’ the detector signals into peaks and numbers. The three main steps of 
mass spectrometry analysis is under close control by computerised systems and are carried out under 
vacuum to avoid collisions of the ions with other molecules.  
LC/MS is always ‘targeted’, i.e. restricted to the detection of either single or a 
small panel of steroids. In contrast, GC/MS allows the detection of all steroid 
compounds within a sample and is often used to measure steroid hormone 
metabolites as well as their respective precursors. This technique is already available 
since the 1970s and is a powerful tool to explore new steroid ‘metabolomes’ as a 
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comprehensive run detects all steroids present in the sample. As a ‘scanned’ run 
including sample preparation takes a couple of days, the method is time-consuming 
(and expensive) compared to the fast, much cheaper high-throughput LC/MS 
approach. Therefore, GC/MS analysis has its role in research to explore novel steroid 
profiles while LC/MS is about to facilitate and maybe revolutionize steroid hormone 
analysis in the clinical setting (Krone et al., 2010). 
2.7.2. Urinary steroid profiling with gas-chromatography/mass-spectrometry 
(GC/MS) 
Analysis of urinary steroid metabolite excretion was performed by a quantitative 
GC/MS selected ion-monitoring method, that allows for selective identification and 
quantification of all major metabolites of androgens, glucocorticoids, 
mineralocorticoids and their respective precursors (Table 9, Figure 20). Steroids 
were enzymatically released from conjugation and, after extraction, chemically 
derivatized before GC/MS analysis (Shackleton, 2008): First, steroids were extracted 
from urine with a SepPak column (Waters, Milford, Ma, USA): 5 ml of urine sample 
were loaded after washing the columns with 4 ml methanol and 4 ml of ddH2O. Then, 
the loaded column was washed with 4 ml ddH2O and the steroids were eluded in 4 
ml methanol into a clean borosilicate tube. After evaporation (heat block at 55oC 
under N2), sulfate and glucoronide groups were enzymatically removed from 
conjugated steroids by incubating for 3 hours at 55oC in the hydrolysis buffer (3 ml 
0.1M acetate buffer [pH 4.8-5.0] + 10 mg ascorbate + 10 mg sulfatase/glucoronidase; 
all ingredients purchased from Sigma, Pool, UK). The cooled sample was then 
loaded again on a SepPak column and eluded into a clean glass tubes with 4 ml 
methanol. Derivatization: After evaporation, three drops of 2% methoxyamine-
pyridine was added; the tube was vortexed vigorously and incubated at 55oC for one 
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hour. After evaporation under N2, 75µl of N-trimethylsilylimidazole (Sigma, Pool, UK) 
were added, vortexed and incubated at 120oC overnight. Then, the samples were 
extracted by adding (1) 2 ml cyclohexane and (2) 2 ml dH2O (vortexing after each 
step). After centrifugation (1,000g for 5 minutes), the bottom later layer was removed 
into waste. Then, another 2 ml dH2O were added, vortexed, centrifuged and 
removed. Finally, the top layer containing the extracted steroids in cyclohexane was 
transferred into injection vials. The samples were then injected into an Agilent 5973 
GC mass-spectrometer. 
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Table 9: Overview of (urinary) steroid hormone metabolites with full names and abbreviations and the 
steroid hormone(s) they are derived from.  
Abbreviation Full name Metabolite of 
 
An Androsterone Androstenedione, testosterone, 5α-
dihydrotestosterone, DHEA 
Et Etiocholoanolone Testosterone, DHEA 
DHEA (and DHEAS) Dehydroepiandrosterone Dehydroepiandrosterone and -sulfate 
11β-OH-An 11β-Hydroxy-androsterone 11β-OH-androstenedione, cortisol 
11β-OH-Et 11β-Hydroxy-etiocholanolone Cortisol 
11-OXO-Et 11-Oxo-etiocholanolone Cortisol 
16α-DHEA 16α-Hydroxy-
dehydroepiandrosterone 
Dehydroepiandrosterone and -sulfate 
PD Pregnadienol Progesterone, 11-deoxy-corticosterone 
5PD Pregnadienol Pregnenolone 
Pregnadienol Pregnadienol Pregnenolone 
17HP 17-Hydroxy-pregnanolone 17-Hydroxy-progesterone 
3α-5α-17HP 3α5α-17-OH-pregnanolone 17-Hydroxy-progesterone and other fetal 
origin 
PT Pregnatrienol 17-Hydroxy-progesterone 
5PT 5-Pregnatrienol 17-Hydroxy-pregnenolone 
PTONE Pregnanetriolone 21-Deoxycortisol 
THDOC Tetrahydrodeoxycorticosterone 11-Deoxycorticosterone 
5αTHDOC 5α-Tetrahydro-
deoxycorticosterone 
11-Deoxycorticosterone 
THS Tetrahydro-11-deoxycortisol 11-Deoxycortisol 
THA Tetrahydro-11-
dehydrocorticosterone 
Corticosterone 
5αTHA 5α-Tetra-11-
dehydrocorticosterone 
Corticosterone 
THB Tetrahydrocorticosterone Corticosterone 
5αTHB 5α-Tetrahydrocorticosterone Corticosterone 
THALDO Tetrahydroaldosterone Aldosterone 
THE Tetrahydrocortisone Cortisol, cortisone 
THF Tetrahydrocortisol Cortisol 
5αTHF 5α-Tetrahydrocortisol Cortisol 
α-cortolone α-cortolone Cortisol, cortisone 
β-cortolone β-cortolone Cortisol, cortisone 
α-cortol α-cortol Cortisol 
β-cortol β-cortol Cortisol 
6β-OHF 6β-Hydroxy-cortisol Cortisol 
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Figure 20: The 24-h urinary steroid metabolite excretion in healthy controls (n = 88). Box plots 
represent median and interquartile ranges; the whiskers represent 5th and 95th percentile, 
respectively. Colour coding of steroid metabolites mirrors that used for depicting the major adrenal 
corticosteroid classes. With kind permission from (Krone et al., 2010). 
 
2.7.3. Steroid measurements with liquid chromatography/tandem mass 
spectrometry (LC/MSMS) 
Steroids were measured by liquid chromatography/ tandem mass spectrometry 
(LC/MSMS) employing a Waters Xevo mass spectrometer with Acquity uPLC 
system, fitted with a HSS T3, 1.8 mm, 1.2 x 50 mm column. LCMS/MS conditions 
were an electrospray ionization source with capillary voltage 4.0 kV, a source 
temperature of 150°C, and a desolvation temperature of 500°C. Steroid oxime 
analysis, which facilitates enhanced detection, i.e. increased sensitivity, by formation 
of oxime derivatives of the steroid oxo-groups (Kushnir et al., 2010), was employed 
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for the measurement of DHEA and androstenedione and carried out in positive 
mode, whereas DHEAS measurement was performed in negative mode. Steroids 
were extracted from cell-culture supernatant or serum using 2 ml tert-butyl-methyl-
ether. Steroids were derivatized into oximes employing 100 ml derivatization mixture 
(0.16 g hydroxylamine in 8 ml pyridine). For protein precipitation and extraction of 
DHEAS and Cholesterol-sulfate, 20ml ZnSO4 0.1 mM and 100 ml acetonitrile were 
added to 20 ml serum before evaporation under constant flow of nitrogen. All steroids 
were separated using an optimised gradient system consisting of methanol with 0.1% 
formic acid and quantified referring to a linear calibration series with appropriate 
internal standards, ranging from 0.1 to 250ng/ml for steroid oxime analysis and 250 
to 100 000 ng/ml for DHEAS/ Cholesterol-sulfate analysis. Each steroid was 
identified by matching retention times and two mass transitions in comparison to a 
deuterated reference compound. 
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3. CHAPTER 3: CONCOMITANT MUTATIONS IN THE 
P450 OXIDOREDUCTASE AND ANDROGEN 
RECEPTOR GENES PRESENTING WITH 46,XY 
DSD AND ANDROGENISATION AT ADRENARCHE 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as: 
Concomitant mutations in the P450 oxidoreductase and androgen receptor 
genes presenting with 46,XY disordered sex development and androgenization 
at adrenarche. 
Idkowiak J, Malunowicz EM, Dhir V, Reisch N, Szarras-Czapnik M, Holmes DM, 
Shackleton CH, Davies JD, Hughes IA, Krone N, Arlt W. 
J Clin Endocrinol Metab. 2010 Jul;95(7):3418-27. doi: 10.1210/jc.2010-0058.  
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3.1. INTRODUCTION 
Disordered sexual development (DSD) in genetic males (46,XY DSD) can be 
due to a number of distinct mutations compromising different stages of sex 
determination and differentiation (Mendonca et al., 2009; Ahmed and Rodie, 2010). 
The most common cause of 46,XY DSD is androgen insensitivity syndrome (AIS) 
due to inactivating mutations of the androgen receptor (AR) gene, which has an 
incidence of 1:20,000 life births (Hughes and Deeb, 2006). More than 300 mutations 
are listed in the AR database (http://androgendb.mcgill.ca) leading to different 
degrees of androgen resistance from azoospermia to complete androgen insensitivity 
syndrome (CAIS). Missense and nonsense mutations in specific regions of the AR 
gene have distinct effects on AR function and can affect ligand binding, 
transactivation or N-terminal-/C-terminal-interaction of the androgen receptor 
molecule (Bevan et al., 1996; Ghali et al., 2003; Jääskeläinen et al., 2006). However, 
the in vitro assessment of AR function may not always match the observed clinical 
phenotype in patients with AIS, with variable degrees of undervirilization in different 
individuals carrying the same distinct AR (Hughes and Deeb, 2006; Hughes and 
Evans, 1987). 
 Upstream of AR action, androgen synthesis may be affected and result in 
46,XY DSD (Mendonca et al., 2009; Krone et al., 2007b). Five enzymes and six 
catalytic reactions are required for the conversion of cholesterol to the most potent 
androgen, 5α-dihydrotestosterone (DHT) (see section 1.1.8). Mutations in the genes 
required for these conversions (CYP11A1, CYP17A1, HSD17B3, HSD3B2 and 
SRD5A2) represent distinct causes of 46,XY DSD, manifesting with a broad 
phenotypic spectrum. The identification of inactivating mutations in the P450 
oxidoreductase gene (POR) (Flück et al., 2004; Arlt et al., 2004) has demonstrated 
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that sex steroid synthesis may also be disrupted by mutations in co-factor enzymes 
(see section 1.3.1). 
 Here, we have investigated a patient with 46,XY DSD and concomitant, 
disease-causing mutations in the AR and POR genes, both fully established causes 
of undervirilization in their own right. 
3.2. METHODS 
3.2.1. Case report 
The patient was born at term after an uneventful pregnancy as the first child of 
non-consanguineous parents of Polish origin (birth weight was 2850g (-1.3 SDS), 
length 52 cm (0.89 SDS), Apgar score 5/8). The postnatal adaptation went well and 
no neonatal complication occurred. However, at birth, the attending pediatrician 
noticed ambiguous genitalia. The external genitalia looked predominantly female, but 
the clitoris was enlarged and a common urogenital sinus and blind ending vaginal 
pouch were present. The gonads were palpable within the inguinal canal. No other 
abnormalities or malformations were noted. The karyotype was 46,XY. 
 At the age of 14 days a slightly elevated serum 17-hydroxyprogesterone 
(17OHP) was measured (Table 10). Circulating androgens and androgen precursors 
were low and testosterone showed a poor response to hCG stimulation while the 
gonadotrophin response to LHRH stimulation was normal (Table 10). Urinary steroid 
profiling by gas chromatography/mass spectrometry (GC/MS) at the age of 14 days 
showed undetectable androsterone, normal levels of foetal adrenal zone steroids, 
normal cortisol and 17OHP metabolite excretion and no evidence of 5α-reductase 
deficiency. 
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Table 10: Hormonal assessment in the patient at 1-2 months and at 9 years. Bilateral gonadectomy 
had been carried out at the age of four years.  * age-specific normal reference range; ** age-specific 
reference ranges for androgens are listed for both girls (f) and boys (m)  
 1-2 months 9 years 
17OHP (nmol/L) 9.38 (1.8-7.5)* 37.9 (< 6) 
60 min after ACTH 250µg/m2 i.v. - 47.2 
Cortisol (nmol/L) - 391 
60 min after ACTH 250 µg/m2 i.v. - 494 
DHEAS (µmol/L) 0.23 (f: 0.04 -1.32)** 2.49 (f: 0.23 - 2.37) 
  (m: 0.04-1.96)  (m: 0.42 -2.13) 
Androstenedione (nmol/L) 0.41 (f:  0.7 - 1.9) 0.73 (f:  0.3 – 1.2) 
  (m: 1.3 – 4.25)  (m: 0.2 – 2.8) 
   4 days after hCG 2000 IU/m2 i.m. 0.35  -  
Testosterone (nmol/L) < 0.20 (f:  0.17 -0.40) < 0.17 (f:  0.17 - 0.30) 
  (m:  1.4 – 8.2)  (m: 0.15 – 0.65) 
   4 days after hCG 2000 IU/m2 i.m.  2.15  -  
ACTH (pg/ml) - 50.9 (10-60) 
LH (U/L) 0.4 - 
60 min after LHRH 75 µg/m2 i.v. 3.7 - 
FSH (U/L) 2.0 - 
60 min after LHRH 75 µg/m2 i.v. 6.7 - 
 
The initial presentation with 46,XY DSD had prompted genetic analysis of the 
androgen receptor (AR) gene, which revealed the hemizygous mutation p.Q798E. 
Despite the finding of low circulating androgens the diagnosis of partial AIS (PAIS) 
was made. The patient was assigned female gender and underwent bilateral removal 
of the inguinal gonads at the age of four years; histopathologic examination identified 
the removed tissue as immature testis. 
 Follow-up was inconsistent due to poor clinic attendance. However, at the age 
of 9 years the patient presented with progressive clitoral enlargement over the 
preceding 18 months. At examination, no other external signs of puberty were 
noticed (Tanner stages PH 1, B1, A1); clitoral length was 3 cm. Except for the 
bilateral gonadectomy, no genital reconstruction surgery had been performed yet, 
largely due to parental doubts about the gender identification of her daughter (male 
hobbies and roles, aggressive behaviour). Psychological assessment including 
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thorough evaluation of her gender preference was offered but declined by the 
parents. Her growth chart showed normal linear growth along the 50th percentile, the 
bone age was significantly delayed (-3 yrs). 
 Hormonal assessment again revealed mildly elevated serum 17OHP. 
However, DHEAS levels were raised slightly above the age-specific reference ranges 
of both girls and boys (Table 10). Serum testosterone was below sensitivity of the 
employed radioimmunoassay (Table 10). Urinary steroid profiling with gas-
chromatography/mass spectrometry (GC/MS) was performed and showed a profile 
suggestive of combined inhibition of 21-hydroxylase and 17α-hydroxylase activities 
and thus indicative for PORD (for detailed analysis see section 3.3.1). A short 
synacthen test revealed a normal baseline cortisol but an impaired cortisol response 
to ACTH stimulation (Table 10). Subsequently, hydrocortisone replacement therapy 
for intercurrent stress, illness and surgery was recommended and patient and 
parents were educated accordingly. 
3.2.2. Urinary steroid profiling 
Analysis of urinary steroid metabolite excretion was performed as described 
previously by a quantitative gas chromatography/mass spectrometry (GC/MS) 
selected ion-monitoring method (section 2.7.1). Steroids quantified included 
corticosterone metabolites (THB, 5αTHB, THA), the progesterone metabolite PD, 17-
hydroxyprogesterone metabolites (PT, 17HP), the 17-hydroxypregnenolone 
metabolite 5-PT, the 21-desoxycortisol metabolite P’TONE, cortisol metabolites 
(THF, 5αTHF and THE), and androgen metabolites (An, Et, DHEA) and 16-OH-
DHEA (see Table 9 for abbreviations of steroid metabolites). 
 Following quantification of steroid metabolites by GC/MS, the following 
substrate/product ratios were calculated to determine the approximate in vivo net 
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activity of specific steroidogenic enzymes: corticosterone over cortisol metabolites 
(17α-hydroxylase; (THA+THB+5αTHB)/(THF+5αTHF+THE)), 17-hydroxy-
progesterone over androgen metabolites (17,20-lyase; (17HP+PT)/(An+Et)), 17-
hydroxyprogesterone over cortisol metabolites (21-hydroxylase; (100xP’TONE/ 
(THF+5αTHF+THE)), and the ratio of progesterone over cortisol metabolites 
(combined 21-hydroxylase and 17-hydroxylase activities, i.e. specific for PORD; 
PD/(THF+5αTHF+THE)). These diagnostic ratios were compared to ratios obtained 
from urine analysis in a normal age matched female reference cohort (n=10). 
3.2.3. Genetic analysis 
 DNA sequencing analysis was carried out with approval of the local research 
ethics committee, after obtaining informed consent from patients and their parents. 
Direct sequencing of the coding regions of POR gene including 15 exons and exon-
intron junctions were performed as described in section 2.2.11. Exon 8 of the 
androgen receptor gene (Batch et al., 1992; Bevan et al., 1996) was performed by 
our collaborators (Prof Ieuan Hughes, Department of Paediatrics, Cambridge, UK). 
Sequencing results were analysed using Lasergene® software (DNASTAR Inc., 
Madison, USA) and mutation numbering was carried out referring to the appropriate 
NCBI reference sequences (see section 2.2.11). The coding sequence variant of the 
androgen receptor was numbered according to M20132.1 (where A of the ATG 
translation initiation codon is +363bp), the protein mutation was numbered relative to 
AAA51729.1. 
3.2.4. Site-directed mutagenesis and in vitro enzymatic activity assays 
The cDNA of the POR missense mutant p.Y607C POR, generated by site-
directed-mutagenesis, was cloned into the yeast expression vector pDE2 and used 
 
Chapter 3            Concomitant Mutations in POR and AR 
___________________________________________________________________ 
 
112 
for microsomal co-expression assays in comparison to wild type POR (WT) 
described in section 2.5.2. For site-directed mutagenesis, the following primer pairs 
were used to introduce the p.Y607C mutation into the WT POR cDNA: forward 
sequence : 5’-GGGAGCAGTCCCACAAGGTCTGCGTCCAGCAC-CTGCTAAAGC-
3’; reverse sequence: 5’-TGCTTTAGCAGGTGCTGGACGCAGACCTTGTGGGACT-
GCTCCC-3’. The detailed conditions are described in section 2.4.3. 
 For in vitro activity assays, yeast microsomes co-expressing wild type or 
mutant Y607C POR and wild type human CYP17A1, CYP21A2 and CYP19A1, 
respectively (see section 2.5.3.2), were incubated with 0.5-5 µM progesterone or 17-
hydroxypregnenolone for 17α-hydroxylase and 17,20-lyase activities of CYP17A1, 
0.5-5 µM progesterone for 21-hydroxylase (CYP21A2) activity, and 50-500 nM 
androstenedione for aromatase (CYP19A1) assays. Steroids were added to the final 
reaction volume of 200 µl in 4 µl ethanol also containing 10,000 cpm [3H] steroid 
substrate (all 55.4 Ci/mol). Purified recombinant cytochrome b5 (Invitrogen, Paisley, 
UK) was added in a final concentration of 10 pM to the 17,20-lyase assays. All 
reactions were initiated by the addition of 200 nM NADPH and subsequently 
incubated at 37°C. Steroids were extracted and TLC performed (see section 2.5 for 
detailed descriptions). The obtained data represent the results of three independent 
experiments carried out in triplicate and are expressed as mean ± standard error of 
the mean (SEM). 
 Microsomal protein quantification was performed (see section 2.3.2) and the 
expression of similar amounts of protein was confirmed by Western blotting (section 
2.3.3) employing antibodies to human POR (Abcam, Cambridge, UK), human 
CYP17A1 (SantaCruz Inc., Heidelberg, Germany), human CYP19A1 (Abcam) and 
CYP21A2 (Abcam).  
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 Kinetic parameters were assessed by non-linear regression, using the 
Michaelis-Menten equation to determine the Michaelis-Menten constant Km and 
maximal velocity Vmax (see section 2.5.2). Catalytic efficiency was defined as the ratio 
Vmax/Km and expressed as percentage of wild type activity. Calculation of enzyme 
kinetic parameters and subsequent statistical analysis was performed using curve-
fitting software (Enzfitter 2.0.9.1; Biosoft, Cambridge, UK). 
3.3. RESULTS 
3.3.1. Urinary steroid profiling 
Gas chromatography/mass spectrometry analysis of urinary steroid metabolite 
excretion in our patient at the age of 9 years revealed a pattern indicative of PORD, 
with diagnostic ratios demonstrating combined 21-hydroxylase, 17α-hydroxylase and 
17,20-lyase inhibition (Figure 21 A-D). 21-hydroxylation as the ratio of the 21-
deoxycortisol metabolite pregnanetriolone over cortisol metabolites was significantly 
compromised as compared to age-specific controls (Figure 21A). Similarly, 17α-
hydroxylation reflected by the ratio of corticosterone over cortisol metabolites was 
significantly impaired (Figure 21B). 17,20-lyase activity, as assessed by the ratio of 
17OHP metabolites over active androgen metabolites was also compromised 
(Figure 21C). Combined inhibition of 17α-hydroxylation and 21-hydroxylation, the 
hallmark biochemical finding in PORD, was reflected in our patient by a markedly 
increased ratio of progesterone over cortisol metabolites (Figure 21D). 
 24-h urinary androsterone and etiocholanolone, the main metabolites of 
androstenedione, testosterone and dihydrotestosterone, were within the age-specific 
mid normal range (Figure 21E). The excretion of the 17-hydroxypregnenolone 
metabolite 5-PT and also DHEA were increased (Figure 21E) indicative of 
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upregulation of adrenal androgen production. The corticosterone metabolites THB, 
5aTHB, and THA were increased and the excretion of free cortisol was decreased, 
reflecting 17α-hydroxylase and 21-hydroxylase inhibition, respectively. 
 
Figure 21: In vivo steroidogenic enzyme activity in the patient at the age of 9 years as determined by 
diagnostic substrate/product ratios (Panels A-D) and total excretion (Panel E) of 24-h urinary steroid 
metabolites measured by gas chromatography/mass spectrometry and shown in comparison to an 
age-matched reference cohort (n=10). Box plots represent interquartile ranges (25th to 75th percentile), 
whiskers the 5th and 95th percentile, respectively, of the normal reference cohort; the patient’s results 
are represented by a closed circle. For steroid metabolite abbreviation and explanation of steroid 
ratios please see method section. 
3.3.2. Genetic analysis 
Sequencing of the coding region of the POR gene revealed compound 
heterozygosity for two POR mutations (Figure 22A). We identified a deletion of 
guanine in exon 13 (g.32062delG) resulting in a stop codon and subsequent 
premature truncation of the POR protein 12 amino acids after the frameshift 
(p.E601fsX12). Secondly, we found a missense mutation in exon 14 (g.32171A>G) 
changing tyrosine at amino-acid position 607 to cysteine (p.Y607C). Segregation 
analysis demonstrated that the Y607C mutation is located on the maternal allele, 
while the frameshift mutation is of paternal origin (Figure 22B). 
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Figure 22: Results of genetic analysis. Panel A, electropherogram depicting the compound 
heterozygous POR mutations in our patient. The deletion of the guanine in Exon 13 (g.75,953delG) 
and the missense mutation in Exon 14 (g.76,062A>G) of the POR gene are marked by black arrows. 
The structure of the POR protein and the approximate location of the mutations are indicated in the 
schematic representation of the POR protein including its three functional domains, which bind the 
three partners of the electron transfer chain, FMN (flavin mononucleotide), FAD (flavin adenine 
dicnucleotide) and NADPH (nicotinamide adenine dinucleotide phosphate). Panel B, pedigree of the 
index family with segregation analysis of the two identified POR mutations. Panel C, electropherogram 
depicting the missense mutation in exon 6 of the AR gene (c.2754C>G) marked with a black arrow. 
The translational effect is indicated in the schematic graph representing the AR protein including its 
functional domains TAD (transactivation domain), DBD (DNA-binding domain), and LBD (ligand 
binding domain).  
 
Our collaborators have confirmed the presence of a missense mutation in the 
AR gene by direct sequencing, a glutamine to glutamic acid change (c.2754C>G) 
resulting in a missense mutation in position 798 within exon 6 of the AR protein 
(p.Q798E) (Figure 22C). This mutation was found in the patient and the mother. 
3.3.3. In vitro assessment of steroidogenic activity assays 
The impact of the maternal Y607C POR mutation on steroidogenic microsomal 
CYP enzymes was assessed by employing yeast microsomal co-expression of WT or 
mutant POR with CYP17A1, CYP21A2 or CYP19A1. 
 Y607C POR decreased catalytic efficiencies of all three enzymes compared to 
wild type protein (Figure 23, Table 11). However, a differential pattern of inhibition 
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was observed. 17α-hydroxylase activity of CYP17A1 showed significant inhibition 
with a residual catalytic efficiency of 56% as compared to WT (Figure 23A, Table 
11). CYP17A1 17,20 lyase activity was also significantly compromised when looking 
at the classic pathway, with only 43% residual activity for the conversion of 17-
hydroxypregnenolone to DHEA, whereas assessment of 17,20 lyase activity within 
the proposed alternative pathway demonstrated moderate impairment only, with 66% 
residual activity for the conversion of 5α-pregnanediolone to androsterone (Figure 
23A, Table 11). 
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Figure 23: Kinetic analysis of steroidogenic enzyme activities. Lineweaver-Burk plots of steroidogenic 
activities as assessed by incubation of yeast microsomes co-expressing human wild type (WT) or 
mutant Y607C POR with human CYP17A1 (A), CYP21A2 (B) or CYP19A1 (C) with either 0.5-5 µM 
progesterone (for 17α-hydroxylase and 21-hydroxylase activities), 0.5-5 µM 17-hydroxypregnenolone 
(for 17,20-lyase activity in the classic pathway), 0.5-5 µM 5-pregnanediolone (for 17,20-lyase activity 
in the alternative pathway) or 50-500 nM androstenedione (for aromatase activity). Representative 
Western blots demonstrate equal expression of POR and the respective CYP enzyme in the 
microsomal preparations employed. 
 In contrast to the pronounced inhibition of 17α-hydroxylase activity, the POR 
mutant Y607C had only a minor effect on 21-hydroxylation, with 79% residual activity 
(Figure 23B, Table 11). CYP19A1 aromatase activity was markedly decreased when 
co-expressed with Y607C POR with 56% residual activity compared to WT POR 
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(Figure 23C, Table 11). Western blotting determined equal amounts of POR and 
CYP enzyme protein in all employed microsome preparations (Figure 23A-C). 
Table 11: Kinetic analysis of the POR mutant p.Y607C according to yeast microsomal co-expression 
assays of either wild type or mutant POR with human CYP17A1, CYP21A2, and CYP19A1. All assays 
were carried out in three independent triplicate experiments; results are presented as means±SEM. 
For CYP17A1, both 17α-hydroxylase and 17,20-lyase activities within the classic and alternative 
androgen pathway were determined. 
  CYP17A1  CYP21A2  CYP19A1 
  17α-
hydroxylase 
17,20-lyase 
(“classic”) 
17,20-lyase 
(“alternative”) 
 21-
hydroxylase 
 Aromatase 
  Prog → 
17OHP 
17Preg → 
DHEA 
5pdiolone → AT  Prog → DOC  A’dione → E1 
Vmax 
(pmol/µg/min) 
 
WT 0.24±0.02 0.22±0.00 0.27±0.01  0.30±0.02  0.014±0.001 
Y607C 0.21±0.02 0.13±0.01 0.16±0.01  0.27±0.02  0.010±0.001 
Km  
(µM) 
 
WT 0.26±0.10 0.71±0.04 0.85±0.14  0.24± 0.08  180 ± 44 
Y607C 0.41±0.13 0.95 ± 0.11 0.75±0.06  0.27± 0.10  262 ± 54 
Catalytic 
Efficiency 
Vmax/Km  
(% WT) 
Y607C 56±3 44±4 66±3  79±2  56±3 
 
3.4. DISCUSSION 
To our knowledge, this is the first report of combined PORD and AIS. At birth, 
the patient presented with severe 46,XY DSD prompting female gender assignment 
and bilateral gonadectomy following the diagnosis of AIS. However, at the age of 9 
years, i.e. around the time of adrenarche, progressive clitoral enlargement and near 
normal androgen levels were detected. 
 The identified AR mutation, Q798E, has been previously associated with the 
clinical phenotype of PAIS  (Quigley et al., 1995; Batch et al., 1992; Bevan et al., 
1996; Hiort et al., 1996; Thai et al., 2005). Interestingly, the same mutation was also 
identified in three patients with azoospermia but no evidence of 46,XY DSD (Wang et 
al., 1998; Hiort et al., 2000; Ferlin et al., 2006). This phenotypic variability currently 
remains unexplained. The Q798E mutation is located in the middle of the AR ligand 
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binding domain, residing in the loop between helix 7-8. Two in vitro studies failed to 
demonstrate impaired AR ligand binding for Q798E (Bevan et al., 1996; Wang et al., 
1998). Furthermore, there was no significant impairment of N-terminal /C-terminal 
interaction, found to be an explanation for the phenotype in some patients with PAIS 
(Jääskeläinen et al., 2006). This is remarkable as mutations in the AR ligand binding 
domain usually have significant functional impact. Luciferase reporter assays for 
Q798E AR function have shown reduced promotor transactivation in vitro (Wang et 
al., 1998; Jääskeläinen et al., 2006; Hiort et al., 1996; Bevan et al., 1996). Of note, its 
transactivation is restored back to wild type activity with increasing androgen 
concentrations (Wang et al., 1998; Jääskeläinen et al., 2006), suggesting that 
increased availability of androgens could enhance mutant Q798E AR action. 
However, in the previously identified four individuals with Q798E no progressive 
virilization at time of adrenarche or puberty has been reported.   
 While patients with AIS due to AR mutations usually have high normal or 
increased androgen levels, the patient from this study presented neonatally with very 
low circulating androgens. This suggests an androgen biosynthesis defect. Indeed, 
this was supported by the results of urinary steroid metabolite analysis at the age of 9 
years, which were indicative of PORD. This diagnosis was confirmed by direct 
sequencing, revealing compound heterozygous mutations. The novel POR frameshift 
mutation E601fsX12 is highly likely to abolish function as previous studies have 
shown that a premature stop codon result in loss of activity in the R616X POR 
mutant (Fluck et al., 2007; Agrawal et al., 2008). This indicates that early truncation 
of POR mRNA may result either in nonsense mediated RNA decay or that the 
integrity of the C-terminus of the POR protein is crucial for electron transfer. The 
missense mutation Y607C POR has been previously identified when screening a 
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large cohort of healthy Americans (Huang et al., 2008). However, this is the first time 
that this mutation has been found in a clinically affected PORD patient and hence 
has been confirmed as disease causing. Our co-expression assays with Y607C POR 
demonstrated only a mild impairment of 21-hydroxylase activity but significant 
inhibition of 17α-hydroxylase. Combined inhibition of both activities is consistent with 
the biochemical finding of normal baseline cortisol but impaired cortisol response to 
synacthen. Furthermore, preferential inhibition of 17α-hydroxylase over 21-
hydroxylase explains the observation of mineralocorticoid metabolite accumulation in 
our patient, as previously described for A287P POR (Dhir et al., 2007). 
 However, one of the most striking features in our patient is the re-emergence 
of androgen production at the age of 9 years, resulting in progressive clitoral 
hypertrophy, a phenomenon not reported yet in patients with PORD (Flück and 
Pandey, 2011; Arlt et al., 2004; Fukami et al., 2009; Krone et al., 2012). This 
suggests that the disruptive effect of mutant POR on 17,20-lyase activity, resulting in 
low or non-detectable androgens during the neonatal period, had been partially 
overcome at time of adrenarche. In vitro assays suggested compromised 17,20-lyase 
activity due to Y607C for both the classic and alternative pathway, though to a lesser 
degree for the latter. However, clinical biochemical assessment certainly suggested 
androgen production via the classic pathway, with high normal circulating 
concentrations of DHEAS and androstenedione, and urinary androgen metabolite 
specific for the alternative androgen pathway, e.g. 5α-17-hydroxypregnanolone, were 
not found to be elevated in our patient. 
 It is obvious that the observed increase in androgen production was of adrenal 
origin as the patient had undergone bilateral gonadectomy five years earlier. It has 
been generally agreed that adrenarche and gonadarche are distinct events and 
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happen independently of each other (see section 1.2.3), and this case study certainly 
illustrates this. At time of adrenarche there is a physiologic increase in the expression 
of the co-factor enzyme cytochrome b5 (CYB5A) within the adrenal zona reticularis, 
the major site of adrenal androgen production (Suzuki et al., 2000). CYB5A 
expression is low in pre-adrenarchal adrenals but steadily increases after 5 years of 
age to reach a plateau at the age of 13 years (Nakamura et al., 2009). CYB5A is 
thought to serve as an allosteric facilitator for the interaction of POR and CYP17A1, 
stabilizing their interaction by forming a CYP-POR-CYB5 complex. There is currently 
no information on the exact interaction site of CYB5 with POR. Based on three-
dimensional modeling Y607C can be predicted to disrupt the binding of NADPH to 
the POR NADPH-binding domain (Wang et al., 1997; Huang et al., 2008). However, 
if one assumes that the hydrophobic surface area near to Y607C could potentially be 
the interaction area with CYB5, it is conceivable that increasing concentrations of 
CYB5 at time of adrenarche could partially overcome the effect of the mutant. All 
microsomal assays in this study were carried in the presence of excess CYB5 
concentrations, and consequently it is likely that the disruptive effect of Y607C POR 
on 17,20-lyase activity would certainly be more significant in a milieu of relative CYB5 
deficiency, i.e. prior to adrenarche. To test the effect of varying quantities of CYB5A 
on Y607C POR would be an interesting experiment for the future. Intriguingly, it was 
recently demonstrated in the domestic ferret that the majority of gonadectomy-
induced androgen-producing adrenal tumours express CYB5, which is physiologically 
not present in normal ferret adrenals (Wagner et al., 2008). Gonadectomy-induced 
adrenal tumourigenesis has also been described in certain mouse strains and 
increased LH stimulation and altered activin/inhibin signalling have been implicated in 
the pathogenesis (Beuschlein et al., 2003). In humans, increased androgen 
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production after gonadectomy has not been reported but if such a cross-talk between 
the gonadal and adrenal axes also exists, it may contribute to the virilization 
observed in our patient. 
 Thus, one could speculate that the increase in both androgen production and 
action at time of puberty is explained by a two-step model. Firstly, the emerging 
CYB5A expression in the adrenal zona reticularis may ameliorate the disruptive 
effect of Y607C POR, resulting in an increase in 17,20-lyase activity and adrenal 
androgen production during adrenarche. Secondly, increasing levels of androgens 
could then potentially enhance the transactivation capacity of the AR mutant Q798E, 
as previously observed in vitro (Wang et al., 1998; Jääskeläinen et al., 2006). This 
subsequently results in improved androgen action and the observed clitoral 
enlargement, which would represent phallic catch-up growth due to increased 
androgen sensitivity in an individual with a male genetic background, as observed 
previously in some 46,XY individuals with idiopathic micropenis (Lee and Houk, 
2004). Of note, virilization at puberty and the subsequent change of gender identity is 
not uncommon in 46,XY DSD individuals with HSD17B3 or SRD5A2 deficiencies who 
where raised as girls (Lee et al., 2007; Cohen-Kettenis, 2005). However, the 
mechanism in these conditions is different as testicular derived androgens 
accumulate prior to the enzyme block (androstenedione in HSD17B3 and 
testosterone in SRD2A2) and are likely to be converted by other isoenzymes (Lee et 
al., 2007). The observed biological response to a relatively sudden increase in 
androgen levels in HSD17B3 and SRD5A2 deficiency patients reflects the 
susceptibility of individuals with a male karyotype to develop phenotypic virilization, 
similar to our case. 
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 In conclusion, our patient illustrates the close interaction of factors involved in 
the regulation of androgen synthesis and androgen action, respectively. Furthermore, 
our case highlights that patients presenting with DSD also require thorough work-up 
of the adrenal axis and vice versa (Metherell et al., 2009; Ahmed and Rodie, 2010), 
to ensure that these patients are not exposed to the unrecognized risk of life-
threatening adrenal crisis, which fortunately did not occur in our case until the 
conclusive diagnosis of adrenal insufficiency was established, nine years after the 
initial presentation with 46,XY DSD. 
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4. CHAPTER 4: PUBERTAL PRESENTATION IN P450 
OXIDOREDUCTASE DEFICIENCY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as: 
Pubertal presentation in seven patients with congenital adrenal hyperplasia 
due to P450 oxidoreductase deficiency. 
Idkowiak J, O'Riordan S, Reisch N, Malunowicz EM, Collins F, Kerstens MN, Köhler 
B, Graul-Neumann LM, Szarras-Czapnik M, Dattani M, Silink M, Shackleton CH, 
Maiter D, Krone N, Arlt W. 
J Clin Endocrinol Metab. 2011 Mar;96(3):E453-62. doi: 10.1210/jc.2010-1607  
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4.1. INTRODUCTION 
P450 oxidoreductase (POR) deficiency (PORD) is a variant of congenital 
adrenal hyperplasia caused by mutations in the POR gene (Flück et al., 2004; Arlt et 
al., 2004) (see section 1.3.1.2).  
 In PORD patients, combined deficiencies of the steroidogenic enzymes 
CYP17A1 and CYP21A2 represent the most striking biochemical findings. Notably, 
PORD patients of both sexes may present at birth with DSD, a puzzling finding that 
can be explained by the existence of an alternative pathway to active androgens 
(1.3.1.2). The skeletal malformations in PORD patients resemble the malformation 
phenotype of Antley-Bixler-Syndrome (ABS, OMIM 207410) (Antley and Bixler, 
1975).  
 Neonatal presentation in PORD has been well described (Arlt et al., 2004; 
Huang et al., 2005; Fukami et al., 2009; Krone et al., 2012). However, there is a 
paucity of detailed data on the pubertal phenotype that is likely to be affected by 
impaired sex steroid synthesis.  
In this chapter, we have clinically, genetically and biochemically characterized 
seven patients (five females, two males) with PORD during puberty. 
4.2. METHODS 
4.2.1. Patients 
The cohort consisted of five female and two male patients from six different 
countries. In all patients appropriate written consent and assent, respectively, had 
been obtained in accordance with local IRB guidelines. Patient characteristics 
including genetic and biochemical findings are summarized in Table 12 for the 
affected girls and in Table 13 for the two male patients. 
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Table 12: Summary of clinical, genetic, and hormonal findings in five female pubertal PORD patients.  
n.m., not measured; SDS, standard deviation score. 
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Case 1: The neonatal presentation of this case, virilized genitalia (46,XX DSD) 
and low circulating androgens, has been described previously (Arlt et al., 2004). At 
the age of 14 years she presented with acute abdominal pain; investigations revealed 
rupture of a large (4.5cm) left ovarian cyst requiring surgical intervention, with 
removal of a largely degenerative polycystic ovary. Physical examination also 
revealed mild dysmorphic features (depressed nasal bridge, arachnodactyly, 
camptodactyly, restricted elbow extension bilaterally, syndactyly of toes 2/3). Tanner 
stages were PH4, B4, M0. However, serum E2 was pre-pubertal and gonadotrophins 
were high (Table 12). 17OHP and progesterone were elevated and cortisol showed a 
subnormal response to ACTH1-24 (Table 12) and hydrocortisone cover during stress 
was recommended. After six months of treatment with synthetic progestin, E2 levels 
slightly increased but gonadotrophins were still high (E2 106 pmol/L; LH 15.3 U/L; 
FSH 8 U/L). Treatment was changed to an oestradiol/progestin combination. Follow-
up one year later showed low E2 levels and elevated gonadotrophins (E2 63 pmol/L; 
LH 40 U/L, FSH 16 U/L), possibly reflecting compliance problems. At the age of 15.8 
years, spontaneous rupture of a right ovarian cyst occurred that required emergency 
surgical intervention resulting in the removal of the residual right ovary. The patient 
now receives continuous oestrogen/progestin replacement therapy.  
Case 2: The patient (46,XX) was born after 42 weeks of gestation as the third 
child of non-consanguineous parents of Polish origin. Her genitalia was virilized at 
birth (clitoromegaly and urogenital sinus). At the age of 11.5 years bilateral ovarian 
masses were diagnosed by ultrasound and CT and subsequently surgically removed. 
Histopathology confirmed ovarian follicular cysts. Endocrine assessment revealed 
undetectable E2 and elevated LH and FSH (Table 12). After 10 months, ovarian 
cysts on both sides recurred and the patient was referred for further endocrine 
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investigations. Tanner stages were B1, PH2, M0. Several dysmorphic features were 
noted, including midface hypoplasia, brachycephaly, dysplastic ears, arachno- and 
camptodactyly and bilaterally restricted elbow extension. Hormonal assessment 
showed elevated 17OHP, progesterone, and ACTH concentrations; however, cortisol 
was high normal at baseline and after i.v. cosyntropin (Table 12). Medical treatment 
of the ovarian cysts with a combination of 17β-oestradiol (1mg/d), GnRH 
superagonists (Dipherelin; 3.75 mg/month) and dexamethasone (0.25 mg/d; 
reduction to 0.125 mg/48h after 2 months) was initiated. On this regimen, the ovarian 
cysts partially regressed in size after 12 months of treatment. At 13.5 years her 
pubertal staging was B4, PH3; she was then started on a combination of 
triamcinolone 2 mg/d, 17β-oestradiol and synthetic progestin, resulting in regular 
withdrawal bleeds. The ovarian cysts further decreased in size and until the present 
age of 18 years there have been no recurrences.  
Case 3: The patient was born with ambiguous genitalia after an uneventful 
pregnancy to consanguineous parents of Italian origin. The baby was raised as a boy 
until the age of 5 when her gender assignment was reconsidered after the birth of a 
sister with obvious 46,XX DSD. A diagnostic laparotomy showed the presence of 
normal internal female genital organs. Multiple genital surgeries including 
vaginoplasty and partial clitoral reduction were performed between 5 and 12 years of 
age. Normal psychomotor development, bone age and growth velocity (50th to 75th 
percentile) were documented. Her younger sister later died aged 8 years after 
developing signs and symptoms of shock shortly after undergoing an appendectomy. 
Pubertal development was induced at the age of 17 years by treatment with 
equine oestrogens and progesterone. At the age of 23 years she was assessed as 
having normal female appearance but with only moderate breast development (Table 
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12). Several mild dysmorphic features were noted (narrow hard palate, low set ears, 
clinodactyly, camptodactyly and brachydactyly of the 4th toe bilaterally). Genetic 
analysis confirmed a 46,XX karyotype. Hormonal evaluation showed elevated serum 
progesterone and 17OHP levels whereas serum androgens were low; serum cortisol 
was low at baseline and did not increase appropriately after i.v. synacthen (Table 
12). After three months of oestrogen withdrawal, the patient’s gonadotrophins were 
increased (LH 53 U/L, FSH 29 U/L). Concurrently large ovarian cysts up to 7 cm in 
diameter developed, which regressed partially following reintroduction of 
oestrogen/progestin treatment, but only resolved after the addition of glucocorticoid 
treatment (dexamethasone 0.375 mg/d). 
Case 4: The patient was the first child born to non-consanguineous parents of 
Dutch origin. There was no genital ambiguity but she underwent early postnatal 
assessment for dysmorphic features including frontal bossing, midface hypoplasia, 
pear shaped nose, low-set ears with flat helices, impaired supination of the forearms, 
arachnodactyly, synostosis of several distal and interphalangeal joints. However, no 
precise diagnosis was established and she was subsequently lost to follow-up.  
 At the age of 19 years she presented with irregular menses. Pubertal 
development was partially delayed (Table 12). Hormonal assessment revealed low 
E2 with normal gonadotrophins; 17OHP and progesterone were elevated; baseline 
cortisol was normal but did not increase sufficiently after i.v. ACTH1-24 and adrenal 
androgens were low (Table 12). An MRI scan of the pelvic region revealed cystic 
enlargement of the right ovary (3 x 4 cm) with normal appearance of the left ovary 
and normal female anatomy of the reproductive system. Combined treatment with E2 
(2 mg daily) and dydrogesterone (10 mg daily) was initiated. At present, the patient 
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has been on hormone replacement therapy for 6 months and repeat imaging has not 
yet been performed. 
Case 5: The girl was born at 36 weeks of gestation after an uneventful 
pregnancy to non-consanguineous parents of German origin. Postnatally, the girl 
needed ventilation due to severe respiratory distress associated with bilateral 
choanal stenosis. At birth there were obvious dysmorphic features including 
brachycephaly, midface hypoplasia, exophthalmus, retrognathia, depressed nasal 
bridge, low set ears and bilateral radiohumeral synostosis. The external genitalia 
were ambiguous with clitoral hypertrophy and an urogenital sinus (Prader stage III). 
Clitoral reduction and vulvo- and vaginoplasty were performed at 2 years of age. 
During childhood the girl had multiple reconstructive surgeries for correction of the 
craniofacial abnormalities.  
 At 16 years of age, she presented to the endocrine clinic because of primary 
amenorrhoea. Tanner staging revealed PH3, B3, M0. Bone age was delayed by two 
years. Pelvic ultrasound revealed an infantile uterus and bilateral polycystic ovaries 
with the largest cyst measuring 1 cm in diameter and with increased total ovarian 
volumes of 8.6 and 10 ml, respectively. Hormonal analysis showed a low E2 with 
upregulated gonadotrophins; baseline cortisol was low and did not increase 
sufficiently after i.v. cosyntropin and adrenal androgens were normal (Table 12). She 
was started on oestradiol valerate for hormone replacement. 
Case 6: The boy was born at 39 weeks of gestation as the first child of a 
Chinese mother and a Costa Rican father. Both testes were undescended but 
palpable in the inguinal canal; the scrotum was hypoplastic. Bilateral orchidopexies 
were performed at the age of 12 months. In addition, at birth, choanal stenosis, facial 
dysmorphism (brachycephaly, frontal bossing, mid-face hypoplasia, pre-auricular skin 
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tags) and multiple skeletal abnormalities, including arachnodactyly, shoulder and 
knee contractures, radio-ulnar synostosis, bilateral coronal synostosis, partial fusions 
of thoracic vertebrae T3/T4, were noted. No conclusive diagnosis was made and the 
patient was lost to follow-up. 
 The patient was referred for endocrine assessment at the age of 10.5 years 
because of poor genital development (Table 13). His genitalia were 
undermasculinized for age (phallus of 15 mm length with little erectile tissue). Serum 
gonadotrophins and androgen levels were pre-pubertal (Table 13). Cortisol was 
normal at baseline but insufficiently stimulated after 250 µg ACTH1-24 revealing partial 
adrenal insufficiency (Table 13). Hydrocortisone replacement therapy (10 mg/m2 
daily) and early pubertal induction with oral testosterone (40 mg daily) was 
commenced but the family then dropped out of care and ceased medications.  
 At age 16 years he presented again after several years of no medication. 
However, pubertal development had spontaneously progressed and the phallus was 
8.5 cm with adequate erectile tissue, appropriate testicular volumes, and advanced 
pubertal staging (Table 13). Hormonal investigations revealed normal androgens but 
upregulated gonadotrophins (Table 13). 
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Table 13: Summary of clinical, genetic, and hormonal findings in two male pubertal PORD patients.  
n.m., not measured; SDS, standard deviation score 
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Case 7: This boy was born after an uneventful pregnancy to non-
consanguineous parents of British origin. At birth, several dysmorphic features were 
noted including choanal stenosis, brachycephaly and joint contractures due to radio-
ulnar synostosis. There was no genital ambiguity; however, his right testicle was 
undescended but palpable in the inguinal canal. Right-sided orchidopexy was 
undertaken at the age of 12 months and the boy underwent a series of osteotomies 
for coronal craniosynostosis.  
 He presented at 12 years of age to the endocrine clinic with lack of pubertal 
development and testicular volumes of 4 and 12 ml, respectively. Adrenal androgen 
concentrations were low; testosterone was high-normal in comparison to age-specific 
reference (Table 13). Baseline cortisol was normal but response to i.v. cosyntropin 
was insufficient (Table 13). Hydrocortisone treatment was initiated (10mg/m2/d) und 
further pubertal development monitored at 6-monthly intervals. Puberty progressed 
spontaneously and when assessed at the age of 13.5 years testicular volumes had 
increased to 10 and 25 ml, respectively (Table 13). DHEAS, testosterone and 
baseline gonadotrophins were within age- specific reference ranges (Table 13). 
4.2.2. Urinary steroid profiling 
Analysis of urinary steroid metabolite excretion was performed as described in 
section 2.7.1. Steroids quantified included corticosterone metabolites (THB, 5αTHB, 
THA), the progesterone metabolite PD, 17-hydroxyprogesterone metabolites PT, 
17HP, the 17-hydroxypregnenolone metabolite 5-PT, the 21-desoxycortisol 
metabolite P’TONE, cortisol metabolites THF, 5αTHF and THE; and androgen 
metabolites An and Et, DHEA and 16-OH-DHEA (see Table 9 for steroid metabolite 
abbreviations) 
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 Following quantification of steroid metabolites by GC/MS the following 
substrate/product ratios to determine the approximate in vivo net activity of specific 
steroidogenic enzymes were calculated: corticosterone over cortisol metabolites 
(17α-hydroxylase; (THA+THB+5αTHB)/(THF+5αTHF+THE)), 17-
hydroxyprogesterone over androgen metabolites (17,20-lyase; (17HP+PT)/(An+Et)), 
17-hydroxyprogesterone over cortisol metabolites (21-hydroxylase; 
(100xPTONE/(THF+5αTHF+THE)), and the ratio of progesterone over cortisol 
metabolites (combined 21-hydroxylase and 17-hydroxylase activities, i.e. specific for 
PORD; PD/(THF+5αTHF+THE)). The diagnostic ratios and overall secretion patterns 
were compared with urinary steroid profiles obtained from a normal reference cohort 
of boys and girls between 12 and 16 years of age (n=12). 
4.2.3. Genetic analysis 
The coding sequence of the POR gene including exon-intron boundaries was 
amplified as described in section 2.2.11. 
4.3. RESULTS 
4.3.1. Clinical and hormonal characteristics 
All seven patients presented with absent or incomplete pubertal development 
leading to the diagnosis of PORD. Three female patients had presented neonatally 
with 46,XX DSD and five of the seven patients had overt skeletal malformations 
noted immediately after birth. However, in all cases this had not prompted the 
establishment of a conclusive diagnosis prior to puberty. 
 Generally, female patients presented with significant pubertal impairment and 
ovarian cysts. In case 1, spontaneous cyst rupture required two surgical emergency 
interventions, resulting in loss of both ovaries despite ongoing oestrogen/progestin 
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therapy. Ovarian cysts in cases 2 and 3 only resolved following the addition of 
glucocorticoids and GnRH agonists to ongoing oestrogen/progestin therapy.  Four of 
the five female patients presented with primary amenorrhea and biochemical 
evidence of primary hypogonadism (Table 12). By contrast, both boys showed 
spontaneous, albeit slightly delayed, pubertal progression, with testicular volumes 
appropriate for age, and biochemical signs of compensated hypogonadism, with 
normal testosterone but upregulated gonadotrophins (Table 13). 
 In all patients, adrenal androgens were either normal or low. All cases had 
elevated 17OHP and progesterone concentrations, accompanied by increased ACTH 
levels in 5 patients. Baseline cortisol secretion was normal in five and borderline low 
in two patients. In all but one patient cortisol secretion was not sufficiently stimulated 
by i.v. cosyntropin, indicative of partial adrenal insufficiency. 
 Auxological investigations in all seven cases showed a normal height at 
investigation within the familial target height range. 
4.3.2. Urinary steroid profiling 
Steroid profiling by GC/MS revealed a typical pattern for PORD in all patients 
studied (Figure 24). 24-h excretion analysis revealed a characteristically increased 
excretion of metabolites of 17-hydroxypregnenolone (5-PT), progesterone (PD), and 
17OHP (17HP, PT, P’TONE) and a mild increase in mineralocorticoid precursor 
metabolites (e.g. THB, THDOC) (Figure 24A), which reflects the concurrent 
impairment of 17α-hydroxylase and 21-hydroxylase activities. In keeping with 
impaired 17,20-lyase activity, androgen and androgen precursor metabolite excretion 
was decreased or low normal (Figure 24A). Cortisol metabolites were low or in the 
lower normal reference range, indicative of impaired 21-hydroxylase activity (Figure 
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24A). Substrate/product ratios clearly demonstrated attenuation of 17α-hydroxylase, 
17,20-lyase and 21-hydroxylase activities in all cases examined (Figure 24B).  
 
Figure 24: In vivo steroidogenic enzyme activities in pubertal PORD patients as determined by total 
24-h urinary steroid metabolite excretion (Panel A) and diagnostic steroid substrate/product ratios 
(Panel B) measured by gas chromatography/mass spectrometry and shown in comparison to an age-
matched reference cohort (n=12). Box plots represent the interquartile ranges (25th to 75th percentile), 
whiskers the 5th and 95th percentile, respectively, of the reference cohort; each pubertal PORD case is 
represented by specific symbols as indicated in the legend. 
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4.3.3. Genetic analysis 
 Sequencing analysis of the POR gene revealed compound heterozygous 
missense mutations p.A287P/p.R457H in case 1. Cases 2 and 3 were homozygous 
for p.A287P, and case 4 showed compound heterozygous mutations comprising a 
missense mutation (p.T142A) and a novel frameshift mutation resulting in a 
premature stop codon (p.Y376LfsX74). Case 5 was compound heterozygous, with a 
p.A287P mutation on one allele, and a novel p.R223X nonsense mutation on the 
other allele. 
 Case 6 was compound heterozygous for p.R457H and p.Y567X whereas case 
7 was compound heterozygous for p.A287P, and a novel duplication disrupting the 
splice donor site of intron 7, IVS7+2dupT. The duplication does not yield an 
alternative splice site according to splice site prediction tool 
http://www.cbs.dtu.dk/services/NetGene2/, thus resulting in translation of intron 7 
until a premature stop codon 64 aa downstream of the last exon 7 codon 
(p.P277PfsX65). 
4.4. DISCUSSION 
Here, we describe the clinical phenotype as well as biochemical and genetic 
findings in seven adolescents with PORD all presenting with disturbed pubertal 
development, manifesting with insufficient pubertal development and primary 
amenorrhea in four of the five girls and delayed, albeit spontaneously progressive 
puberty in the two boys.  
 All five females presented with ovarian cysts. This is a common finding in 
females affected by steroidogenic disorders and has been reported in 21-hydroxylase 
deficiency (21OHD) (New, 1993; Hague et al., 1990), 17α-hydroxylase deficiency 
(17OHD) (Rosa et al., 2007; Kate-Booij et al., 2004; Mallin, 1969), congenital lipoid 
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adrenal hyperplasia (CLAH) due to mutant steroidogenic acute regulatory protein 
(StAR) (Fujieda et al., 1997; Shima et al., 2000; Tanae et al., 2000), P450 aromatase 
deficiency (Belgorosky et al., 2003; Mullis et al., 1997), and also in PORD (Fukami et 
al., 2005; 2009). Of note, two infants with PORD have been described who even 
developed large ovarian cysts at two and four months of age, respectively (Fukami et 
al., 2006; Sahakitrungruang et al., 2009). Excessive LH-mediated ovarian stimulation 
as a consequence of primary hypogonadism is an obvious underlying mechanism. 
Interestingly, girls with CLAH often spontaneously undergo puberty and have normal 
circulating E2 levels (Fujieda et al., 1997) but still present with large ovarian cysts. It 
has been suggested that this may be the consequence of chronic anovulation rather 
than LH overstimulation (Shima et al., 2000), a concept that is supported by a study 
in a patient with amenorrhea, ovarian cysts and inactivating mutations of the LH 
receptor gene (Latronico et al., 1996). Similarly, multiple ovarian cysts can be found 
in women with steroidogenic disorders resulting in androgen excess such as 21OHD 
(Hague et al., 1990; Falhammar et al., 2008), which again could be a consequence of 
chronic anovulation or potentially direct androgen effects. 
 A unique mechanism driving ovarian cyst development in females affected by 
PORD in addition to high gonadotrophins resulting from oestrogen deficiency might 
be the disruptive impact of mutant POR on sterol synthesis and metabolism (Figure 
25). 14α-lanosterol demethylase (CYP51A1) requires electron transfer from POR for 
catalytic activity and catalyses the conversion of lanosterol to meiosis-activating 
sterols (MAS). FF-MAS (follicular fluid MAS) have been shown to be crucial for the 
resumption of oocyte meiosis at puberty and also supports oocyte maturation 
(Byskov et al., 1995; Grondahl et al., 2000; 1998).  
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Figure 25: Schematic representation of the possible mechanisms leading to ovarian cysts in female 
patients with PORD. Impaired sex steroid synthesis results in low estradiol levels (right panel) causing 
hypergonadotropic hypogonadism with subsequent stimulation of the ovaries by the upregulated 
gonadotrophins. In addition, mutant POR affects the cholesterol synthesis pathway due to impairment 
of CYP51A1 activity (left panel) leading to decreased generation of meiosis activating sterols (MAS) 
that are important for meiotic resumption and oocyte maturation. LH, luteinizing hormone; FSH, follicle 
stimulating hormone; FF-MAS; follicle fluid MAS; T-MAS, testicular MAS; each black arrow indicates 
an enzymatic reaction; dotted crosses indicate impairment of pathway reactions; grey arrows indicate 
increased (or decreased) serum levels. 
The detailed mechanism underlying the effects of FF-MAS on oocyte 
maturation is not clear yet but may involve the PKC pathway (Jin et al., 2006) or 
hedgehog signalling pathways  (Nguyen et al., 2009; Mann and Beachy, 2004). FF-
MAS is further converted to T-MAS (testicular MAS), which has been found to be 
highly expressed in mammalian testis, especially in spermatozoa, suggesting a role 
in male fertility (Mann and Beachy, 2004); however, its precise role in male human 
reproduction remains to be elucidated. Importantly, CYP51A1 is highly expressed in 
murine and human gonads (Rozman et al., 2002) and its inhibition in vitro results in 
oocyte arrest (Wang et al., 2009). Interestingly, it has recently been shown that 
gonadotrophins induce upregulation of CYP51A1 in mice and rabbits (Wang et al., 
2009; 2010), suggesting that POR-dependent CYP51A1 may be a crucial contributor 
to oocyte maturation at puberty. Thus it is conceivable that female PORD patients 
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have to take a “double hit” driving ovarian cyst development, disrupted MAS 
synthesis and high gonadotrophins due to low oestrogen production (Figure 25). 
This may possibly explain why the cysts appeared to be more difficult to control in 
PORD than in patients with other steroidogenic disorders, with two patients from this 
case series requiring long-acting glucocorticoids in addition to sex steroid 
replacement to control the effects of excess LH secretion. 
 In contrast to the findings in the five female cases, pubertal development in 
our two male PORD cases was more mildly affected. Case 6 presented with poor 
development at the age of 10 years but subsequently he and the other male patient 
spontaneously progressed through puberty with near normal testosterone production. 
This may indicate that sex steroid production in the testicles during puberty is less 
dependent on fully functional POR than ovaries or adrenals. Fukami et al. (Fukami et 
al., 2009) previously reported that three out of six male PORD patients had a normal 
pubertal development while all seven pubertal age girls in their cohort had impaired 
pubertal development; however, only limited detail on the pubertal findings and no 
longitudinal data were provided. The only other paper previously reporting on 
pubertal age PORD patients described two young women aged 17 and 19 years, one 
of them presenting with normal breast development but primary amenorrhea, the 
other with complete lack of pubertal development (Sahakitrungruang et al., 2009). 
 Interestingly, circulating androgens in this case series of pubertal patients 
were relatively normal, though low androgen levels in infants and younger children 
with PORD are well documented. The relative increase in androgen production at 
pubertal age despite POR-dependent inhibition of sex steroid synthesis by CYP17A1 
could possibly be explained by increased expression of cytochrome b5 (CYB5) that 
acts as an allosteric facilitator of POR and CYP17A1 (Auchus et al., 1998) thereby 
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facilitating CYP17A1 17,20-lyase activity. CYB5 is expressed pre- and postnatally in 
human adrenal and testicular tissues (Dharia et al., 2004). However, its expression 
increases in the adrenal zona reticularis around the age of adrenarche (Suzuki et al., 
2000) and a similar increase in testicular Leydig cells could enhance 17,20-lyase 
activity significantly to rectify androgen production during adrenarche and puberty 
despite partially impaired POR function. The case report of severe 46,XY DSD 
(chapter 3 of this thesis), who presented with normal adrenal androgens and phallic 
catch-up growth during adrenarche, supports this hypothesis. 
 A diagnosis of adrenal insufficiency was established in all but one of our cases 
at presentation during puberty, generally displaying normal baseline cortisol levels 
but failure to respond appropriately to ACTH. Of note, despite neonatal presentation 
with DSD of unknown origin, none of the patients had previously undergone 
assessment of adrenal function, which had put them at considerable risk of adrenal 
crisis in case of intercurrent illness, inflammatory stress or surgery. The untimely 
death of the younger sister of case 3, who also presented with 46,XX DSD and died 
at the age of 8 years of unexplained shock following a routine appendectomy, 
illustrates the dramatic consequences that overlooking adrenal insufficiency can 
have.  
 Some of the phenotypic variability we observed in our patients may be 
explained by the differential effects of distinct POR mutations on electron-accepting 
CYP enzymes (Dhir et al., 2007). Interestingly, the three patients with either 
homozygous or compound heterozygous missense mutations presented with rather 
mild skeletal malformations and lack of pubertal progression. By contrast, the four 
patients carrying a major loss of function mutation in addition to a missense mutation 
on the other allele presented with severe skeletal malformations but only relatively 
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mildly impaired pubertal development. Genotype-phenotype analysis in large 
Caucasian (Krone et al., 2012) and Japanese (Fukami et al., 2009) PORD cohorts 
confirm that a severe skeletal phenotype is associated with a major loss-of-function 
mutation on one allele, however the prediction for gential- and biochemical 
phenotype is poor. The most common POR mutation in Caucasians, p.A287P 
(Huang et al., 2005), was found on seven alleles in five of our patients. p.R457H, the 
most common POR mutation in Japan (Adachi et al., 2006), was found in two of the 
patients, who were of Polish and Chinese origin, respectively. p.A287P decreases 
17α-hydroxylase to 20-40% of wild type (WT) activity but retains 70% of 21-
hydroxylase WT activity; p.R457H equally disrupts CYP17A1 and CYP21A2 activities 
(Dhir et al., 2007). p.T142A has been reported to only mildly impair CYP17A1 activity 
(Huang et al., 2005) and was found in case 4, the only patient with spontaneous 
menarche and a considerable degree of spontaneous pubertal development.  
In summary, pubertal development of children with PORD is impaired and 
frequently manifests with primary hypogonadism in girls, requiring medical induction 
of puberty and monitoring for ovarian cyst development. Affected boys may have the 
capacity for spontaneous pubertal development justifying a primarily observatory 
approach. Importantly, adequate hydrocortisone replacement and stress dose cover 
to prevent life-threatening adrenal crisis is crucial in PORD patients. The late 
diagnosis of adrenal insufficiency in one of the patients and the death of a sibling 
likely to have suffered from PORD emphasizes the need for concurrent assessment 
of adrenal and gonadal function not only in PORD but in all DSD patients with an 
unclear diagnosis. This will facilitate early diagnosis of partial adrenal insufficiency, 
thus hopefully preventing adrenal crisis-related deaths in PORD, and timely 
establishment of a conclusive diagnosis in affected patients. 
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5. CHAPTER 5: BROAD PHENOYTPIC SPECTRUM 
OF 17ALPHA-HYDROXYLASE (CYP17A1) 
DEFICIENCY 
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5.1. INTRODUCTION 
17α-hydroxylase deficiency (17OHD, MIM# 202110) is a rare autosomal 
recessive disorder and a variant of congenital adrenal hyperplasia (CAH) 
representing about 1% of all CAH cases (section 1.3.1.1). The underlying defect is 
impaired activity of the cytochrome P450 (CYP) enzyme CYP17A1 (also P450c17), 
which is located at a major branch point in human steroidogenesis and exhibits two 
distinct catalytic activities: 17α-hydroxylase, crucial for adrenal GC synthesis, and 
17,20 lyase, the key step in the generation of C19 androgen precursors in adrenals 
and gonads (see section 1.1.8.1. and Figure 4). 
The CYP17A1 gene is located on chromosome 10q24.3 and consists of eight 
exons (Picado-Leonard and Miller, 1987). To date, about 70 mutations in the 
CYP17A1 gene have been described (www.hgmd.cf.ac.uk), and the majority is 
associated with a phenotype of combined 17α-hydroxylase/17,20 lyase deficiency. 
Lack of CYP17A1 17α-hydroxylase activity results in low cortisol levels. Activation of 
the HPA axis leads to overproduction of corticosterone and deoxycorticosterone 
causing hypertension with hypokalaemia. The partial affinity of corticosterone for the 
glucocorticoid receptor may compensate for low cortisol levels and patients do not 
present with severe salt-wasting adrenal crisis. The lack of CYP17A1 17,20 lyase 
activity results in disturbances of sex steroid production leading to disordered sex 
development (DSD) in genetically male individuals (46,XY DSD) or delayed or absent 
pubertal development including primary amenorrhoea in 46,XX females. The residual 
mutant enzyme activity in 17OHD correlates well with the severity of disease 
expression. A few missense mutations in the CYP17A1 gene have been described to 
exhibit only moderate impairment of CYP17A1 17α-hydroxylase activity, while the 
17,20 lyase activity was always greatly reduced (see section 1.3.1.1). These patients 
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with apparently ‘isolated’ 17,20 lyase deficiency have normal blood pressure and 
cortisol levels but reduced sex steroid production. This suggests that CYP17A1 17α-
hydroxylase activity is the determining component leading to a wider phenotypic 
spectrum of 17OHD. 
5.2. METHODS 
5.2.1. Patients 
Case 1: The patient (46,XX) was born at term as the third child of non-
consanguineous parents of Polish origin. At the age of 15 years she was admitted to 
an endocrinologist for further investigation of disturbed pubertal development and 
arterial hypertension. She presented with lack of pubertal development (Tanner 
stages PH1, B2, M0) and had elevated blood pressure (150/90 mmHg; 3.6/3.0 SDS 
for height), normal sodium and low-normal potassium (Table 14). Further hormonal 
investigations revealed low plasma renin activity (PRA); ultrasound investigations 
excluded renal and cardiac hypertension. Baseline cortisol was low and did not 
increase after ACTH1-24 stimulation; 17OHP was normal and ACTH was elevated. 
Sex steroids including androstenedione and oestradiol (E2) were low with elevated 
gonadotrophins, indicating hypergonadotrophic hypogonadism (Table 14). 
Case 2: The boy (46,XY) is the fourth child of consanguineous parents of 
Afghan origin. He presented at the age of 12 years with learning difficulties, 
gynaecomastia, microphallus (2.5 cm), glandular hypospadias and cryptorchidism 
and had a history of orchidopexy for a left undescended testis at the age of 5 years. 
His Tanner pubertal stages were G1, PH3. His blood pressure was normal, and his 
serum potassium and sodium levels were within the age and sex specific normal 
range (Table 14). His serum testosterone level was within the lower normal range 
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and his raised gonadotrophins revealed compensated hypergonadotrophic 
hypogonadism (Table 14). Baseline cortisol was low and did not increase after iv 
ACTH1-24; 17OHP at baseline was mildly elevated (Table 14). 
Case 3: The older sister (46,XX) of case 2 presented in the endocrine clinic at 
the age of 15 years because of delayed pubertal development. She had normal 
breast development (Tanner B4) but did not develop pubic hair nor experienced 
menarche. Cortisol was low at baseline and did not increase sufficiently after ACTH1-
24 stimulation (Table 14). 17OHP was 2.7 nmol/l at baseline and increased to 3.5 
nmol/l after ACTH1-24. DHEAS was undetectable by several measurements. E2 was 
pre-pubertal with gonadotrophins at baseline within the pubertal reference range 
(Table 14). Blood pressure was normal at random baseline measurements and 
within the age- and height adjusted 50th – 90th centiles in a 24h blood pressure 
measurement. 
Case 4: The 4 week old baby (46,XX) was assessed for prolonged jaundice. A 
baseline cortisol was 25 nmol/L and did not increase after synacthen stimulation 
(Table 14). ACTH was highly elevated suggesting severe primary adrenal 
insufficiency. 17OHP was undetectable. Serum potassium and sodium levels were 
within the normal range. The physical examination showed normal female external 
genitalia. Urinary steroid profiling with GC/MS showed trace amounts of cortisol 
metabolites, absence of androgen metabolites with a small amount of corticosterone 
metabolites indicating incapacity of cortisol and androgen biosynthesis.  
Case 5: The patient (46,XY) was born as the only child of non-consanguineous 
parents of Caucasian origin in Romania. He presented in the endocrine clinic at the 
age of 23 years due to fertility problems and for consultation for plastic surgery for his 
small phallus. On examination, there was no phallus detectable with a single perineal 
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opening. The left testicle was descended and palpable in the scrotum. The blood 
pressure was normal. Hormonal investigations showed normal cortisol levels at 
baseline and after ACTH1-24 stimulation (Table 14). 17OHP and ACTH was within the 
age-specific reference range. Sodium, potassium, renin and aldosterone were 
normal. Androgen levels (DHEAS and testosterone) were low but 17-Preg was 
elevated (57 nmol/L; NR < 13).  
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Table 14: Summary of clinical, genetic, and hormonal findings from all patients with CYP17A1 
deficiency. SDS, standard deviation score 
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5.2.2. Urinary steroid profiling 
Analysis of urinary steroid metabolite excretion was performed with GC/MS as 
described in section 2.7.1. Steroids quantified included corticosterone metabolites 
THB, 5αTHB, THA, the 17-hydroxyprogesterone metabolite PT and androgen 
metabolites An, Et, DHEA and 16-OH-DHEA (see Table 9 for a full list of steroid 
abbreviations). 
 Following quantification of steroid metabolites, the following substrate/product 
ratios were calculated to determine the approximate in vivo net activity of specific 
steroidogenic enzymes: corticosterone over cortisol metabolites (17α-hydroxylase; 
(THA+THB+5αTHB)/(THF+5αTHF+THE)), 17-hydroxy-progesterone over androgen 
metabolites (17,20-lyase; (PT)/(An+Et)). These diagnostic ratios were compared to 
ratios obtained from urine analysis in a healthy, combined male and female reference 
cohort (n=26; age range 12-30 years). 
5.2.3. Genetic analysis 
The coding sequence of the CYP17A1 gene including exon-intron boundaries 
was amplified as described in section 2.2.11. 
5.2.4. Molecular cloning and site-directed mutagenesis 
The bicistronic mammalian expression vector pIRES harbouring the human  
cDNA for WT/mutant CYP17A1 (in MCA) and WT CYB5A (in MCB) was used for in 
vitro functional analysis. Site-directed mutagenesis for p.F53/54del, p.A398E, 
p.R347H, p.G111V, p.P409L and g.177dupA of CYP17A1 was performed in the 
pcDNA6 vector as described in section 2.4.3 by using the following primers (the 
mutated nucleotide is highlighted in bold): C17-R347H-Fwd: 5’-
ACTATCAGTGACCATAACCGTCTCCTC-3’; C17-R347H-Rev: 5’-GAGGAGACGG-
TTATGGTCACTGATAGT-3’; C17-F53del-Fwd: 5’- GGCCATATGCAATAACAACTT-
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CAAGCTGCAGAAAAAATAGGC-3’; C17-F53del-Rev: 5’- GCCATATTTTTTCTGCA-
GCTTGAAGTTGTTATGCATATGGCC-3’; C17-A398E-Fwd: 5’- AATCTGTGGGAG-
CTGCATCAC-3’; C17-A398E-Rev: 5’-GTGATGCAGCTCCCACAGATT-3’; C17-
G111V-Fwd: 5’-AACCGTAAGGTTATCGCCTTC-3’; C17-G111V-Rev: 5’-GAAGGCG-
ATAACCTTACGGTT-3’; C17-P409L-Fwd: 5’-TGGCACCAGCTGGATCAGTTC-3’; 
C17-P409L-Rev: 5’-GAACTGATCCAGCTGGTGCCA-3’; C17-dupA-Fwd: 5’-GCAG-
AAAAAAATATGGCCCCA-3’; C17-dupA-Rev: 5’-TGGGGCCATATTTTTTTCTGC-3’. 
Correct insertion of the mutation and integrity of the inserts were checked by 
direct sequencing. Next, the WT and mutant coding sequences of CYP17A1 (plus 
V5-tag) were subcloned into the MCA of the pIRES vector harbouring the WT cDNA 
for CYB5A in its MCB (see section 6.2.5). 
5.2.5. In vitro functional analysis 
HEK293 cells were transfected with 2 µg of pIRES plasmid as described in 
section 2.1.4. 48h after transfection, cells were incubated at 37°C with 1 ml full MEM 
supplemented with 200 nM nicotinamide adenine dinucleotide phosphate in the 
presence of 1000 nmol/litre progesterone for 17α-hydroxylase assays or 500 
nmol/litre 17Preg for 17,20 lyase assays. Optimal incubation times for wild type and 
mutants were assessed in pilot experiments. After incubation, cell supernatant was 
removed and 10µL of a 1000ng/mL solution of progesterone-d4, 17OHP-d4, 17Preg-
d4, DHEA-d4 (all Cambridge Isotope Laboratories Inc., Andover, MA) were added to 
the medium as an internal standard to normalize extraction efficiency and mass 
spectrometry variability. Steroids were extracted with 4 ml methyl tert-butyl ether as 
described in section 2.5.5 and resuspended in 1ml 50/50 (v/v) methanol/water 
(LC/MS grade). A Waters Xevo mass spectrometer with ACQUITY ultra performance 
liquid chromatography™ (UPLC) system was used fitted with a HSS T3, 1.8 µM, 1.2 
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x 50 mm column (Waters Corporation, Milford, MA). Each steroid was quantified by 
comparison to a calibration series with respect to their internal standard. Quantitation 
was completed using TargetLynx 4.1 software (MassLynx 4.1, Waters). The assays 
were linear over a range of 1-500 ng/ml for progesterone and 17OHP and 0.5-500 
ng/ml for 17Preg and DHEA (R2=0.998). Steroid conversion rates were calculated as 
described in section 2.5.2 and results were visualized in GraphPad Prism Software 
version 4.0 (GraphPad Inc., San Diego, USA).  
Western blot was performed as described in section 2.3.3 using an anti-V5 
antibody (Sigma Aldrich, St Louis, MO, USA). 
 
5.3. RESULTS 
5.3.1. Urinary steroid profiling 
Urinary steroid profiling with GC/MS showed a consistent pattern in all patients 
(except case 4 whose urinary steroid profile was not available for this study). 
Mineralocorticoid metabolites (THA, THB, and 5αTHB) as well as progesterone and 
pregnenolone metabolites (5-PT, PT, and 5-PD) were elevated, but androgen 
metabolites (An and Et) were low with borderline-low metabolites of active 
glucocorticoids (THF, 5α-THF, cortolones) (data not shown). This pattern is highly 
indicative of reduced in vivo CYP17A1 enzyme activity, with both catalytic activities 
significantly impaired. Substrate-product ratios have been applied (Figure 26) to 
compare in vivo net activities of CYP17A1 between the four cases analysed. An 
elevation of this ratio compared to the reference cohort indicates deficiency of the 
respective enzyme activity. The ratio of mineralocorticoid over glucocorticoid 
metabolites (THA+THB+5aTHB)/(THE+THF+5aTHF), reflecting the 17α-hydroxylase 
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activity of CYP17A1, was most severely impaired in case 1 (185.7; NR 0.07-0.18). 
This ratio was moderately elevated in cases 2 and 3 (6.8 and 12.3, respectively), but 
only very mildly elevated in case 5 (1.7) (Figure 26). The diagnostic ratio reflecting 
the 17,20 lyase activity of CYP17A1 [(PT)/(An+Et)] was highest in case 5 (10; NR 
0.09-0.31) and lower in case 1 (3.6), case 2 (2.2) and case 3 (1.1) (Figure 26). 
 
Figure 26: In vivo assessment of CYP17A1 17α-hydroxylase and 17,20 lyase activities as indicated 
by urinary steroid metabolite analysis. Diagnostic steroid metabolite ratios in the four cases analysed 
with CYP17A1 deficiency are represented by closed symbols (white, case 1; black, case 2; grey, case 
3).  White box plots represent the interquartile ranges of the reference cohort (healthy males and 
females, 10-30 years; n=26), whiskers represent the 5th and 95th percentiles, respectively. For steroid 
abbreviations please see methods. 
 
5.3.2. Genetic analysis 
The identification of mutations in the CYP17A1 gene was carried out by direct 
sequencing in all 5 cases and is summarized in Figure 27. 
Case 1 was compound heterozygous for two missense mutations of the 
CYP17A1 gene (g.2004 G>T in exon 1 and g.5831 C>T in exon 7) resulting in 
substitution of glycine by valine at position 111 (p.G111V) and a substitution of 
proline by leucine at position 409 (p.P409L) of the amino acid sequence. 
Segregational analysis revealed that the p.P409L mutation derived from the father 
and the p.G111V mutation was inherited from the mother. 
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Case 2 (p.F53/54del hom.) 
Case 3  (p.F53/54del hom.) 
Case 5 (p.A389E/p.R347H) 
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Figure 27: Summary of the genetic findings in the CYP17A1 gene (exons are indicated by green 
boxes) including segregational analysis in 5 patients with 17OHD. The following mutations in the 
CYP17A1 gene are novel: p.G111V and p.P409L (case 1), p.Y60IfsK88X (case 2) and p.A398E (case 
5). 
Cases 2 and 3 were found to be homozygous of a three nucleotide deletion 
(g.157_159delTTC) in exon 1 of the CYP17A1 gene resulting in deletion of a 
phenylalanine residue of the amino acid sequence (p.F53/54del). Genetic work-up of 
the family revealed that both consanguineous parents are heterozygous carriers of 
the p.F53/54del mutation. Moreover, five siblings of the patient have the mutation in 
the heterozygous state while one sibling carries the wild type sequence on both 
alleles. 
Case 4 carries a novel mutation in exon 1 of the CYP17A1 gene causing a 
duplication of adenosine in position 177 of the genomic sequence (g.177dupA). On 
the protein level, this duplication leads to a frameshift with an introduction of a stop 
codon at position 88 (p.Y60IfsK88X). The older symptomatic sister of the patient 
carries p.Y60IfsK88X mutation on both alleles as well. The mother was the 
heterozygous carrier of the mutation and the father was not available for genetic 
analysis. 
Fig. 2 
Cases 2 and 3 
Case 4 
R347H/ 
A398E 
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Case 5 was compound heterozygous for two missense mutations in exon 6 
(g.4752 G>A) and in exon 7 (g.5804 C>A) of the CYP17A1 gene resulting in 
substitution of an arginine residue by histidine (p.R347H) and substitution of an 
alanine residue by glutamic acid (p.A398E), respectively. Parental DNA was not 
available to carry out segregational analysis. 
 
5.3.3. In vitro functional assays 
All mutants assessed for residual enzymatic activity of both CYP17A1 catalytic 
reactions show greatly reduced or even absent activity in vitro (Figure 28). However, 
three mutants (p.R347H, p.A398E and p.F53/54 del) retain some residual 17α-
hydroxylase activity of about 10-15 % of WT activity. Amongst these, the p.347H 
mutation has the highest residual activity (15.6 %) with p.A398E and p.F53/54del 
retaining about 10% of WT enzyme activity (Figure 28A). The 17,20 lyase activity 
was greatly reduced to about 1% or less of WT activity for all mutant CYP17A1 
protein studied (Figure 28B). Amongst all mutant proteins, p.P409L, p.G111V and 
the frameshift mutation most severely reduce CYP17A1 catalytic function for both 
17α-hydroxylase and 17,20 lyase activities, with the two latter mutations completely 
abolishing protein function. 
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Figure 28: Residual mutant enzyme activity values are depicted for the two catalytic activities of 
CYP17A1. Panel A for the conversion of progesterone (Prog) to 17-hydroxyprogesterone (17OHP), 
reflecting 17α-hydroxylase activity; panel B reflects the 17,20 lyase activity as assessed by the 
conversion of 17-hydroxypregnenolone (17Preg) to DHEA. Residual enzyme activity is expressed at 
percentage of wild type (WT) activity, which is defined as 100%. Substrate conversion rate for WT 
protein was 14.4 ± 0.4 nmol/mg protein/min for Prog and 5.8 ± 1.5 nmol/mg protein/min for 17Preg. All 
experiments were performed in triplicate in three independent experiments. Error bars represent ± 
SEM (in percent). 
 
5.4. DISCUSSION 
We have described five cases with inactivating mutations in the CYP17A1 gene 
causing 17α-hydroxylase deficiency and demonstrated in vivo (urinary metabolite 
analysis) and in vitro (functional characterizations) that residual 17α-hydroxylase 
activity of distinct CYP17A1 mutations is associated with non-classical manifestations 
of this disorder.  
The complete absence of 17α-hydroxylase activity, as illustrated in case 4, 
caused by the severe homozygous frameshift mutation, resulted in a severe neonatal 
presentation with adrenal insufficiency. Neonatal presentation resembling primary 
adrenal insufficiency is very unusual in 17OHD and has not been reported in the 
literature so far. The majority of patients present ‘classically’, i.e. with 46,XY DSD or 
lack of pubertal development in 46,XX girls, hypokalaemic hyporeninaemic 
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hypertension and compensated glucocorticoid deficiency due to partial activation of 
the GC receptor by MC precursors (Goldsmith et al., 1967; Yanase, 1995; Miura et 
al., 1996; Krone and Arlt, 2009; Miller and Auchus, 2011); this phenotype is 
illustrated by patient 1 of this case series. Some excretion of MC metabolites in the 
baby (case 1) - as detected in her urine sample - might have prevented her from 
severe salt-wasting crisis, but was also directional in establishing the diagnosis as 
other causes of primary adrenal insufficiency had already been considered (i.e. 
mutations in NR5A1, DAX1 or CYP11A1). Another severe mutation, in a 
homozygous state, resulting in early truncation of the protein (p.Y27X) was 
previously reported in an adult woman, who had no signs of pubertal development, 
and interestingly, did not present with arterial hypertension (Müssig et al., 2005). 
However, the urinary steroid profile in this patient with high MC metabolites but 
undetectable 17-oxygenated C21 and C19 steroids represented the typical 
biochemical fingerprint of severe combined 17α-hydroxylase/17,20 lyase deficiency.  
About 10% of patients with 17OHD are normokalaemic and normotensive, 
despite the fact that they carry severe disease-causing mutations (Kater and Biglieri, 
1994; Auchus, 2001). The exact explanation for this phenotypic variability is not 
known and underlying mechanisms remain to be elucidated. 
The p.F53/54del mutation in CYP17A1 has been frequently reported and is one 
of the most prevalent mutations in patients of Asian origin, usually associated with 
partially combined inactivation of 17α-hydroxylase/17,20 lyase activities (Miura et al., 
1996; Bao et al., 2011; Yanase et al., 1989). The predominant phenotype of patients 
with this mutation is 1) a variable degree of hyperaldosteronism with hypokalaemic 
hypertension not always present and 2) milder sex steroid deficiency with absent or 
mild DSD in 46,XY individuals and compensated hypergonadotrophic hypogonadism 
 
Chapter 5           Phenotypic Variability of 17OHD 
___________________________________________________________________ 
 
157 
in both sexes (Yanase, 1995; Miura et al., 1996). These features are consistent with 
the clinical presentations of the two siblings with homozygous p.F53_54del from this 
case series (case 2 and 3) and the in vitro functional analysis of this mutation 
retaining about 10% residual activity of 17α-hydroxylase and some residual activity of 
17,20 lyase (section 5.3.3) may explain the observed phenotype. 
Case 5 presented with the clinical and biochemical features of ‘isolated’ 17,20 
lyase deficiency. Isolated 17,20 lyase deficiency is a rare condition and only around 
25 cases have been described in the literature so far (Yanase et al., 1991) (see also 
sections 1.3.1.1 and 6.4). Importantly, the initial reports on the condition provided 
only the clinical and hormonal characterizations without identifying a distinct genetic 
abnormality in six families with 46,XY DSD patients and two families with 46,XX 
patients that presented with lack of pubertal development [reviewed and discussed in 
(Yanase et al., 1991)]. So far, 15 cases of isolated 17,20 lyase deficiency with a 
complete clinical, hormonal, genetic, and functional work-up have been reported 
Underlying causes were four distinct missense mutations in the CYP17A1 gene 
(p.R347H; p.R347C p.R358Q; p.E305G) (Geller et al., 1997; Sherbet et al., 2003; 
Van Den Akker et al., 2002) and one POR missense mutation (p.G539R) 
(Hershkovitz et al., 2008). Recently, a CYB5A nonsense mutation (p.W27X) has 
been reported resulting in early protein truncation and thus loss of CYB5A function 
(Kok et al., 2010). Case 5 carried the known missense mutation p.R347H on one 
allele and a novel missense mutation p.A398E on the other allele. A unifying 
characteristic of all individuals with 17,20 lyase deficiency is severe sex steroid 
deficiency, with hormonal measurements confirming a lack of adrenal and gonadal 
androgen synthesis. However, it is noteworthy that all patients with underlying 
CYP17A1 or POR mutations concurrently showed significant impairment of 
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glucocorticoid production, with insufficient cortisol responses to ACTH stimulation; a 
comprehensive overview of all the published cases with a genetic work-up available 
is shown in Table 17. Of note and to our current knowledge, case 5 is the first patient 
with isolated 17,20 lyase deficiency due to mutant CYP17A1 who has normal ACTH-
stimulated cortisol levels (Table 14), however urinary steroid metabolome analysis 
demonstrated mild impairment of 17α-hydroxylase activity. A comparison of urinary 
metabolite ratios reflecting 17α-hydroxylase activities between the patients of this 
case series shows that this ratio is the lowest in this patient, indicating a higher 
residual in vivo 17α-hydroxylase activity (Figure 26). In addition, the degree of 17α-
hydroxylase inhibition reflected by this ratio mirrors the in vitro functional 17α-
hydroxylase activity of the mutant enzymes  (Figure 28). A comparison of these 
ratios reflecting between the cases from this thesis and published cases presenting 
with either classical combined CYP17A1 deficiencies (Neres et al., 2010) or isolated 
17,20 lyase deficiencies (Tiosano et al., 2008) is shown in Figure 29. This figure also 
depicts the three siblings with isolated 17,20 lyase deficieny due to mutant CYB5A, 
as described in Chapter 6, and data from the Birmingham cohort of patients with 
PORD (Krone et al., 2012). Clearly, case 5 (represented by the open diamond) has 
only a mild elevation the 17α-hydroxylase ratio; however, biochemically, the 
enzymatic activity is inhibited, although there is no clinical or hormonal evidence for 
impaired GC production or MC excess.  
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Figure 29:  In vivo assessment of CYP17A1 17α-hydroxylase and 17,20 lyase activities as indicated 
by urinary steroid metabolite analysis. Diagnostic steroid metabolite ratios in the three siblings with 
isolated 17,20 lyase deficiency (ILD) due to homozygous p.H44L CYB5A are represented by closed 
circles on the left of each panel (white, case 1; black, case 2; grey, case 3).  The white diamond 
symbol represents the ratio obtained from the patient with ILD due to mutant CYP17A1 (case 5 in this 
chapter; p.A398E/p.R347H) and the three patients with a more classical presentation of 17OHD 
(circle: case 1, p.G111V/p.P409L; triangle: case 2; square: case 3, both p.F53_54del hom). White box 
plots represent the interquartile ranges of the reference cohort (healthy males and females, 4-20 
years; n=98), whiskers represent the 5th and 95th percentiles, respectively. Grey box plots indicate the 
ranges and medians for the same steroid ratios measured in 20 patients with classic 17α-hydroxylase 
deficiency (CYP17A1 17OHD; Neres et al. 2010); six patients with apparently isolated 17,20 lyase 
deficiency due to CYP17A1 p.E305G (CYP17A1 ILD; Tiosano et al. 2008), and 21 patients with P450 
oxidoreductase deficiency (Krone et al. 2012). The triangles represent two patients with the POR 
mutation p.G539R reported as associated with apparently isolated 17,20 lyase deficiency (Hershkovitz 
et al., 2008). For steroid abbreviations please see methods. 
 
Thus, urinary steroid profiling represents a powerful diagnostic tool, not only to 
simplify diagnosis of distinct steroidogenic disorders but also to potentially predict the 
severity of the mutation, as illustrated in this case series. Importantly, true isolated 
17,20 lyase deficiency, i.e. no clinical, hormonal or biochemical evidence of impaired 
GC or MC biosynthesis and action, is not observed in mutations of the CYP17A1 and 
POR genes. 
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6. CHAPTER 6: MUTANT CYTOCHROME B5 (CYB5A) 
CAUSES TRUE ISOLATED 17,20 LYASE 
DEFICIENCY OF CYP17A1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published as: 
 
A missense mutation in the human cytochrome b5 gene causes 46,XY disorder 
of sex development due to true isolated 17,20 lyase deficiency. 
Idkowiak J, Randell T, Dhir V, Patel P, Shackleton CH, Taylor NF, Krone N, Arlt W. 
J Clin Endocrinol Metab. 2012 Mar;97(3):E465-75. doi: 10.1210/jc.2011-2413. Epub 
2011 Dec 14.  
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6.1. INTRODUCTION 
Androgen synthesis in humans crucially relies on the CYP17A1 that is primarily 
expressed in the adrenals and the gonads (see section 1.1.8.1): CYP17A1 exhibits 
two distinct catalytic activities. Its 17α-hydroxylase activity facilitates adrenal 
glucocorticoid synthesis. The 17,20-lyase activity of CYP17A1 converts 17-Preg to 
the principal androgen precursor dehydroepiandrosterone (DHEA) and, with 50-fold 
lesser efficiency (Auchus et al., 1998), 17OHP to androstenedione. Both the 17α-
hydroxylase and the 17,20 lyase activities of CYP17A1 require electron transfer from 
NADPH via the electron donor POR. CYP17A1 17,20 lyase activity requires 
additional interaction of CYP17A1 and POR with the haeme-containing protein 
cytochrome b5 (CYB5A) (Onoda and Hall, 1982). Previous studies suggest that 
CYB5A is not directly involved in electron transfer but rather facilitates allosteric 
interaction of the POR and CYP17A1 proteins, thereby enhancing electron flux 
(Auchus et al., 1998).  
 Isolated 17,20 lyase deficiency results in sex steroid deficiency and clinically 
presents with male undermasculinization, i.e. 46,XY disorder of sex development 
(46,XY DSD), and with absent or disturbed pubertal development in both 46,XY and 
46,XX individuals. In accordance with lack of impairment of 17α-hydroxylase activity, 
affected patients have been reported to not present with cortisol deficiency or 
mineralocorticoid excess, which are typically observed in classic, complete CYP17A1 
deficiency (Yanase, 1995; Miller and Auchus, 2011). To date, four different missense 
mutations in CYP17A1 have been reported to cause apparently isolated 17,20 lyase 
deficiency (Geller et al., 1997; Van Den Akker et al., 2002; Sherbet et al., 2003). A 
recent case report described a patient presenting with isolated 17,20 lyase deficiency 
and normal CYP17A1 sequence, in whom an inactivating mutation in the POR gene 
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was identified as the cause of disease (Hershkovitz et al., 2008). Recently, a 
nonsense mutation resulting in early truncation of the CYB5A protein has been 
described in a 46,XY DSD patient diagnosed with isolated 17,20 lyase deficiency 
(Kok et al., 2010).  
6.2. METHODS 
6.2.1. Patients 
I have investigated three siblings with 46,XY DSD and a biochemical 
presentation suggestive of isolated 17,20 lyase deficiency from a consanguineous 
family of Pakistani origin; the parents were first cousins.  
The index patient (Case 1) was born at 41 weeks gestation after an uneventful 
pregnancy and delivery; routine ultrasound examinations during pregnancy had 
predicted a female baby. However, at birth, ambiguous, predominantly female 
genitalia were observed, with enlarged, mildly scrotalized labia majora that contained 
palpable gonads. The phallus appeared similar to a female clitoris (7mm stretched 
length). Due to a skinfold between the labia, the urethral orifice and vaginal opening 
were not clearly detectable but the baby was able to pass urine. The karyotype was 
46, XY. Hormonal measurements three days after birth revealed elevated 17OHP 
(120 nmol/L; NR < 5.0), a normal testosterone (7.2 nmol/L; NR 5-15) normal 
androstenedione (1.8 nmol/L; NR < 7.7), and low gonadotrophins (LH < 0.5 U/L, FSH 
< 0.5 U/L). Serum electrolytes were normal when measured three weeks after birth  
(Na 140 nmol/L, NR 135-145; K 5.2 nmol/L, NR 3.5-5.5). An hCG stimulation test 
was performed at the age of 6 weeks and again at 5 months, both times revealing a 
low baseline testosterone that did not increase sufficiently three days after hCG 
administration (Table 15). The decision was taken to raise the baby as a boy.  
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The older sister (case 2) did not develop any signs of puberty by the age of 13 
yrs. On examination her genitalia looked predominantly female but with a single 
perineal opening, separate labio-scrotal folds with no palpable gonads and a mildly 
enlarged clitoris (15 mm). Clinically, she had an entirely pre-pubertal appearance 
including absence of pubic or axillary hair, indicating lack of adrenarche (Tanner 
stages B1, PH1). Her karyotype was 46,XY. Biochemical investigations revealed low 
androgens, a pre-pubertal oestradiol and early pubertal gonadotrophins (Table 15). 
There was a normal cortisol response in the short synacthen test but adrenal 
androgen precursors remained undetectable; 17OHP was mildly elevated (Table 15).  
Table 15: Summary of hormonal investigations in three siblings with cytochrome B5 deficiency. Hb: 
haemoglobin; MetHb: methaemoglobin. *: hCG test performed at 5 months of age; **: measured at 13 
years before the removal of bilateral intra-abdominal gonads. 
 Sibling 1  
(Index case) 
Sibling 2 Sibling 3 
Age at presentation  neonatal 12.75 yrs neonatal 
Karyotype 46,XY 46,XY 46,XY 
Age at time of 
investigation 
5 yrs 15 yrs 8 months 
Cortisol (nmol/L)    
at baseline 194 107 386 
60 min after ACTH1-24 807 (> 550) 726 (> 550) 901 (> 550) 
17OHP (nmol/L) 1.1 (2.0 -9.0) 9.5 (2.0-9.0) 30.0 (0-12.0) 
DHEAS (µmol/L)    
at baseline < 0.4 (0.4-3.7) < 0.4 (8.3-49) < 0.4 (0.5-20) 
60 min after ACTH1-24 < 0.4 < 0.4 < 0.4 
Androstenedione (nmol/L)    
at baseline < 1.1 (1.5-2.7) < 1.1 (1.8-4.8) < 1.1 (1.5-2.7) 
60 min after ACTH1-24 < 1.1 < 1.1 < 1.1 
Testosterone (nmol/L)    
at baseline 0.2* (0.5-2.0) 1.1 (fem. NR: 0-2.8.0) 0.6 (0.5-2.0) 
3 days after 1,500 U hCG 0.2* n.m.  
Oestradiol (pmol/L)  60**  
LH (U/L) 0.8 2.1** (0.3-2.5)  
FSH (U/L) 2.8 3.2** (1.3-6.6)  
MetHb (mmol/mmol Hb) 0.063 (< 0.015) 0.061 (< 0.015) 0.085 (< 0.015) 
 
The youngest child of the family (case 3; 46,XY) was born with ambiguous 
genitalia, including bifid scrotum, a very small penis with hardly any corporal tissue 
present and perineal hypospadias. His testes were not descended into the scrotum 
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but palpable in the inguinal region. He had an elevated 17OHP and a normal cortisol 
response to ACTH (Table 15). Corrective surgery for hypospadias and bifid scrotum 
are scheduled for after the child’s first birthday. 
All 3 affected siblings had elevated clinically inapparent methaemoglobin 
levels (Table 15).  
6.2.2. Urinary steroid profiling 
Analysis of urinary steroid metabolite excretion was performed as described in 
section 2.7.1. Steroids quantified included corticosterone metabolites THB, 5αTHB 
and THA, the progesterone metabolite PD, 17-hydroxyprogesterone metabolites PD 
and 17HP, the 17-hydroxypregnenolone metabolite 5-PT, the 21-desoxycortisol 
metabolite P’TONE, cortisol metabolites THF, 5αTHF and THE, and androgen 
metabolites An, Et, DHEA and 16-OH-DHEA (see Table 9 for steroid abbreviations). 
 Following quantification of steroid metabolites by GC/MS I have calculated 
substrate metabolite/product metabolite ratios to reflect the net in vivo activity of 17α-
hydroxylase, i.e. corticosterone over cortisol metabolites (THA+ 
5αTHA+THB+5αTHB)/(THF+5αTHF+THE), and 17,20-lyase, i.e. 17OHP over 
androgen metabolites (17HP+PT)/(An+Et).  
 
6.2.3. Genetic analysis 
DNA analysis was performed after obtaining informed assent and consent 
from patients and parents, respectively, with approval from institutional research 
ethics committees. Genomic DNA was extracted from peripheral blood leukocytes for 
cases 1-3 and the parents, using a DNA blood and cell culture kit (Qiagen, GmbH, 
Hilden, Germany). From all other siblings and parents, DNA was extracted from 
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saliva using a commercially available kit (Oragene DNA OG250 and OG300, DNA 
Genotek, Ontario, Canada).  
The coding sequences of the CYB5A, POR and CYP17A1 genes including 
exon-intron boundaries were amplified as described in section 2.2.11 for the index 
patient. For all other family members, only exon 2 of the CYB5A gene was amplified 
and sequenced. 
6.2.4. In silico analysis 
The x-ray structure of human oxidized microsomal cytochrome b5 was used 
as a template for in silico analysis (PDB ID: 2I96; M. Nunez-Quintana, G. Truan, C. 
van Heijenhoort. Solution structure of human cytochrome b5). The structural 
representations were generated using the program Molsoft ICM Browser Pro (Molsoft 
L.L.C., La Jolla, CA). 
6.2.5. Molecular cloning and site-directed mutagenesis 
Human CYP17A1 cDNA was tagged with the V5 epitope by sub-cloning into the 
pcDNA6 vector (section 2.4.1.2). The CYP17A1 template cDNA was derived from 
human CYP17A1 cDNA in the yeast expression vector V10 (see section 2.4.1.1). 
The following hybrid primers were designed for PCR-based cloning with the In-
Fusion® cloning system (section 2.4.2.3), containing HindIII (5’) and BamHI(3’) 
restriction sites (gene-specific sequence is highlighted in bold): Fwd_HindIII: 5’-
GTTTAAACTTAAGCTTATGTGGGAGCTCGTGGCTCTCTTG-3’; Rev_BamHI: 5’-
CTGGACTAGTGGATCCGGTGCTACCCTCAGCCTGGGCT-3’. For the PCR, high 
fidelity Pfu-polymerase (Roche, Basel, Switzerland) was employed. The integrity of 
the inserts was checked by direct sequencing.  
Human CYB5A cDNA in the yeast expression vector V10 was kindly donated by 
Dr Richard Auchus (Ann-Arbor, Michigan, USA). Site-directed mutagenesis for 
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p.H44L CYB5A was performed as described in section 2.4.3 by using the following 
primer (the mutated nucleotide is highlighted in bold): Fwd: 5’-CA-
AATTTCTGGAAGAGCTTCCTGGTGGGGAAGAAG-3’; Rev: 5’- CTTCTTCCCCACC-
AGGAAGCTCTTCCAGAAATTTG-3’.  
Then the V5-tagged CYP17A1 cDNA and human WT and mutant (p.H44L) 
CYB5A cDNA were cloned into the bi-cistronic expression vector pIRES (section 
2.4.1.3) by using the PCR-based Infusion® cloning approach. Primers were 
generated to clone CYP17A1-V5-6xHis from pcDNA6 into the MCA of pIRES, 
employing restriction sites NheI (5’) and MluI (3’) (gene-specific sequence highlighted 
in bold): Fwd: 5’-CTCACTATAGGCTAGCATGTGGGAGCTCGTGGC-3’; Rev: 5’-
TGCATGCTCGACGCGTTCAATGGTGATGGTGATGATG-3’. WT and mutant 
CYB5A were cloned in the MCB of pIRES, employing restriction site SalI (5’) and 
NotI (3’): Fwd: 5’-ATCCTCTAGAGTCGACATGGCAGAGCAGTCGGAC-3’; Rev: 5’-
TAAAGGGAAGCGGCCGCCAGTCCTCTGCCATGTATAGGC-3’. Correct insertion 
of the mutation and integrity of the inserts were checked by direct sequencing. 
6.2.6. In vitro functional analysis 
 For in vitro functional analysis, the human embryonic kidney cell line HEK293 
(section 2.1.1) was used for transient transfection with the generated pIRES 
constructs and analysis of both catalytic activities of CYP17A1 was performed as 
follows: cells were transfected with three types of pIRES plasmids as decribed in 
section 2.1.4: (1) WT CYP17A1 with WT CYB5A; (2) WT CYP17A1 with p.H44L 
CYB5A and (3) WT CYP17A1 alone (empty MCSB in pIRES). Kinetic constants were 
determined 48 h following transfection. For 17α-hydroxylase activity assays, cells 
were incubated in 500 µl MEM full growth medium with 0.5, 1, 2, and 5 µmol/L 
progesterone in the presence of 0.2 µCu 3H-labelled progesterone (101.3 Ci/mol; 
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Perkin Elmer, Waltham, MA). For 17,20 lyase activity assays, cells were incubated 
with 0.25, 0.5, 1.25 and 2.5 µmol/L 17-Preg containing 0.2 µCu 3H-labelled 17-Preg 
(53.7 Ci/mol; Perkin Elmer, Waltham, MA). To enhance the efficiency of the 
enzymatic reaction, NADPH was added to the medium in a final concentration of 200 
nmol/L. Steroids were extracted and then separated by thin layer chromatography 
and quantified (section 2.5.6). Kinetic parameters were calculated as described in 
section 2.5.2. 
 Protein amounts were measured using the Bradford method (section 2.3.2) 
after lysing the cells in PBS containing protease inhibitors and 0.1% Triton X-100. To 
ensure similar expression levels, Western blotting was performed as described in 
section 2.3.3 with some minor modifications. In brief, cell lysates (8-15 µg) were 
separated by SDS-PAGE electrophoresis, transferred onto nitrocellulose membranes 
(Amersham Biosciences) at 30 V for 90 min and blocked with 5% skimmed milk 
powder (w/v) in PBST (PBS, 0.1% (v/v) Tween 20) for 1-2 hours. Primary antibodies 
were incubated overnight employing the following dilutions: rabbit polyclonal to 
cytochrome b5 (Abcam) 1:250; mouse monoclonal to V5 (Invitrogen) 1:1,000; mouse 
monoclonal to β-actin (Abcam) 1:25,000. Secondary horseradish-peroxidase 
conjugated antibodies and detection by enhanced chemiluminescence (Immobilon, 
Millipore, Watford, UK) was performed according to the manufacturer’s protocol.  
 
6.3. RESULTS 
6.3.1. Urinary steroid profiling 
GC/MS analysis of urinary steroid metabolites revealed low androgen 
metabolite excretion with increased excretion of the 17-Preg metabolite pregnenetriol 
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(5PT), suggestive of 17,20 lyase deficiency; concurrently, mineralocorticoid and 
glucocorticoid metabolite excretion appeared normal, suggesting preserved 17α-
hydroxylase activity (Figure 30). In keeping with these findings, 17α-hydroxylation as 
assessed by the ratio of corticosterone over cortisol metabolites was not 
compromised in either sibling whereas 17,20 lyase activity as determined by the ratio 
of 17OHP over androgen metabolites was significantly elevated, suggestive of 
isolated 17,20 lyase deficiency (Figure 31).  
 
 
Figure 30: Urinary steroid profile as determined by total 24-h steroid metabolite excretion analysis by 
GC/MS in one of the affected patients at the age of 13.5 years (case 2; represented as closed circles) 
in comparison to an age- and sex-matched reference cohort (box plots). For steroid metabolite 
abbreviations please refer to the methods section.  
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Figure 31: In vivo assessment of CYP17A1 17α-hydroxylase and 17,20 lyase activities as indicated 
by urinary steroid metabolite analysis. Diagnostic steroid metabolite ratios in the three siblings with 
isolated 17,20 lyase deficiency due to homozygous p.H44L CYB5A are represented by closed circles 
(white, case 1; black, case 2; grey, case 3).  White box plots represent the interquartile ranges of the 
reference cohort (healthy males and females, 4-20 years; n=98), whiskers represent the 5th and 95th 
percentiles, respectively. For steroid abbreviations please see methods. 
 
6.3.2. Genetic analysis 
Sequencing of the coding regions of the CYP17A1 and POR genes did not 
reveal mutations in any of the three affected siblings. However, we identified a 
homozygous missense mutation at the beginning of exon 2 of the CYB5A gene 
(g.28,400 A>T) changing a histidine at position 44 to leucine (p.H44L) (Figure 32A). 
Segregation analysis demonstrated heterozygosity for the p.H44L variant in both 
father and mother. Further sequencing analysis of the other clinically unaffected 
siblings revealed heterozygous p.H44L CYB5A in four and WT CYB5A in the 
remaining four of the siblings (Figure 32B). 
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Figure 32: Panel A, electropherogram depicting the homozygous missense mutation in the CYB5A 
gene identified in the index patient (P), with heterozygosity in mother (M) and father (F). The mutation 
g.28,400 A>T is located at the beginning of exon 2 as indicated in the schematic representation of the 
CYB5A gene. Exons are shown as grey rectangles and introns as thin lines; numbers indicate the 
sizes of the intronic regions. Panel B, pedigree of the index family with segregation analysis of the 
identified CYB5A mutation. The arrow depicts the index patient. 
 
6.3.3. In vitro functional assays 
The observed catalytic constants for the 17α-hydroxylase reaction did not differ 
following co-expression of CYP17A1 with and without wild type or mutant CYB5A 
(Figure 33, Table 16). In contrast, CYP17A1 17,20 lyase activity (Bhattacharya et 
al., 1999; Schröder et al., 2012; Hershkovitz et al., 2008) was greatly reduced in the 
presence of p.H44L CYB5A as compared to incubations with WT CYB5A, almost 
down to the level observed after the expression of CYP17A1 without CYB5A (Figure 
33B). This decrease in catalytic efficiency was mainly a consequence of a marked 
reduction of the maximal reaction velocity Vmax while Km (indicative of substrate 
affinity) appeared not to be affected by p.H44L (Table 16). The residual activity of the 
p.H44L mutant on the 17,20 lyase reaction was about 5% of WT (Figure 33C).  
A B 
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Figure 33: Panels A+B, results of kinetic analysis of CYP17A1 activities.  The panels show 
Lineweaver-Burk plots of 17α-hydroxylase (A) and 17,20 lyase (B) activities as assessed in HEK293 
cells transiently transfected with CYP17A1 with or without wild type (WT) or mutant p.H44L CYB5A. 
Panel C, residual enzyme activity expressed as percentage of wild type (WT) activity, defined as 
100%, based on measurements carried out at substrate concentrations around Km, i.e. 1µM and 0.5 
µM for 17α-hydroxylase and 17,20 lyase activitiy, respectively. For defining the impact of p.H44L on 
17,20 lyase activity, the conversion rate observed following expression of CYP17A1 alone was 
subtracted from those observed after co-expression of CYP17A1 with WT and mutant CYB5A, 
respectively, prior to calculation of residual activities. Panels A-C: Error bars represent the mean ± 
SEM (%) of at least three independent triplicate experiments. Panel D, a representative Western blot 
demonstrating equal expression levels of WT and mutant CYB5A and CYP17A1 with β-actin as a 
control for equal loading 
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Table 16: Kinetic constants (± SEM) of human CYP17A1 catalytic activities after equal co-expression 
of human wild type CYP17A1 with either human wild type (WT) or mutant (p.H44L) cytochrome b5 
(CYB5A) as compared to the expression of CYP17A1 without CYB5A in HEK293 cells. 
 
 
 
 
 
 
 
 
 
6.3.4. In silico analysis 
 The histidine residue at position 44 is localized in the haeme-binding pocket 
within the core domain of the CYB5A protein (Figure 34A). The imidazole side chain 
of H44 appears to coordinate the haeme iron and keep the redox active haeme 
molecule attached to the CYB5A protein (Figure 34B) (Mathews, 1985). Substitution 
with non-polar lysine in the same position appears to disrupt the interaction between 
the CYB5A core domain and the haeme molecule (Figure 34C). 
 17α-hydroxylase 17,20 lyase 
Vmax (µmol/mg x hour) (nmol/mg x hour) 
CYP17A1 + CYB5A WT 4.71 ± 0.24 118 ± 5  
CYP17A1 + CYB5A H44L 5.24 ± 0.16   41 ± 2 
CYP17A1  4.99 ± 0.19   35 ± 2 
Km (µM) (µM) 
CYP17A1 + CYB5A WT 2.3 ± 0.25 0.55 ± 0.07 
CYP17A1 + CYB5A H44L 2.4 ± 0.15 0.48 ± 0.06 
CYP17A1  2.4 ± 0.20 0.48 ± 0.07 
Catalytic efficiency (Km/Vmax) (Km/Vmax) 
CYP17A1 + CYB5A WT 2.05 214 
CYP17A1 + CYB5A H44L 2.18 85 
CYP17A1  2.08 73 
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Figure 34: Panel A, three-dimensional model of CYB5A. The protein is composed of a core domain 
containing the haeme molecule and a hydrophobic tail domain. Panel B, magnification of the core 
domain highlights residue H44 in close proximity to the central iron atom of the haeme molecule. 
Panel C, L44 disrupts the interaction with the haeme molecule. 
 
6.4. DISCUSSION 
Here we have described the first human CYB5A missense mutation identified in 
three children from a large consanguineous family presenting with 17,20 lyase 
deficiency, 46,XY DSD and mild methaemoglobinaemia.  
Isolated 17,20 lyase deficiency is a rare condition and only around 25 cases 
have been described in the literature so far (Yanase, 1995; Geller et al., 1997; 
Hershkovitz et al., 2008; Simsek et al., 2005; Van Den Akker et al., 2002; Sherbet et 
al., 2003; Tiosano et al., 2008; Kok et al., 2010). The commonly agreed hormonal 
phenotype of isolated 17,20 lyase deficiency comprises a selective decrease in 
DHEA and androstenedione biosynthesis and normal glucocorticoid and 
mineralocorticoid production (Gupta et al., 2001). Importantly, the initial reports on 
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the condition provided only the clinical and hormonal characterizations without 
identifying a distinct genetic abnormality in six families with 46,XY DSD patients 
(Goebelsmann et al., 1976; Campo et al., 1979; Forest et al., 1980; Zachmann et al., 
1982; Kaufman et al., 1983) and two families with 46,XX patients that presented with 
a lack of pubertal development (Larrea et al., 1983; de Peretti et al., 1984). These 
reports have been summarized and discussed in the review of Yanase et al. (Yanase 
et al., 1991). 
 So far, 15 cases of isolated 17,20 lyase deficiency with a complete clinical, 
hormonal, genetic, and functional work-up have been reported (Table 17). 
Underlying causes were three distinct missense mutations in the CYP17A1 gene 
(p.R347H; p.R358Q; p.E305G) (Geller et al., 1997; Van Den Akker et al., 2002; 
Sherbet et al., 2003) and one POR missense mutation (p.G539R) (Hershkovitz et al., 
2008). It appears likely that another patient suggesting 17,20 lyase deficiency, 
presenting with 46,XX DSD and low circulating androgens (de Peretti et al., 1984), 
may also have suffered from POR deficiency, but at the time no genetic work-up was 
performed. Recently, a CYB5A nonsense mutation (p.W27X) has been reported 
resulting in early protein truncation and thus loss of CYB5A function (Kok et al., 
2010) (Table 17). A unifying characteristic of all these individuals is severe sex 
steroid deficiency. However, it is noteworthy that all patients with underlying 
CYP17A1 or POR mutations concurrently showed significant impairment of 
glucocorticoid production, with insufficient cortisol responses to ACTH stimulation 
(Table 17). This is further reflected by in vitro results that show a reduction of 17α-
hydroxylase activities to 13-65% and 46% of wild type activity for the CYP17A1 and 
POR mutations, respectively (Table 17). The only exception is the CYP17A1 mutant 
E305G for which normal or enhanced 17α-hydroxylase activity has been found in 
vitro (Sherbet et al., 2003). 
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Table 17: Overview of patients with 17,20 lyase deficiency that have been reported with complete 
information on clinical, biochemical and genetic work-up, including the functional work-up of the 
causative mutations. All mutations were found in the homozygous state. 
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However, patients homozygous for this mutation failed to show an appropriate 
cortisol response to ACTH and urinary steroid metabolite analysis demonstrated 
significantly impaired 17α-hydroxylase activity (Tiosano et al., 2008). Hence, 
although the impairment of 17,20 lyase activity dominates, none of the previously 
reported mutations in CYP17A1 or POR cause truly isolated 17,20 lyase deficiency. 
This is of clinical importance, as those patients will require not only sex steroid but 
also hydrocortisone replacement to avoid adrenal crisis during intercurrent illness or 
surgery. Future studies in patients with isolated 17,20 lyase deficiency including a 
complete genetic and hormonal characterization will show whether preservation of 
CYP17A1 17α-hydroxylase activity can only be observed in CYB5A deficiency.  
 In our family, clinical investigations, hormonal measurements and in vitro 
functional assays clearly document true isolated 17,20 lyase deficiency in the 
presence of completely preserved 17α-hydroxylase activity. Similarly, the recently 
reported patient carrying a homozygous CYB5A nonsense mutation showed an 
entirely normal cortisol response in the short synacthen test (Kok et al., 2010).  
The low excretion of urinary androgen metabolites was consistent with the 
documented low or non-detectable circulating androgens, with the exception of an 
apparently normal early neonatal testosterone level in case 1, an observation most 
likely due to cross-reactivity of the assay with foetal steroids that are still circulating in 
high concentrations during the early days of life. The urinary steroid profile analysis 
carried out in our patients also had a pivotal role in establishing the correct diagnosis 
in our family, but also impressively illustrated that CYB5A deficiency is the only 
condition that shows normal 17α-hydroxylase activity in the presence of 17,20 lyase 
deficiency. By contrast, 17α-hydroxylase activity, as reflected by the corticosterone 
over cortisol metabolite ratio, was clearly compromised in previously reported 
patients with apparently isolated 17,20 lyase deficiency due to mutant CYP17A1 or 
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POR, although to a lesser degree than in patients considered to have classical, 
complete 17OHD (Neres et al., 2010; Tiosano et al., 2008). 
 At the molecular level, it has been reported that CYB5A is not directly involved 
in electron transfer when facilitating the interaction between CYP17A1 and POR 
(Auchus et al., 1998), even though it carries a haeme molecule and is therefore 
potentially able to reduce interaction partners. This is based on in vitro observations 
that CYP17A1 17,20 lyase activity was not altered if co-incubated with apo-b5, i.e. 
cytochrome b5 devoid of the haeme, or with the haeme-containing holo-protein. This 
has also been demonstrated for the interaction of cytochrome b5 with the drug-
metabolising enzyme CYP3A4  (Auchus et al., 1998; Yamazaki et al., 1996a). 
Distinct amino acid residues within CYB5A, specifically p.E48 and p.E49, have been 
shown to retain normal electron transfer properties when mutated, whilst resulting in 
severely reduced capacity to support 17,20 lyase activity, lending support to the 
assumption that CYB5A acts as an allosteric facilitator rather than as an electron 
donor in supporting 17,20 lyase activity (Naffin-Olivos and Auchus, 2006). In silico 
analysis of the CYB5A mutation detected in our patient reveals close proximity of wild 
type histidine 44 to the haeme molecule, with polar bonds between the positively 
charged imidazole ring of histidine and the core haeme iron atom (Figure 34B). 
Replacement with leucine at this position, i.e. creating p.H44L, appears to disrupt this 
interaction (Figure 34C), which is highly likely to result in loss of the haeme moiety. 
This assumption is further supported by previous studies with rat CYB5A that have 
shown that the haeme-holding ability of cytochrome b5 depends mostly on the strong 
axial ligation provided by histidine residues 39 and 63 (Falzone et al., 1996; Wang et 
al., 2003) which are equivalent to histidines 44 and 68 in the human CYB5A protein 
(Figure 34C). Loss of the haeme, i.e. the transition from the CYB5A holo-protein to 
the apo-protein, has been shown to result in a striking conformational change 
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(Mukhopadhyay and Lecomte, 2004), which is likely to occur in p.H44L. From this we 
conclude that the haeme group of CYB5A may be of more significance in supporting 
CYP17A1 17,20 lyase activity than previously assumed, which challenges the 
previous concept that the haeme is not required. 
 Of note, in addition to supporting 17,20 lyase activity, cytochrome b5 is also 
involved in a number of other processes requiring interaction with this distinct haeme-
containing protein, including drug metabolism (Yamazaki et al., 1996a), fatty acid 
desaturation (Guillou et al., 2004) and, importantly, hemoglobin reduction. Thus, 
CYB5A deficiency represents another multi-system disorder due to co-factor 
mutations. This is similar to POR deficiency, which results not only in disordered 
steroidogenesis but also in impaired drug metabolism (Tomalik-Scharte et al., 2010), 
and PAPS synthase 2 (PAPSS2) deficiency (Noordam et al., 2009) that disrupts 
DHEA sulfation, to cause androgen excess, and also other sulfation processes 
including hepatic drug metabolism.  
 In our three affected siblings we found mild, clinically inapparent 
methemogobinemia, in keeping with the findings in the recently reported patient with 
a CYB5A nonsense mutation (Kok et al., 2010) resulting in a non-functional protein. 
Of note, one further CYB5A mutation has been reported previously, resulting in a 16 
bp deletion due to a splice site mutation (Giordano et al., 1994). This patient 
presented with severe cyanosis seven days after birth and significant 
methaemoglobinaemia of 12-19% (Hegesh et al., 1986), which is more similar to the 
range of methaemoglobin increases commonly found in cytochrome b5 reductase 
(CYB5R3) deficiency, i.e. recessive congenital methaemoglobinaemia (Percy and 
Lappin, 2008). A clinical work-up later revealed 46,XY DSD with an entirely female 
genital phenotype (Giordano et al., 1994); however, the patient did not undergo 
endocrine assessment. Importantly, as methaemoglobinaemia is not expected in 
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17,20 lyase deficiency due to mutant CYP17A1 or POR, assessing methaemoglobin 
levels in patients with isolated 17,20 lyase deficiency is very likely to represent a 
useful and presumably highly predictive screening tool for the detection of CYB5A 
deficiency.   
 In conclusion, we have described the first human CYB5A missense mutation, 
which results in true isolated 17,20 lyase deficiency as documented by in vivo and in 
vitro assessment. The mutation is highly likely to result in loss of CYB5A haeme 
binding, suggesting that presence of the haeme is crucial for support of 17,20 lyase 
deficiency. Lack of impairment of 17α-hydroxylase activity can be considered as 
highly suggestive of CYB5A mutations in patients presenting with biochemical 
evidence of 17,20 lyase deficiency, whereas, impaired 17α-hydroxylation points 
towards mutant CYP17A1 or POR as the cause of disease. Future studies will need 
to clarify the impact of CYB5A mutations on other organs and systems, with 
methaemoglobinaemia commonly present.  
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7. CHAPTER 7: MOLECULAR REGULATION OF 
DHEA SULFATION BY THE TWO HUMAN PAPS 
SYNTHASE ISOFORMS 
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7.1.  INTRODUCTION 
DHEA sulfation has been previously identified as a novel mechanism of pre-
receptor metabolism, regulating the availability of active androgens (Noordam et al., 
2009): a molecular defect of the PAPS synthase isoform 2 (PAPSS2) results in 
decreased DHEA inactivation to DHEAS with subsequent downstream conversion of 
DHEA to testosterone (see sections 1.1.9.1 and 1.3.1.4). This discovery reveals 
DHEA sulfation as a gatekeeper of androgen activation. However, based on this 
seminal case, it is unclear and intriguing why the other PAPSS1 isoform, which is 
ubiquitously expressed, cannot compensate for defect PAPSS2. 
Here, we investigate the molecular interplay of proteins involved in DHEA 
sulfation, namely SULT2A1 and its co-factors PAPSS1 and PAPSS2. 
7.2. METHODS 
7.2.1. Plasmids and transient overexpression in HEK293 cells 
For all overexpression experiments in this chapter, the cDNA of the PAPSS2b 
sequence variants was employed (in the progress of this chapter simply referred to 
as ‘PAPSS2’). For overexpression experiments, the bicistronic vector pIRES™ was 
employed in order to equally express SULT2A1 with a PAPSS isoform (see section 
2.4.1.3). The constructs harbouring SULT2A1 in MCS B and with PAPSS1, PAPSS2 
or without a coding sequence in MCS A as well as pIRES constructs harbouring 
PAPSS isoforms tagged with the cDNA of the fluorescent dye, enhanced green 
fluorescent protein (eGFP), were generated and kindly donated by Dr Vivek Dhir 
(University of Birmingham, UK). For the functional studies on subcellular localization 
of PAPSS variants, cDNAs of PAPSS isoforms cloned into the mammalian 
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expression vector pEGFP-N1 were kindly donated by Dr Jonathan Mueller (then: 
University of Duisburg-Essen, Germany) (Table 18).  
Table 18: Overview of PAPSS sequence variants with their sub-cellular expression pattern [observed 
by Schroeder et al. (2012)]. 
PAPSS isoform Variant (p.) subcellular localization 
PAPSS1 WT Nuclear > cytoplasmic 
RR111,112AA Nuclear 
KK9,10AA Cytoplasmic 
PAPSS2 WT Cytoplasmic > nuclear 
RR101,102AA Nuclear 
KK6,8AA Cytoplasmic 
 
These constructs were transiently co-transfected with a pcDNA6 plasmid 
containing SULT2A1 cDNA generated by restriction digest of SULT2A1 from pIRES 
with subsequent ligation into linearized pcDNA6, employing the HindIII and XbaI 
restriction sites. Transfections of 2 µg PAPSS/SULT2A1-pIRES and 1 µg PAPSS-
pEGFP-N1 with 1 µg SULT2A1-pcDNA6 plasmids in HEK293 cells were carried out 
in 6-well plates as described in section 2.1.4. 
7.2.2. siRNA knock-down  
Small interfering RNAs (siRNAs) were designed with the Block-iT™ RNAi 
designer tool (http://rnaidesigner.invitrogen.com/rnaiexpress). This tool identifies 
suitable siRNA oligos within the mRNA sequence of the gene of interest based on 
guidelines for highly-efficient siRNA knock-down (Ui-Tei, 2004).  
Three siRNA oligos were selected for each target (PAPSS1, PAPSS2 and 
SULT2A1). A custom-made control siRNA oligo, which is not directed to any mRNA, 
served as a negative control for all knock-down experiments. The green fluorescent 
positive control BLOCK-iT™ (Invitrogen/Life Technologies, Grand Island, NY, USA) 
was added to each experiment to estimate transfection efficiency. 
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Table 19: Sequences (sense strand only) of siRNA oligonucleotides used for transfection in the 
knock-down experiments for PAPSS1, PAPSS2 and SUL2A1. 
Target  
(mRNA position) 
RNA sequence (Sense strand) 
 (5’!3’) 
PAPSS1 (309) CCUGGUUUGUCAUGGUAUU 
PAPSS1 (419) GCAUCGCAGAAGUUGCUAA 
PAPSS1 (1380) GCAGGAUACCCAUAAGCAA 
PAPSS2 (612) CCAGCUUUAUUUCUCCAUU 
PAPSS2 (899) GCAGAACAUUGUACCCUAU 
PAPSS2 (1180) CCGUCUCUGCAGAGGAUAA 
SULT2A1 (169) GCAUAGCUUUCCCUACUAU 
SULT2A1 (622) GGUCAUGGUUUGACCACAU 
SULT2A1 (763) CCGAAGAACUGAACUUAAU 
control GCCACGUAAGAUGAGUCAA 
 
NCI-H295R cells (section 2.1.3) were seeded, 4 x 104 cells per well in 24-well 
plates, to grow to 30-40% confluence. After 24 hours, cells were transfected with 
siRNA oligos using the Jet-SI ENDO transfection reagent (Peqlab, Erlangen, 
Germany): for each well, 49 µl of serum-free medium and 1 µl of transfection reagent 
were mixed in a 1.5 ml reaction tube and incubated for 10 minutes at room 
temperature. In a separate tube, 48.75 µl of serum-free medium was mixed with 1.25 
µl of pooled siRNA from a 2 mM stock (i.e. 50 nM final concentration). Then, the 50 
µl transfection reagent solution was added to the 50 µl of siRNA oligo solution. After 
swift and gentle mixing by vortexing for 10 seconds at medium velocity, the mixture 
was incubated for 15 minutes at room temperature. Finally, all 100 µl were pipetted 
drop wise into the well followed by gently swirling the plate. To avoid toxicity, the 
medium was removed after 6 hours and replaced by 500 µl of full growth medium. 
Previous experiments from our group showed that the efficiency of the knock-down 
was greater if the transfection was performed twice. Therefore, the procedure was 
repeated after 72 hours of incubation and the cells were processed for expression 
analysis and in vitro functional analysis 24 hours after the second transfection. 
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7.2.3. DHEA sulfation assays  
48 hours after transfection of the vector DNA, HEK293 cells were incubated 
with 0.5 ml full growth medium in the presence of 250 nM DHEA and 0.2 µCi 3H-
labelled DHEA (101.3 Ci/mol, Perkin Elmer, Waltham, USA) at 37°C in a cell culture 
incubator. For siRNA knock-down studies, NCI-H295R cells were incubated 24 hours 
after the second siRNA knock-down in the presence of 1 µM trilostane, a HSD3B 
inhibitor, in 0.5 ml serum-free medium at 37°C. After one hour, the medium was 
replaced with 0.5 ml serum free medium containing 1µM trilostane, 100 nM DHEA 
and 0.2 µCi 3H-labelled DHEA and cells were incubated for one hour at 37°C in a cell 
culture incubator. Steroids were extracted from medium with 5 ml of dichloromethane 
as described in section 2.5.5 with the following modifications: to increase the 
extraction efficiency of (intracellular) DHEAS, cell membranes were ruptured by 
adding 1 ml 100% methanol to the cells followed by 10 min incubation at room 
temperature on an orbital shaker. The methanol and dichloromethane were 
combined in one glass tube, evaporated on a heat block at 55°C and then separated 
by TLC followed by quantification of DHEA and DHEAS peaks on a bioscanner as 
described in section 2.5.6. 
7.2.4. mRNA expression analysis by real-time quantitative PCR 
Total RNA has been isolated from whole cells after in vitro functional analysis 
as described in section 2.2.1. cDNA was generated by reverse transcription of mRNA 
(section 2.2.3) and real-time PCR performed as described in section 2.2.10. The 
following customised, exon-spanning gene expression assays have been employed 
(all: TaqMan® Assays, Life Technologies™, Grand Island, NY, USA): SULT2A1: 
Hs00234219_m1; PAPSS1: Hs00968937_m1; PAPSS2: Hs00989921_m1. An assay 
to detect eukaryotic 18S ribosomal RNA (HS99999901_s1) was employed as a 
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control to correct for equal loading and to calculate dCt values. All probes were 
labelled with 6-carboxyfluorescein (FAM), the 18S probe with the VIC® fluorophore. 
mRNA expression was quantified as delta Ct values for each target gene (see 
section 2.2.10). To calculate the ‘fold change’ following si-RNA knock-down 
experiments, dCTs of the respective gene after targeted si-RNA knockdown were 
subtracted from the dCt values of the same gene and within the same experiment 
following transfection with control siRNA (i.e. delta delta Ct, ddCt), then by applying 
the following equation: !"#$!!ℎ!"#$ = 2(!!!"#) 
7.2.5. Immunofluorescence studies 
For indirect immunofluorescence, NCI-H295R1 cells were seeded on sterilized 
cover slips placed in 6-well plates at 20,000 cells per well and grown in full growth 
medium to attach overnight. Cell were fixed with 100% ice-cold methanol and 
incubated at -20°C for 20 mins. Cells were washed three times in PBS. To avoid 
unspecific binding, cells were incubated with 5% (m/v) bovine serum albumin (BSA) 
in PBS supplemented with 0.1% (v/v) Triton X100 (all Sigma, Pool, UK). Cells were 
incubated at 4°C overnight with monoclonal mouse antibodies against PAPSS1 and 
PAPSS2 at a concentration of 1:50 diluted in PBS/0.1% Triton X100/1% BSA 
(PAPSS1: ab56398; PAPSS2: ab56393; Abcam, Cambridge, USA). After washing 
three times with PBS/0.1% Triton X100, the samples were incubated with a 
fluorescein-labelled (FITC) anti-mouse IgG antibody (1:200 in PBS/0.1% Triton 
X100/1% BSA) at room temperature for 1 hour. After washing the cells three times, 
coverslips were mounted on microscope slides with Vectashield® mounting medium 
containing DAPI for nuclear staining (Vector Laboratories, Burlingame, USA).  
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Cells transiently transfected with pIRES vectors containing eGFP-tagged 
PAPSS cDNA seeded on coverslips were fixed 48 hours after transfection with 1 ml 
of Glyo-Fixx solution (Thermo Scientific, Cramlington, UK) for 2 hours at room 
temperature on an orbital shaker. After washing the cover slips three times with PBS, 
cells were incubated with 85% ethanol for 1 hour and washed again with PBS/0.1% 
Triton X100. Nuclei were stained with a propidium iodide solution (1:100 in PBS/0.1% 
Triton X100, containing 100µg/ml RNAse A; all Invitrogen, Carlsbad, USA) at 37°C 
for 20 mins. Images were obtained from a cell culture microscope (Leica, Wetzlar, 
Germany) for live-cell imaging and on a confocal microscope (Zeiss, Jena, 
Germany). 
7.2.6. Western blot 
To assess expression levels of PAPSS isoforms and SULT2A1 on the protein 
level after overexpression and knock-down experiments, cells were harvested in cold 
PBS (with Complete® proteinase inhibitor; Roche, Basel, Switzerland) 48 or 24 hours 
after transfection, respectively. For protein expression, an extra well of transfected 
cells has been prepared, which was not used for steroid extraction as the necessary 
methanol treatment (7.2.3) denatures the protein, making it unsuitable for Western 
blot analysis. SDS-PAGE and Western blot has been performed as described in 
section 2.3.3.  
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Table 20: Primary and secondary antibodies used for Western blot and immunofluorescence studies. 
Target Species, type Product no Supplier Concentration 
WB (IF) 
Primary antibodies: 
PAPSS1 Mouse, monoclonal ab56398 Abcam  1:1,000 (1:50) 
PAPSS2 Mouse, monoclonal ab56393 Abcam  1:1,000 (1:50) 
SULT2A1 Rabbit, polyclonal ab38416 Abcam  1:200 
β-Actin Mouse, monoclonal Ab20272 Abcam  1:25,000 
α-tubulin Mouse, monoclonal Sc-5286 Santa Cruz   
Lamin Mouse, monoclonal ab8980 Abcam 1:1000 
 
Secondary antibodies: 
Anti-mouse IgG, HRP-
conjugated 
Goat, polyclonal A5278 Sigma 1:1,000 
Anti-rabbit IgG, HRP-
conjugated 
Goat, polyclonal A6667 Sigma 1:1,000 
Anti-mouse, Alexa 
Fluor® 488 
Goat, polyclonal P36930 
 
Life 
technologies 
(1:100) 
 
7.2.7. Extraction of cytosolic and nuclear fractions from whole cell lysates 
A nuclear extraction kit (Chemicon/Millipore®, Billerica, USA) was used to 
isolate nuclear and cytoplasmic fractions of four different mammalian cell lines: NCI-
H295R1, NCI-H295R3, HEK293 and the hepatocellular carcinoma cell line Hep G2. 
Cells were grown to 70-90% confluence and pelleted after short (2-5 minutes) 
trypsinisation (section 2.1) from 6 x T75 flasks (Greiner Bio-One, Stonehouse, UK). 
Cells were washed twice in 40 ml ice-cold PBS and all subsequent steps were 
performed on ice/4°C. The volume of the pellet was estimated and five cell pellet 
volumes of chilled Cytoplasmic Lysis Buffer was added; to homogenise the cells, the 
tube was then gently inverted. The cell suspension was incubated for 15 minutes and 
subsequently centrifuged at 250 x g for 5 minutes.  The supernatant was discarded 
and the pellet was re-suspended in two volumes of Cytoplasmic Lysis Buffer. Then, 
cytoplasmic cell lysis was facilitated by drawing the cell homogenate into a syringe 
with a 27-gauge needle and ejecting the content back in to the tube. The procedure 
was repeated five times. The disrupted cell suspension was centrifuged at 8,000 x g 
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for 20 minutes and the supernatant containing the cytosolic fraction of the cells was 
snap-frozen and stored at -80°C until further processing. 
To extract the nuclear fraction, the cell pellet was re-suspended in 2/3 of its 
original volume in Nuclear Extraction Buffer. Nuclei were disrupted by drawing and 
ejecting the pellet five times into a fresh syringe with a 27-gauge needle. Then, the 
suspension was agitated on an orbital shaker for 45 minutes and centrifuged at 
16,000g for 5 minutes. The supernatant, containing the nuclear extract, was stored at 
-80°C until further processing. Protein content was measured by using the BioRad 
method (section 2.3.2) and 20 µg of each fraction as well as whole cell lysate were 
loaded per lane. 
7.3. RESULTS 
7.3.1. Effects of PAPS synthases on DHEA sulfation in vitro 
7.3.1.1. Overexpression studies 
HEK293 cells were transiently transfected with three different pIRES 
constructs/combinations: (1) SULT2A1 alone or in the presence of (2) PAPSS 
isoforms 1 or (3) PAPSS2. An empty vector served as a negative control. After 
transfection, expression analysis was carried out on the mRNA (Figure 35) and 
protein level (Figure 36).  
Transfection of pIRES constructs resulted in strong expression of the respective 
ORFs for all for all targets investigated, indicating successful transcription (Figure 
35). Baseline target mRNA expression was observed at dCt values of about 21-22 
cycles at baseline (transfection with empty vector) and increased to dCt values of 4-5 
after transient transfection of the respective constructs. There were no statistical 
differences of mRNA levels between the different experimental set-ups. The dCt 
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values for SULT2A1 were of similar range between the three different settings with 
equally high expression of PAPSS mRNA in constructs that also contained the 
PAPSS 1 and 2 ORFs (Figure 35). 
   
Figure 35: mRNA expression represented as delta Ct (dCt) values of SULT2A1, PAPSS1 and 
PAPSS2 following transient transfection of pIRES constructs harbouring cDNAs of either SULT2A1 
alone or in the presence of PAPSS1 or PAPSS2 in HEK293 cells. An empty pIRES vector served as a 
negative control. The data were obtained from three independent experiments and variation of mRNA 
expression is represented as ± standard deviation (SD), illustrated as error bars.  
On the protein level, Western blot analysis detected strong staining for 
SULT2A1 and PAPSS 1/2 in the cell lysates of transfected HEK293 cells, indicating 
successful transcription of mRNA into protein (Figure 36). However, the intensity of 
the SULT2A1 band is decreased when co-expressed with PAPSS1. This finding was 
confirmed in five repeats of the Western blot of independent experiments. 
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Figure 36: A representative Western Blot of transiently transfected HEK293 cells with pIRES 
constructs harbouring cDNAs of SULT2A1 alone or in the presence of PAPSS isoforms 1 and 2. Cells 
transfected with an empty pIRES vector served as a negative control. As PAPSS1 and PASS2 have 
nearly the same molecular weight, two membranes were incubated with the respective PAPSS 
antibody. 10 µg of total protein were loaded for each lane. Beta-actin staining served as a control for 
equal loading. 
To assess the impact of the two PAPSS isoforms on SULT2A1 activity on a 
functional level, DHEA sulfation assays were performed in transfected HEK293 cells 
(Figure 37). Co-expression of PAPSS1 with SULT2A1 resulted in a significant 
decrease of DHEA sulfation to about 60% of the activity observed when SUL2A1 is 
present alone. In contrast, co-expressing PAPSS2 strongly increased DHEA to 
DHEAS conversion and was about 5-6 fold higher as observed when SUL2A1 is 
expressed on its own. This also reached statistical significance. 
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Figure 37: DHEA sulfation (% DHEA to DHEAS conversion) carried out in HEK293 cells transiently 
transfected with pIRES constructs harbouring cDNAs of SULT2A1 alone or in the presence of PAPSS 
isoforms. To assess the impact of either PAPSS isoforms on SULT2A1 activity, the conversion rates 
were compared to SULT2A1 alone, which is 100%. The data were obtained from three independent 
experiments and variation of DHEA sulfation is represented as ± standard deviation (SD), also 
illustrated as error bars. An unpaired Student’s T-Test was performed to calculate the p-value for 
significance levels. 
7.3.1.2. siRNA knock-down studies 
As a mirror image approach, transient siRNA knock-down of SULT2A1, 
PAPSS1 and PAPSS2 was performed in the adrenal NCI-H295R1 cell line. SiRNA 
knockdown was successful for all three targets and knock-down efficiency varied 
between 60% to 80% (Figure 38). To further investigate potential co-regulatory 
mechanism on the transcriptional level, mRNA expression of SULT2A1 and PAPSS 
isoforms was measured by real-time PCR for each knock-down scenario (Figure 38): 
siRNA knock-down of SULT2A1 resulted in a significant increase of PAPSS2 
expression (p = 0.044; Figure 38, left panel). Knock-down of PAPSS1 did not affect 
the expression levels of SULT2A1, but PAPSS2 mRNA expression was significantly 
up regulated (p = 0.013; Figure 38 middle panel). Finally, both mRNAs of SULT2A1 
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and PAPSS1 were higher expressed in cells were PAPSS2 was knocked down, 
however only the SULT2A1 up-regulation reached statistical significance (SULT2A1: 
p = 0.039; PAPSS1: p = 0.109; Figure 38 right panel). 
  
Figure 38: mRNA expression after transient siRNA knock-down of SULT2A1, PAPSS1 and PAPSS2 
in adrenal NCI-H295R cells. Data are presented as fold change based on delta dCt (ddCt) values for 
comparison to a control knock-down using random, non-targeted siRNA-oligos (control = 1). The dCt 
values are listed in the table below the bar graph. All experiments were performed in at least three 
independent experiments. * = p < 0.05. 
To investigate the effects of these siRNA knock-down experiments on the 
protein level, Western blot experiments were carried out from whole cell lysates of 
NCI-H295R1 cells. Knock-down of SULT2A1 resulted in stronger expression of 
PAPSS2 but also PAPSS1 protein (Figure 39, left). Knock-down of PAPSS1 resulted 
in a mild increase of SULT2A1 and PAPSS2 expression (Figure 39, middle). In cells 
were PAPSS2 expression was decreased, SULT2A1 expression was stronger 
compared to control (Figure 39, right).  
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Figure 39: A representative Western blot from adrenal NCI-H295R whole cell lysates after siRNA 
knock-down (kd) of SULT2A1, PAPSS1 and PAPSS2 (ctrl: cells transfected with a non-targeted 
control oligo). 20µg of protein were loaded per lane.  
To further assess the functional impact of siRNA knock-down of either 
SULT2A1, PAPSS1 and PAPSS2, in vitro DHEA sulfation assays were performed 
following each knock-down scenario (Figure 40). 
Knock-down of SULT2A1 mRNA dramatically reduced DHEAS generation in 
these cells. Knock-down of the PAPSS1 isoform in the presence of SULT2A1 no 
effect on DHEA sulfation; intruigingly, knock-down of the PAPSS2 isoform reduced 
DHEA sulfotransferase activity to about 30 % compared to control (Figure 40). 
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Figure 40: DHEA sulfation (% DHEA to DHEAS conversion) in adrenal NCI-H295R cells following 
transient siRNA knock-down of SULT2A1, PAPSS1 and PAPSS2. The conversion rates for each 
knock-down experiment were compared to a control knock-down with an untargeted siRNA oligo, 
which is 100%. The data were obtained from three independent experiments and variation of DHEA 
sulfation is represented as ± standard deviation (SD), also illustrated as error bars. An unpaired 
Student’s T-Test was performed to calculate the p-value for statistical significance. 
 
7.3.2. Subcellular localization studies 
To further investigate underlying mechanisms why PAPSS1 can not 
compensate for defect PAPSS2, expression studies focusing on the subcellular 
localisation of molecules involved in DHEA sulfation were performed.  
7.3.2.1. Fractionation studies 
Nuclear and cytoplasmic fractions of NCI-H295R cells (substrains 1 and 3) as 
well as the liver carcinoma cell line Hep G2 were isolated and Western blot for the 
two PAPSS isoforms was performed (Figure 41). I have verified the integrity and 
quality of the two fractions by co-staining with the nuclear marker lamin and the 
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cytosolic marker α-tubulin, and have observed very little contamination of each 
fraction (data not shown). 
 
Figure 41: Western blot showing protein staining for PAPSS isoforms in nuclear (N), cytosolic (C) 
extracts and whole cell lysates (W) from two NCI-H295R substrains (R1 and R3) and the liver 
carcinoma cell line Hep G2. 
PAPSS1 protein was predominantly detected in the nuclear fraction of all three 
cell types and comparably reduced in the cytosolic fractions. In contrast, an 
increased expression of PAPSS2 was found in the cytoplasmic compared to the 
nuclear fraction, with minimal PAPSS2 detection in the nuclear compartments of the 
adrenal cell substrains and no detection in the nuclear fraction of the Hep G2 cell 
line. 
7.3.2.2. Immunofluorescence studies 
To extend the sub-cellular localization studies of the PAPSS isoforms further, 
immunofluorescence studies were carried out in the adrenal NCI-H295R cell line. 
Firstly, indirect immunofluorescence with commercially available primary antibodies 
was performed in methanol-fixed cells (Figure 42): both PAPSS isoforms were 
expressed predominantly in the nuclear compartment, however, a less intense 
cytoplasmic stain has been observed for both PAPSS isoforms, which was slightly 
stronger for PAPSS2 compared to PAPSS1. 
Frac%on % n(studies(
N C W N C W N C W 
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Figure 42: Indirect immunofluorescence of PAPSS isoforms in adrenal NCI-H295R cells. Bar: 50 µm. 
As cross-reactivity of the primary antibodies could potentially lead to inaccurate 
staining of the PAPSS isoforms by indirect immunofluorescence, I have transiently 
transfected NCI-H295R1 cells with pIRES constructs harbouring the cDNAs of 
PAPSS 1 and 2 tagged with eGFP. Here, a similar pattern is found as observed in 
the indirect immunofluorescence studies: PAPSS1-eGFP appears to be 
predominantly expressed in the nuclear compartment, both in living cells (Figure 
43A) and after fixation and co-staining with the nuclear marker propidium iodide 
(Figure 43 B). For PAPSS2, I have observed a stronger staining intensity in the 
nuclear compartment, but also some cytosolic staining both in living cells as well as 
after fixation. Confocal imaging suggests that the staining distribution varies and the 
staining intensity can also be found equally strong in both the cytosol as well as in 
the nucleus in some cells (Figure 43 B). 
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Figure 43: Imaging of living cells (panel A) and confocal microscopy (panel B) of NCI-H295R cells 
transiently transfected with the pIRES vector harbouring eGFP-tagged PAPSS1 (left) and PAPSS2 
(right) cDNAs. Nuclei were visualized in panel B with propidium iodide (PI, red signal). Bar in panel A: 
100 µm, panel B: 75 µm. 
 
7.3.2.3. Functional consequences of subcellular localization of PAPS 
synthases 
To assess the functional consequences of a cytosolic versus nuclear 
localization of PAPSS1 and PAPSS2, I have performed in vitro DHEA sulfation 
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assays in HEK293 cells of PAPSS variants that are exclusively expressed in the 
cytoplasm or the nucleus co-transfected with SULT2A1. These sequence variants of 
PAPSS isoforms were generated by site-directed mutagenesis and identified based 
on a mutagenesis screen to show a nearly exclusive cytosolic or nuclear expression 
pattern (Schröder et al., 2012).  
 
Figure 44: Functional analysis of PAPSS sequence variants co-transfected in HEK293 cells with 
SULT2A1. Panel A: DHEA substrate conversion rates of the four localization variants and empty 
vector (EV) control compared to wild type PAPSS; the subcellular localization of the respective 
variants are indicated as nuclear (nuc) and cytoplasmic (cyt). Panel B: Live-cell imaging of transfected 
HEK293 cells with eGFP-tagged PAPSS1 variants to illustrate the subcellular localization pattern. 
Panel C: Substrate conversion rates expressed as %WT activity. All values are expressed as the 
mean (± SEM) of triplicate assays from three independent experiments. An unpaired student’s t-test 
was performed to calculate the p-values. 
For all four sequence variants examined, I have observed a decrease in 
SULT2A1 activity compared to the respective WT PAPSS isoform, which reached 
statistical significance for both the cytoplasmic and nuclear PAPSS1 variant 
(p.KK9,10AA and p.RR111,112AA), but only for the nuclear-expressed PAPSS2 
variant (p.RR101,102AA) (Figure 44). The DHEA conversion rates were generally 
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lower for all PAPSS1 variants and SULT2A1 activity was decreased to about 50% 
when co-transfected with WT PAPSS1 compared to WT PAPSS2 (Figure 44A). The 
most marked decrease was observed for the cytoplasmic PAPSS1 variant, which 
was 61% of WT PAPSS1 activity (Figure 44B). 
mRNA and protein expression levels indicate successful overexpression of 
SULT2A1 and PAPS synthases (Figure 45 and Figure 46). However, the dCt levels 
of SULT2A1 were about one dCt value higher when co-expressed with PAPSS1 
variants, suggesting decreased mRNA expression. At the same time, the PAPSS1 
mRNA levels were higher compared to PAPSS2 variants with a difference of two to 
three dCt values.  
 
 
Figure 45: mRNA expression represented as delta Ct (dCt) values of SULT2A1, PAPSS1 and 
PAPSS2 following transient co-transfection in HEK293 cells of p-eGFP-N1 constructs harbouring 
cDNAs for PAPSS1 and 2 sequence variants with SULT2A1 in pcDNA6. The empty vector (EV) refers 
to empty p-eGFP-N1 co-trasnfected with SULT2A1. The data were obtained from three independent 
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SULT2A1 11.04 ± 0.32 10.67 ± 0.86 10.63 ± 0.48 10.86 ± 0.12 9.89 ± 0.89 9.75 ± 0.58 9.18 ± 0.63 
PAPSS1 20.21 ± 0.75 6.01 ± 0.43 6.25 ± 0.36 5.97 ± 0.77 17.07 ± 0.64 18.86 ± 0.38 18.08 ± 0.61 
PAPSS2 19.44 ± 0.23 18.86 ± 0.42 19.01 ± 0.59 20.36 ± 0.91 8.53 ± 0.98 8.64 ± 0.35 8.08 ± 0.70 
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experiments and variation of mRNA expression is represented as ± standard deviation (SD), illustrated 
as error bars. 
The variation of SULT2A1 expression as indicated by the real-time mRNA 
expression data is also reflected on the protein level by Western blot analysis 
(Figure 46): The SULT2A1 bands appear less intense in the lysates derived from 
cells co-transfected with PAPSS1 variants. Also, the SULT2A1 protein expression is 
lower in the cells co-transfected with empty pEGFP-N1 vector (EV). In addition, a 
strong and slightly ‘higher’ PAPSS2 band has been observed when PAPSS1 was co-
transfected; this suggests strong cross-reactivity of the PAPSS2 antibody with 
PAPSS1 (Figure 46). 
 
Figure 46: A representative Western blot from HEK293 whole cell lysate after co-transfection of 
PAPSS1 and 2 variants with SULT2A1. 15µg of protein were loaded per lane and beta-actin was used 
as a control for equal loading.  
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7.4. DISCUSSION 
Both in the overexpression studies and in the siRNA knock-down experiments, I 
could recapitulate in vitro that PAPSS2 but not PAPSS1 supports SULT2A1 and 
DHEA sulfation, an observation that was made from a previously published case 
study (Noordam et al., 2009).  
Transient co-expression of SULT2A1 with PAPSS2 resulted in a 300% increase 
of DHEA sulfation compared to when SULT2A1 only relies on the endogenously 
expressed PAPS synthases of HEK293 cells. Notably, not only the PAPSS1 
overexpression reduces SULT2A1 activity, it also reduces the protein expression of 
SULT2A1, which I have observed in several replicates of the experiment. To rule out 
technical artefacts related to the IRES cassette not consistently expressing both 
cDNAS as described recently (Mansha et al., 2012), I have performed co-
transfections with two pcDNA6 plasmids harbouring the cDNAs of PAPSS and 
SULT2A1, respectively, which gained essentially the same results (data not shown). 
To exclude a cell-type specific effect, I have also repeated the experiments in the 
monkey kidney cell line COS7 and obtained similar results (data not shown). As 
SULT2A1 mRNA expression was equal in each co-expression scenario, reduced 
SUL2A1 protein expression could indicate an interaction between PAPSS1 and 
SULT2A1 on the post-translational level. High levels of PAPSS1, which is 
endogenously lowly expressed in HEK293 cells, could destabilize SULT2A1 protein 
or increase its metabolism within the cell, either by exerting direct effects or mediated 
by other factors. To elucidate underlying mechanism and to identify possible 
interaction partners would be an important question to address for future studies.  
Whilst there may be still unresolved uncertainties concerning the 
overexpression system, the data generated from the siRNA knock-down studies 
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clearly show the dependence of SULT2A1 on PAPSS2 as its knock-down reduces 
the enzyme’s activity dramatically; in contrast, PAPSS1 knock-down did not change 
its activity. Additionally, I have also observed interaction of PAPSS isoforms with 
SULT2A1 on the transcriptional level and found significant up-regulation of SULT2A1 
mRNA expression in cells where PAPSS2 was down regulated. The Western blot 
data suggest that this is also reflected on the protein level. Interestingly, PAPSS1 
knockdown did not change SULT2A1 expression not mirroring the findings from the 
overexpression studies. The different molecular environment of the adrenal NCI-
H295 cells compared to the non-steroidogenic kidney cell could explain this different 
behaviour; moreover, a dose-dependency could be an explanation as the PAPSS1 
expression levels are extremely high after transfection (dCt: 5-6) compared to its 
much lower endogenous expression levels of NCI-H295R cells (dCt: 15-16). 
However, the expression data from both experiments strongly indicate interaction of 
PAPSS isoforms with each other as well as SULT2A1, on the transcriptional and 
post-transcriptional level.  
In the search for potential mechanism underlying the findings that PAPSS1 can 
not compensate for PAPSS2, different routes of investigations have been proposed 
and have partly been addressed in previous studies: Different catalytic activities for 
PAPSS isoforms have been reported with a 10-15fold higher global activity for 
PAPSS2 compared to PAPSS1 in one study (Fuda et al., 2002). However, these 
findings were not confirmed by Grum et al. investigating the catalytic activity of the 
APS kinase domain of the two PAPSS isoforms in isolation and upon hetero-dimer 
formation (Grum et al., 2010). The same group has investigated PAPS synthases for 
protein stability and strikingly found that the PAPSS2 unfolded protein has a very 
short half-life time of several minutes compared to PAPSS1, which essentially 
remains structurally intact under physiological conditions (van den Boom et al., 
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2012). Interestingly, the PAPSS2 isoform is stabilized by low concentrations of 
nucleotide adenosine-5’phosphosulfate (APS), which is also the product of its ATP 
sulfurylase activity (van den Boom et al., 2012); APS therefore may represent an 
intracellular modulator of PAPS formation and sulfation processes as a whole 
(Mueller and Shafqat, 2013). Therefore, future studies aiming to identify other 
molecules or proteins that interact with, stabilize or modify PAPS synthases are 
required in order to understand sulfation processes in their particular cell-type 
specific environment. 
Another line of observations potentially leading to a better understanding of 
their differential roles derives form the distinct subcellular localization patterns of 
PAPS synthases. Besset reported that the human PAPSS1 isoform is located in the 
nucleus of mammalian cells and is functionally active in sulfation-depleted yeast 
cells; in contrast, human PAPSS2 is expressed in the cytosol of mammalian cells, but 
re-locates into the nucleus when co-expressed with PAPSS1 (Besset et al., 2000). I 
have confirmed these findings in steroidogenic and non-steroidogenic cells, with 
PAPSS1 being mostly localized in the nucleus; in contrast to these findings, I have 
also found that the PAPSS2 isoform is expressed more heterogeneously being also 
localized to a lesser extend in the cytoplasm. In addition, I have observed that some 
cells express PAPSS2 equally in the cytoplasm and the nucleus. These findings were 
confirmed in recent study employing a quantitative approach in mammalian non-
steroidogenic cell lines and the authors report a predominant nuclear expression of 
PAPSS1 but a predominant cytoplasmic distribution for PAPSS2 (Schröder et al., 
2012). Through mutagenesis-screen based on in silico analysis of the PAPSS 
proteins, distinct motifs crucial for cytoplasmic-nuclear shuttling have been identified; 
here, a distinct nuclear localization signal (NLS) at the N-terminus of the protein is 
present in both PAPSS isoforms and appears to be stronger for PAPSS1 than 
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PAPSS2; this motif consists of a highly conserved lysine pattern (KK-x-K) and 
replacement of these residues with non-polar alanine results in a striking re-location 
of PAPSS1 and PAPSS2 to the cytoplasm in vitro (Schröder et al., 2012). In addition, 
for nuclear export a highly conserved Arg-Arg motif within an α-loop of the APS 
kinase domain has been identified, which is crucial for cytosolic re-location (Schröder 
et al., 2012). Through collaboration with this group I have investigated the functional 
impact of these PAPSS localization variants in order to determine whether an 
exclusively nuclear or cytosolic localization of the PAPSS isoforms supports or 
inhibits SULT2A1 activity. I have observed a decrease of DHEA sulfation for all 
PAPSS variants, apart from the cytoplasmic PAPSS2 variant, which does not change 
SULT2A1 activity compared to WT PAPSS2. Interestingly, also the nuclear PAPSS1 
variant reduces SULT2A1 activity, although the nucleus has been reported as the 
natural environment for the PAPSS1 isoform (Besset et al., 2000; Schröder et al., 
2012). This suggests that at least some cytoplasmic PAPSS1 expression is required 
for PAPS generation of this isoform to support DHEA sulfation.  
The fact that the DHEA conversion rate does not dramatically differ for each 
‘dislocalized’ PAPSS variant (i.e. the nuclear PAPSS2 and the cytoplasmic PAPSS1) 
compared to the WT activity is a surprise, but could be explained by the high 
expression of PAPSS and SULT2A1, providing un-physiological high levels of PAPS. 
As PAPS is a small molecule, it can pass the nuclear membrane freely and its ample 
production, independent of its site of generation, would deliver abundant activated 
sulfate to support SULT2A1. 
In summary, my data indicate that the expression of the molecular compounds 
of the DHEA sulfation cascade, SULT2A1, PAPSS1 and PAPSS2, are co-regulated 
suggesting compensatory mechanism. Strikingly, PAPSS2 only supports DHEA 
sulfation in vitro, confirming the previously reported in vivo findings (Noordam et al., 
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2009). Subcellular localisation of PAPSS isoforms might explain their differential 
roles and I have observed different patterns of sub-cellular distribution, confirming 
data from a recent study (Schröder et al., 2012). The in vitro system I have employed 
for functional studies on PAPSS variants did not deliver any clear results, which 
enhance our understanding that subcellular localisation of PAPSS plays a role in the 
DHEA sulfation process. Future studies would need to focus on the identification of 
interaction partners of PAPS synthases and SULT2A1 in order to explain 
mechanistically the co-regulative expression of the proteins as well as the differential 
roles of PAPSS1 and PAPSS2. 
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8. CHAPTER 8: THE STEROID METABOLOME OF 
PATIENTS WITH STEROID SULFATASE (STS) 
DEFICIENCY REVEALS A PHYSIOLOGICAL ROLE 
OF STS IN ANDROGEN ACTIVATION BEFORE 
PUBERTY 
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8.1. INTRODUCTION 
8.1.1. Steroid sulfatase (STS) and sex steroid metabolism 
STS hydrolyses the sulfate moiety of sulfated 3β-hydroxysteroids and has high 
substrate affinity to DHEAS, the most abundant hormone in the human circulation. 
This generates DHEA, the principal sex steroid precursor (Figure 47; section 1.1.9). 
DHEA is synthesized from cholesterol in the adrenal ZR, which also expresses the 
enzyme DHEA sulfotransferase (SULT2A1) in high levels. SULT2A1 catalyses the 
sulfation of DHEA to generate the hydrophilic sulfate ester DHEAS, the main product 
of the ZR.  
DHEAS has virtually no affinity to the androgen receptor; it is essentially 
inactive. Mainly due to its chemical properties being highly amphiphilic and bound to 
plasma albumin, it cannot freely pass the cell membrane and be converted to active 
androgens by intracellular steroidogenic enzymes (Figure 9). The DHEAS plasma 
concentration, however, is much higher than any other steroid, and its half-life in 
blood is much longer than the half-life of DHEA (20 hours for DHEAS vs. 6 hours for 
DHEA).  
Indeed, DHEAS is the most abundant steroid hormone in the human circulation. 
As it does not exhibit any androgenic or oestrogenic properties itself, it has been 
thought to serve as a constant storage pool for the regeneration of DHEA, which can 
be downstream-converted to active androgen or oestrogens like dihydrotestosterone 
or oestradiol (Figure 47).  
In this context, STS is the key enzyme responsible to regenerate DHEA from 
inactive DHEAS and thereby counteracting adrenal SULT2A1 activity (Figure 47).  
Hence, circulating androgen levels are therefore considered to be partly regulated by 
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the production of DHEA in the adrenal cortex as well as the metabolism of DHEA 
regulated by SULT2A1 and STS enzymatic activities. 
 
 Figure 47: STS and adrenal sex steroid generation and metabolism. STS regenerates DHEA from 
inactive DHEAS in peripheral target tissues and counteracts the enzyme SULT2A1 expressed in the 
adrenal ZR. Subsequently, DHEA can be downstream converted to active sex steroids activating sex 
steroid receptors.  
 A defect of DHEA sulfation due to a mutations in the PAPSS2 gene, a crucial 
co-factor of SULT2A1, has been previously reported to increase circulating androgen 
levels in humans (Noordam et al., 2009). On the contrary, it seems plausible that a 
defect of the opposite enzymatic reaction, DHEA de-sulfation catalysed by STS, 
results in reduced sex steroid levels. However, the role of STS in vivo has not been 
entirely elucidated yet. 
STS has an important role during pregnancy and is highly expressed in the 
placenta. In fact, the placenta serves as an endocrine organ on its own and converts 
the vast amounts of DHEAS produced by the foetal adrenals into oestrogens by 
placental STS and P450 aromatase (CYP19A1). Hence, placental STS creates the 
‘oestrogenic environment’ of pregnancy. 
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A previous study in healthy adult men shows that STS has no impact on 
androgen re-activation from DHEAS: After intravenous infusion of DHEAS, 
volunteers did not show any increase of DHEA; in contrast both DHEA and DHEAS, 
including downstream androgens, increased after an oral dose of DHEA (Hammer, 
2005).  
Only a few studies in adult men with STSD/XLI explored sex steroid 
metabolism, but without providing detailed clinical information on pubertal 
development or clinical features in these patients (Lykkesfeldt et al., 1985a; Milone et 
al., 1991; Delfino et al., 1998).  However, severe androgen deficiency has not been 
reported yet in patients with STSD/XLI; and in fact, infertility is not part of the clinical 
spectrum of STSD/XLI (Fernandes et al., 2010). 
Therefore, this study aimed to explore androgen metabolism in a genetically 
characterized cohort of patients with XLI/STSD employing steroid metabolomics in 
serum und urine. 
8.1.2. STS deficiency (X-linked ichthyosis) 
Mutations or deletions of the STS gene result in a skin condition called x-linked 
recessive ichthyosis (XLI), which is in 80-90% of cases due to complete deletions of 
the STS gene (Fernandes et al., 2010; Bonifas et al., 1987; Ballabio et al., 1989). It is 
one of the common inherited metabolic disorders with a frequency of 1:2000 – 
1:6000 life births (Delfino et al., 1991; Shapiro et al., 1978). 
Generally, ichthyosis refers to genetically and acquired disorders of the skin 
characterized by abnormal keratinisation; the skin of often resembles ‘fish scales’, 
explaining the origin of the term ichthyosis from greek ‘ichthys’ = ‘fish’. XLI has first 
been recognized as a distinct form of ichthyosis in the 1960s (Wells and Kerr, 1965; 
1966). The pathophysiology of the deficient STS enzyme resulting in the typical dark-
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coloured scaling in patients is not fully understood. However, as STS is expressed 
within the epidermis, it is thought to play a role in cutaneous regulation of lipid 
metabolism (Fernandes et al., 2010). An increased amount of cholesterol-sulfate has 
been found in the stratum corneum of patients with XLI/STSD (Williams and Elias, 
1981). Hence, a pathological increase of hydrophilic cholesterol-sulfate in the 
epidermis might be responsible for disturbed desquamation and excess scaling. 
Clinically, XLI is characterized by large, dark-brown scales primarily located 
symmetrically on the trunk, neck and the extensor surfaces (Figure 48). The scalp is 
nearly always affected, however plantar and palmar surfaces are spared. Clinical 
symptoms start a few months after birth, and generally tend to improve during the 
summer months. 
 
Figure 48: Typical dermatological finding in a patient with XLI: large, dark-brown, tightly-adherent  
scales on the extensor surfaces. Reprinted with kind permission from Fernandes et al. 2010. 
 
Extra-cutaneous manifestations have been reported in patients with STSD, 
mainly ocular abnormalities and cryptorchidism. Corneal opacities are the most 
common ocular abnormalities, occurring in 20-50% of XLI patients (Jay et al., 1968; 
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Costagliola et al., 1991). These are usually asymptomatic and have a fine, flour-like 
appearance due to deposits in the posterior corneal stroma or Descemet membrane. 
Interestingly, these can also be found in about 25% of female carriers (Costagliola et 
al., 1991).  
Cryptorchidism has been reported in up to 20% of patients with XLI (Bradshaw 
and Carr, 1986; Lykkesfeldt et al., 1985b; Traupe and Happle, 1983; Harkness, 1982; 
Traupe and Ropers, 1982). As the patients from these reported case series were not 
genetically characterized, it is unclear whether the testicular maldescend is a direct 
consequence of STS deficiency or secondary to deletions of genes adjacent to the 
STS locus. Indeed, syndromic presentations with XLI due to contiguous gene 
deletions are reported, including Conradi syndrome (limb shortening, epiphyseal 
stripplig, craniofacial defects, short stature) and Rud syndrome (cryptorchidism, 
retinitis pigmentosa, epilepsy and mental retardation) (Bick et al., 1989; Ballabio et 
al., 1991; Wulfsberg et al., 1992; Bouloux et al., 1993; Paige et al., 1994; Maya-
Nunez et al., 1999; Stoll and Eyer, 1999; Langlois et al., 2009). Concomitant 
deletions of the neighbouring KAL1 locus result in Kallmann syndrome characterized 
by hypogonadotropic hypogonadism and anosmia. 
An association between STSD and testicular cancer independent of testicular 
descend has been hypothesised and reported in two patients with XLI (Lykkesfeldt et 
al., 1983); however, these reports are the only ones published so far. 
Recent studies have shown an association of XLI with behavioural disorders, 
including autism, attention-deficit-hyperactivity disorder (ADHD) and social 
communication deficits; however, in the affected subjects large gene deletions have 
been found that included the NLGN4 gene encoding neuroligin 4, a synaptic peptide 
that has been previously implicated in x-linked autism and mental retardation (Kent et 
al., 2008). However, the same group performed genotyping of the STS gene in 384 
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patients with ADHD and identified two single nucleotide polymorphisms of the STS 
gene that are significantly associated with ADHD (Brookes et al., 2008). The authors 
hypothesised that disturbed neuronal DHEA-DHEAS metabolism might result in 
altered neurotransmitter function contributing to the observed behavioural 
abnormalities. Of note, the key phenotype in sts deficient mice is a behavioural 
disorder that resembles human ADHD (Davies et al., 2009; Trent et al., 2012). 
The very first clinical presentation of XLI may occur at birth, and women 
carrying a child affected by XLI frequently experience prolonged labour due to 
insufficient dilatation of the cervix (cervical dystocia) (Harkness, 1982; Lykkesfeldt 
and Bock, 1985; Bradshaw and Carr, 1986). This can be a severe and unexpected 
birth complication and perinatal death has been reported in STSD (Rizk and 
Johansen, 1993). Prenatal diagnosis of STSD is possible as maternal oestrogen 
excretion is decreased; GC/MS analysis of maternal urine also distinguishes foetal 
STSD from other conditions (like aromatase deficiency) as sex steroid precursor 
metabolites are found at normal levels (Glass et al., 1998; Shackleton, 2011).  
8.2.  MATERIALS AND METHODS 
8.2.1. Patients 
Patients were recruited from an existing cohort of STSD patients based in the 
Department of Paediatric Dermatology at the Birmingham Children’s Hospital. In 
addition, the study was advertised through the website and newsletters of the 
Ichthyosis Support Group, UK. Healthy volunteers were invited to join the study 
following advertisement in the Birmingham Children’s Hospital in- and outpatient 
departments, children of staff or children of families who heard of the study via study 
participants or staff. Inclusion criteria:  boys and young men with confirmed diagnosis 
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of X-linked ichthyosis/ STS deficiency (cases only; either clinically or following 
biochemical or genetic testing), age-range for all participants was 6-30 years. 
Exclusion criteria: chronic severe disease potentially affecting DHEA secretion (i.e. 
rheumatoid arthritis, ulcerative colitis, cancer, etc); chronic glucocorticoid or sex 
steroid treatment over the past 12 months; impairment of liver or kidney function due 
to concomitant disease or medication.  
8.2.2. Study Protocol 
Prior to the study visit, a urine collection bottle (empty, no additives) was posted 
by mail together with detailed instructions for the a 24h-urine collection. Participants 
arrived at the Wellcome Trust Research Facility (Birmingham Children’s Hospital and 
Queen Elisabeth Hospital for young men ≥ 17 yrs) between 8:00 and 12:00. At 
baseline, participants were assessed by taking a clinical history and physical 
examination, including a detailed assessment of pubertal development (Tanner 
stages and testicular volume) and a dermatological assessment. Height, weight, BMI 
was measured by the study nurse. Testicular volumes were measured with a Prader 
orchidometer. Blood samples were obtained at baseline for all participants, including 
serum for steroid hormone measurements as well as EDTA blood for DNA extraction 
and genetic analysis of the STS gene. The study protocol was approved by the 
Coventry and Warwickshire Research Ethics Committee. All patients or parents/ 
guardians (in patients younger than 16 years who are not deemed Gillick competent) 
gave written informed consent prior to enrolment. 
8.2.3. Genetic analysis 
DNA was extracted from peripheral blood leukocytes as described in section 
2.2.11. 90% of the genetic abnormalities in patients with X-linked ichthyosis are 
deletions of the STS gene. To detect complete or partial STS deletions, multiplex-
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ligation-dependent probe amplification (MLPA) was employed. This assay was 
designed by MRC Holland (Amsterdam, The Netherlands) and comprised 10 probes 
each specifically targeting the coding exons of the STS gene. In addition, the assay 
also targets the coding exons of the neighbouring KAL1 locus as well as the HDHD1 
locus. The assay was performed by MRC Holland on a research basis as part of a 
collaboration (Dr Raymon Vijzelaar). In patients without any abnormalities in the 
MLPA analysis, PCR amplification of the entire coding region of the STS gene (9 
fragments) including intron/exon boundaries from genomic DNA was performed 
(conditions: see section 2.2.11; primer: see Table 21). Direct sequencing was carried 
out using an ABI3730 sequencer (Applied Biosystems Inc., Foster City, CA, USA) 
and sequencing analysis was carried out using the CLC Main Workbench software 
(CLC bio, Cambridge, MA, USA).  
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Table 21: Primer for PCR amplification and sequencing of the STS gene. 
Name 
 
Sequence  
(5'-3') 
GC 
(%) 
Tm  
(°C) 
Length 
(bp) 
Fragment 
length (bp) 
STS EXON1 FWD TCCGCCTCACATTATCTG 50 55 18 347 
STS EXON1 REV TGCAACACAAGCAGGTAG 50 56 18 
 STS EXON 2 FWD TGGGCAACATAACAAGAC 44 53.3 18 422 
STS EXON 2 REV CTATGAATACAGCCATGTG 42 54 19 
 STS EXON 3/4 FWD TGGGTGACAGAGTGAGAT 50 55.7 18 482 
STS EXON 3/4 REV CCCATTCCCATACCTATAGA 45 55.6 20 
 STS EXON 5 FWD GTAATACCTTAGCGTTTGTG 40 53.3 20 665 
STS EXON 5 REV TCCACGAGAAATAACCCAG 47 55 19 
 STS EXON 6 FWD GACACAACAGAGACTTACC 47 54.6 19 375 
STS EXON 6 REV ACAAGGAGGCAAAGACTTA 42 55 19 
 STS EXON 7 FWD TCCACCTTGAGAAATTAGCC 45 56.3 20 334 
STS EXON 7 REV AAGTAGCAGAAGAACTATGG 40 54.3 20 
 STS EXON 8 FWD ACATTGAGCACGAAAGAG 44 55.8 18 393 
STS EXON 8 REV AATTGACCTGCCTCAAAC 44 55 18 
 STS EXON 9 FWD AGAAGGACATTTGAGAACAC 40 55 20 365 
STS EXON 9 REV TGTGACCAGAACGAAAAGAG 45 56 20 
 STS EXON 10 FWD CACATGGCAGCATAATTTC 42 54.1 19 585 
STS EXON 10 REV AATCAGTCCAAATCCAAGGT 40 57 20 
  
8.2.4. Serum steroid hormone measurements 
Steroids were extracted from 200 µl of serum via liquid–liquid extraction using 2 
ml tert-butyl-methyl-ether for DHEA and downstream androgens. Sulfated 
compounds (DHEAS and cholesterol sulfate) were extracted by a protein-crash 
method employing 20µl ZnSO4 (0.1 mM) and 100 µl acetonitrile. See section 2.7.3 for 
further details. 
8.2.5. Urinary steroid metabolites 
Analysis of steroid hormone metabolites excretion was performed by a 
quantitative gas chromatography/mass spectrometry (GC/MS) selected ion-
monitoring method, as described in section 2.6. For steroid abbreviations, please 
refer to Table 9.  
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Beside the global excretion (expressed in µg/24 hours), a distinct set of ratios 
was applied to further explore androgen metabolism. Global 5α-reductase activity 
was assessed by calculating substrate/product ratios employing 5α-reduced 
metabolites as numerators (5α-THF, 5α-THB, An), and their 5β-reduced counterpart 
as denominator (THF, THB, Et, respectively). The relation between active androgen 
metabolites and androgen precursor metabolites was expressed as a ratio of (An + 
Et)/ (DHEA+16OH-DHEA+5PT+5PD). 
8.2.6. Statistical Analysis 
For comparison, a non-parametric test (Mann-Whitney-Wilcoxon) was used to 
compare the two independent parameters from each cohort (control vs. affected). A 
p-value of 0.05 was assumed to be statistical significant. Data were expressed as 
median (± interquartile [boxes] and ± 10th/90th centile [whiskers] ranges). The 
software GraphPad Prism® was used for statistical analysis. 
8.3. RESULTS 
8.3.1. Patients characteristics 
30 patients with STSD and 38 healthy volunteers (controls) were enrolled in this 
study. There were no significant differences between weight, height, BMI and age 
(Table 22). 13 STSD patients and 15 controls and were clinically pre-pubertal 
according to testicular volumes. One patient (age 6.7 years) had an undescended 
testicle on the left side. No patient had delayed puberty (i.e. pubertal onset after the 
age of 14 years) with physical development (Tanner stages) and testicular volumes 
being appropriate for chronological age.  
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Table 22: Subject characteristics. Values are mean ± SD. Values are compared by using the t-test 
and did not reach statistical significance for all categories. 
 STSD (n=30) Controls (n=38) 
Height (cm) 155.85 ± 21.42 158.27 ± 22.13 
Height SDS 0.374 ± 1.11 0.04 ± 1.16 
Weight (kg) 48.96 ± 20.22 56.0 ± 20.67 
Weight SDS 0.309 ± 1.30 0.58 ± 1.0 
BMI (kg/m2) 19.31 ± 4.10 21.38 ± 3.48 
BMI SDS 0.093 ± 1.42 0.66 ± 1.02 
Age (years) 13.94 ± 5.85 16.5 ± 7.38 
 
All patients had clinically typical dermatological findings of X-linked ichthyosis 
with different degrees of severity. In the majority of the STSD patients, the diagnosis 
has been established based on clinical findings (n=20); in 7 patients, a lymphocyte 
assay for STS activity has been performed, which showed decreased activity; 3 
patients underwent genetic testing to confirm the diagnosis. 
There were four pairs of siblings and another three brothers amongst the STSD 
patients. There was no consanguinity reported in any of the patient’s families and 
there were no infertility problems reported in any of the patient’s family histories. 
11 patients had additional conditions, mostly atopic disease like mild asthma 
(n=6) and/or hayfever (n=4), eczema (n=1) or multiple allergies (n=1); one patient 
has been diagnosed with attention deficit hyperactivity disorder (ADHD). No patient 
was on regular steroid medication, including inhalers.  
13 patients were pre-pubertal, according to testicular volumes (≤ 3ml) and 
physical changes (Tanner stages; see Table 23). Another 5 patients were peri-
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pubertal with testicular volumes between 4 and 10 ml and low Tanner stages; the 
remaining 12 STSD patients were post-pubertal with testicular volumes > 10ml and 
physically fully developed secondary characteristics as assessed by Tanner stages 
(Table 23). According to the clinical assessment, baseline gonadotrophins (Table 23) 
and also medical history from the post-pubertal subjects, no STSD participant had 
delayed puberty according to standard guidelines (no signs of pubertal development 
until the age of 14 years). One six-year old boy from the STSD cohort had an 
undescended left-sided testicle, which prompted a referral to the paediatric endocrine 
service for further investigation. 
For further analysis and comparison of two cohorts (STSD and controls), 
subjects were assembled into two subgroups according to their pubertal 
development: 1) the pre-/peri-pubertal subgroup (STSD n=18; controls n= 19) and 2) 
the post-pubertal subgroup (STSD n=12; control n=19).  
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Table 23: Characteristics of the STSD cohort emphasising pubertal assessment (Tanner stages, 
testicular volumes and baseline gonadotrophins). Tanner stages: P = pubic hair, G = genitals, A = 
axillary hair. LH=luteinizing hormone, FSH=follicle stimulating hormone; n.m. = not measured 
 
Study 
Number 
Age 
(yrs) 
BMI 
(kg/m2) 
Tanner  
pubertal stages 
 Testicular 
volume 
 
Gonadotrophins 
P G A 
 Left  
(ml) 
Right 
(ml) 
 LH 
(U/L) 
FSH 
(U/L) 
Pr
e-
pu
be
rt
al
 
P12 6.15 13.74 1 1 1  2 2  <0.5 0.7 
P15 6.73 23.01 1 1 1  n.d. 2  <0.5 <0.5 
P11 6.86 16.17 1 1 1  2 2  <0.5 0.9 
P10 7.54 14.96 1 1 1  3 3  <0.5 <0.5 
P14 7.60 18.13 1 1 1  3 3  <0.5 0.6 
P06 9.09 15.19 1 1 1  2 2  n.m. n.m. 
P22 9.18 14.59 1 2 1  3 3  <0.5 <0.5 
P16 9.22 24.08 1 1 1  3 3  <0.5 1 
P09 9.97 16.46 1 1 1  3 3  <0.5 0.7 
P23 10.83 16.11 1 1 1  3 3  <0.5 1.8 
P02 11.01 14.60 1 1 1  3 3  0.9 1.3 
P07 11.14 17.33 1 1 1  2 2  <0.5 1.4 
P17 11.22 23.16 1 1 1  3 3  0.8 2.3 
Pe
ri-
pu
be
rt
al
 P08 11.67 17.47 1 2 1  4 3  1 4.9 
P01 12.75 18.58 2 2 1  4 4  n.m. n.m. 
P05 13.28 16.62 1 2 1  3 4  1.8 2 
P19 13.43 14.79 1 2 1  5 4  1.1 1.6 
P21 13.43 16.89 1 2 1  5 5  1.3 1.7 
Po
st
-p
ub
er
ta
l 
P03 14.29 19.32 5 5 2  10 15  5.1 3.4 
P20 15.81 17.75 5 5 2  20 20  4.4 2.1 
P13 15.83 23.52 5 4 2  20 20  2.2 1.8 
P04 15.93 20.71 5 5 2  25 25  3.9 3 
P18 16.27 24.28 5 5 2  15 15  2.4 6.2 
P096 18.03 15.55 5 5 2  20 20  6.6 3.8 
P099 19.57 24.99 6 5 2  25 20  6.5 1.4 
P100 20.80 19.31 5 5 2  20 20  4.2 3.6 
P098 22.86 23.87 6 5 2  20 20  6.2 2.6 
P095 24.75 25.74 6 5 2  25 25  5.9 1.7 
P094 26.45 24.93 5 5 2  20 20  6.3 8.5 
P097 26.56 27.47 6 5 2  20 20  9 1.7 
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8.3.2. Genetic analysis 
Genetic abnormalities of the STS gene have been confirmed in all patients. As 
90% of the alterations of the STS gene are deletions (Ballabio et al., 1989), multiplex 
ligand-probe amplification (MLPA) was performed in the first place in all patient’s 
DNA samples. Examples of graphical representations of the MLPA analysis are 
shown in Figure 49. 27 patients of this cohort had complete deletions of the STS and 
of the HDHD1A genes, but no deletions of further exons at the Xp22.31/32 locus; in 
particular, there were no deletions of the KAL1 gene in all patients of this study 
(Figure 49 panel B). One patient (patient 5) had a deletion of exon 7 only (Figure 49 
panel C; Table 22). In two brothers there were no alterations in the MLPA analysis 
and Sanger sequencing of the STS gene was performed and both patients had the 
same hemizygous non-synonymous missense mutation in exon 9 (Table 22): a 
cytosine to thymidine change at position g.114,414 results in the replacement of 
arginine to cysteine on the protein level (p.R454C); this mutation has been previously 
reported in a patient with XLI (González-Huerta et al., 2003). 
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Figure 49: Representation of the results of the genetic analysis. Panel A and B: exemplary graphical 
representations of multiplex ligation-dependent probe amplification (MLPA). Panel A shows a 
complete deletion of the STS and the HDHD1A genes; panel B shows the one patient with a deletion 
of exon 7. Blue boxes represent the variation of the reference samples. Dots indicate the ratio of the 
analysed sample with whiskers representing the variation of the probe ratio of the sample compared to 
the reference runs. The red horizontal line indicates the threshold for deletions (below 0.75), whereas 
the green horizontal line marks the threshold for duplications (above 1.3). The red box indicates the 
position of deleted exons of the STS gene. Probe lengths in the grey-shaded area at the right side of 
the panels indicate reference probes that are used to create a normalization constant for data-
normalization. Numbers on the x-axis indicate the lengths of the amplification probes. Panel C: 
Sanger sequencing analysis of exon 9 in two patients reveal a non-synonymous substitution at 
position g.114,414 (cytosine to thymidine) resulting in p.R454C. The NCBI reference sequence is 
shown at the top with the yellow bar indicating the coding sequence of exon 9; the blue bar indicates 
the beginning of the downstream intron. 
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8.3.3. Serum steroid analysis 
The serum androgen precursor DHEA, its sulfate ester DHEAS and the active 
androgen testosterone were measured in all study subjects at baseline from a 
morning blood sample. In addition, cholesterol-sulfate levels were assessed as a 
biochemical marker for STSD and found to be highly elevated in the entire STSD 
cohort (Table 24). 
DHEA levels were lower in the entire STSD cohort with high statistical 
significance for both pre-pubertal and peri-/post-pubertal subgroups (Table 24, 
Figure 52B). DHEAS levels were significantly higher in the pre-/peri-pubertal 
subgroup; however in the post-pubertal STSD subgroup DHEAS levels did not differ 
(Table 24, Figure 52A). 
Table 24: Serum steroid hormone measurements including Cholesterol-sulfate in STSD patients 
compared to controls. Values are expressed as median (25th, 75th centile). For statistical analysis a 
Mann-Whitney-U test was applied for non-parametric data. 
 subgroup STSD Controls P-value 
DHEA 
nmol/L 
All 6.60 (3.1, 9.1) 19.97 (13.1, 31.7) < 0.0001 
Pre-pubertal 5.04 (4.2, 2.4) 20.14 (14.2, 32.8) < 0.0001 
Post-pubertal 10.73 (9.0, 6.8) 18.43 (11.1, 29.9) 0.0033 
DHEAS 
µmol/L 
All 5.14 (4.1, 7.5) 3.50 (1.37, 9.61) 0.3783 
Pre-pubertal 4.57 (2.0, 5.9) 1.37 (0.71, 3.02) 0.002 
Post-pubertal 7.13 (6.2, 9.6) 10.08 (6.58, 13.03) 0.3498 
DHEA/DHEAS All 0.87 (0.10, 1.43) 4.86 (2.29, 16.89) < 0.0001 
Pre-pubertal 0.43 (0.14, 0.95) 15.81 (8.50, 36.89) < 0.0001 
Post-pubertal 1.23 (0.03, 1.5) 2.56 (1.27, 4.48) 0.0196 
Testosterone 
nmol/L 
 
All 4.0 (0.35, 11.0) 10.07 (0.35, 17.62) 0.1455 
Pre-pubertal 0.35 (0.35, 0.69) 0.35 (0.35, 1.21) 0.9745 
Post-pubertal 11.81 (10.41, 15.62) 22.56 (15.28, 25.0) 0.0251 
Cholesterol-
sulfate 
µmol/L 
All 51.20 (29.49, 68.22) 0.80 (0.75, 1.16) < 0.0001 
Pre-pubertal 50.72 (39.04, 72.52) 0.77 (0.73, 1.0) < 0.0001 
Post-pubertal 51.20 (25.92, 56.68) 1.12 (0.82, 1.27) < 0.0001 
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To express the individual in vivo capacity for DHEA sulfation, a ratio of DHEA 
over DHEAS has been calculated, which reflects SULT2A1 activity. A higher 
DHEA/DHEAS ratio suggests increased STS activity with a shift towards DHEA and 
active androgens. This ratio was significantly lower in all STSD subjects compared to 
controls; subgroup analysis shows a higher significance level for the pre-/peri-
pubertal subgroup (p < 0.0001 vs. p 0.0196). With the DHEA/DHEAS ratio being less 
than 1 in all STSD subjects throughout all age groups, I have found a marked 
increase of the DHEA/DHEAS ratio in the younger control subgroup (Table 24 and 
Figure 51). This ratio decreases from a mean pre-pubertal value of 15.8 to 2.5 in 
normal/healthy post-pubertal boys (Table 24) and is a consequence of equally high 
DHEA and lower DHEAS levels before puberty (during adrenarche) (Figure 51). This 
suggests increased physiological STS activity prior to puberty. 
Testosterone levels were lower in STSD in the post-pubertal subgroup (Table 
24, Figure 52). As expected, testosterone levels were generally low and almost at 
the limit of detection in the pre-/peri-pubertal subgroups of STSDs and controls 
(Figure 52). 
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Figure 50: Serum DHEA (panel A) and DHEAS (panel B) levels in STSD patients compared to 
controls. The graph in the right upper corner of each panel shows each single value plotted against 
age (open circle: control, closed circle: STSD). The box plots indicate the median and the interquartile 
ranges, whiskers the 10th and 90th centile, respectively. Values (y-axis) are expressed in µmol/L for 
DHEAS and nmol/L for DHEA. For statistical analysis a Mann-Whitney-U test was applied for non-
parametric data. ** p<0.001; *** p< 0.0001. 
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Figure 51: Graphic representations of the serum DHEA over DHEAS ratios in patients with STSD and 
controls. The box plots indicate the median and the interquartile ranges, whiskers the 10th and 90th 
centile, respectively. Values (y-axis) are expressed in µmol/L for DHEAS and nmol/L for DHEA. For 
statistical analysis a Mann-Whitney-U test was applied for non-parametric data. *** p< 0.001. 
 
Figure 52: Serum testosterone levels in STSD patients compared to controls. The graph in the right 
upper corner shows each single value plotted against age (open circle: control, closed circle: STSD). 
The box plots indicate the median and the interquartile ranges, whiskers the 10th and 90th centile, 
respectively. Values (y-axis) are expressed in µmol/L for DHEAS and nmol/L for DHEA. For statistical 
analysis a Mann-Whitney-U test was applied for non-parametric data. * p<0.05. 
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8.3.4. Urinary androgen metabolite analysis 
According to their origin, urinary androgen metabolites were grouped into 
metabolites derived from active androgens (An and Et) and metabolites from 
androgen precursors (DHEA, 16-OH DHEA, 5-PT and 5-PD); their excretion rates 
over 24 hours were compared between STSD subjects and controls (Table 25). 
There was tendency of lower amounts of secreted active androgen metabolites 
(An and Et) in post-pubertal STSD subjects, however this did not reach statistical 
significance (Table 25). In contrast, androgen precursor metabolites were 
significantly higher in STSD subjects compared to controls (Table 25). The DHEA 
detected during the GC/MS analysis reflects excretion of both sulfated and 
unsulfated DHEA, with DHEAS contributing to the majority (< 95%) of the DHEA (our 
unpublished findings). Urinary DHEA (=DHEAS) is higher in all STSD subjects and 
reaches high statistical significance in both STSD subgroups (Table 25). Also, the 
16α-hydroxylated DHEA compound is elevated in all STSD subjects.  
Androgen precursor metabolites upstream of DHEA, like 5-pregnetriol (5-PT) 
and pregnenediol (5-PD), derived from pregnenolone and 17-pregnenolone, 
respectively, are also elevated in all STSD subjects, indicating increased androgen 
generation. The total excretion rates for 5-PD and 5-PT reach statistical significance 
in both STSD subgroups apart from 5-PT excretion in the post-pubertal subgroup 
(Table 25). 
 
 
 
Table 25 (next page): 24-hours excretion rates of urinary androgen metabolites in STSD subjects and 
controls. Androsterone (An) and Etiocholanolone (Et) are derived from active androgen metabolites; 
DHEA, 5-pregnenetriol (5-PT), pregnenediol (5-PD) and 16-hydroxy DHEA (16OH DHEA) are derived 
from androgen precursor metabolites. Excretion rates are expressed as µg/24 hours as means 
(interquartile ranges). For statistical analysis a Mann-Whitney-U test was applied for non-parametric 
data. 
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 Metabolite subgroup STSD Controls P-value 
A
ct
iv
e 
A
nd
ro
ge
ns
 (µ
g/
24
h)
 
An All 409 (155, 2192) 403 (117, 2301) 0.8203 
Pre-pubertal 143 (60, 309) 124 (56.3, 206.4) 0.476 
Post-pubertal 2440 (1521, 3670) 2468 (2035, 3365) 0.8663 
Et All 231 (96, 1018) 329 (98, 1569) 0.3093 
Pre-pubertal 109 (70, 130) 110 (40, 229) 0.7604 
Post-pubertal 1021 (917, 1332) 1663 (1045, 2048) 0.1605 
An + Et All 604 (231, 3526) 2295 (235, 4067) 0.5887 
Pre-pubertal 237 (177, 415) 311 (96, 414) 0.8588 
Post-pubertal 4055 (2722, 4779) 4563 (3184, 5461) 0.5874 
A
nd
ro
ge
n 
pr
ec
ur
so
rs
 (µ
g/
24
h)
 
DHEA All 207 (117, 716) 43 (10, 165) 0.0009 
Pre-pubertal 105 (52, 236) 11 (3, 34) <0.0001 
Post-pubertal 626 (291, 1905) 165 (62, 784) 0.0453 
5-PT All 160 (82, 318) 51 (13, 163) 0.0048 
Pre-pubertal 77 (53, 169) 14 (4, 42) 0.0001 
Post-pubertal 338 (189, 792) 234 (78, 366) 0.0695 
5-PD All 401 (295, 657) 143 (92, 317) 0.0008 
Pre-pubertal 289 (180, 380) 79 (54, 131) 0.0008 
Post-pubertal 687 (529, 1062) 317 (215, 364) 0.0014 
16OH-DHEA All 520 (211, 767) 115 (39, 366) 0.0003 
Pre-pubertal 217 (137, 535) 39 (13, 76) 0.0003 
Post-pubertal 744 (656, 985) 398 (170, 580) 0.0008 
DHEA+16OH-
DHEA+5-
PT+5-PD 
All 1355 (889, 2419) 453 (215, 1410) 0.0225 
Pre-pubertal 787 (389, 1297) 212 (156, 315) 0.0007 
Post-pubertal 2499 (1675, 5311) 1410 (834, 2898) 0.0923 
R
at
io
 
(An+Et)/ 
(DHEA+ 
16OH-DHEA+ 
5-PT+5-PD) 
All 0.490 (0.289, 1.042) 1.985 (0.984, 3.325) <0.0001 
Pre-pubertal 0.327 (0.203, 0.428) 1.119 (0.82, 1.925) 0.0005 
Post-pubertal 1.017 (0.685, 1.991) 3.325 (1.809, 4.174) 0.0233 
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In order to express a relation of urinary androgen precursor metabolites to 
active androgen metabolites, a ratio of (An + Et)/(DHEA + 16OHDHEA + 5-PT + 5-
PD) was calculated to assess the relationship between androgen activation towards 
androgen generation. This ratio was decreased in all STSD subgroups and reached 
statistical significance (Table 25, Figure 53). 
 
Figure 53: Androgen metabolism in patients with STSD compared to healthy controls as reflected by 
a ratio of active androgen metabolites (An and Et) over androgen precursor metabolites (DHEA, 
16OH-DHEA, 5-PT and 5-PD). The box plots indicate the median and the interquartile ranges, 
whiskers the 10th and 90th centile, respectively. Values (y-axis) are expressed in µmol/L for DHEAS 
and nmol/L for DHEA. For statistical analysis a Mann-Whitney-U test was applied for non-parametric 
data. * p<0.05; *** p< 0.0001. 
Global 5α-reductase activity was assessed by three different diagnostic ratios 
composed of 5α-reduced compounds (5αTHF, 5αTHB, An) over their respective 5β-
reduced counterpart (THF, THB and Et). An increased ratio indicates increased 
global 5α-reductase activity. These ratios were elevated in all STSD subjects, 
however statistical significance was only achieved for the 5αTHF/THF ratio (all 
subgroups) and in the post-pubertal subgroup for 5αTHB/THB (Table 26, Figure 54).  
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Table 26: Global 5α-reductase activities as assessed by three different diagnostic ratios composed of 
5α-reduced urinary metabolites over their respective 5β-reduced counterpart. Values are expressed 
as mean (interquartile range). For statistical analysis a Mann-Whitney-U test was applied for non-
parametric data. 
 Ratio subgroup STSD Controls P-value 
 
5αTHF/THF All 2.5 (1.8, 3.2) 1.39 (0.95, 1.7) < 0.0001 
Pre-pubertal 2.37 (1.55, 3.11) 1.23 (0.9, 1.32) < 0.0001 
Post-pubertal 2.69 (1.94, 3.39) 1.57 (1.07, 2.26) 0.0029 
5αTHB/THB All 5.55 (4.63, 7.35) 4.44 (2.59, 5.2) 0.0067 
Pre-pubertal 5.07 (3.18, 6.5) 4.46 (2.54, 4.99) 0.1305 
Post-pubertal 6.26 (5.52, 7.58) 4.3 (3.07, 5.2) 0.0115 
An/Et All 2.05 (1.39, 2.96) 1.57 (0.96, 2.1) 0.0906 
Pre-pubertal 1.73 (0.88, 2.35) 1.27 (0.92, 1.27) 0.118 
Post-pubertal 2.53 (1.32, 3.15) 1.92 (1.46, 2.4) 0.2537 
 
 
Figure 54: Global 5α-reductase activity as assessed by the ratio of 5α-reduced THF over THF in 
patients with STSD compared to controls. Box plots indicate the median with interquartile ranges, 
whiskers represent the 90th and 10th centiles, respectively. For statistical analysis a Mann-Whitney-U 
test was applied for non-parametric data. * p< 0.05; *** p< 0.0001. 
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8.4. DISCUSSION 
Here, we have explored androgen metabolism and pubertal development in a 
large, genetically fully characterized paediatric cohort of patients with STSD/XLI. I 
found no gross abnormalities regarding the pubertal/physical development in children 
with STSD, but their steroid metabolome is indicative of mild androgen deficiency; in 
addition, mechanisms of compensation are an increase of androgen activation 
(global 5α-reductase activity) and possibly also an increase of (adrenal) androgen 
generation. In addition, we found evidence for an increase of STS activity in healthy 
boys prior to puberty. 
We have genetically characterized the entire cohort and found genetic 
abnormalities of the STS gene in all patients. Complete deletions were detected in 
27/30 of STSD patients. Complete deletions of the STS gene are the commonest 
genetic abnormality in XLI and reported in 80-90% of patients (Ballabio et al., 1987b; 
Bonifas et al., 1987). Importantly, deletions of the neighbouring KAL1 gene resulting 
in Kallman syndrome were not present in this cohort, which – if present - would be an 
exclusion criteria due to its presentation with central hypogonadism. In a similar way, 
there were not any other forms of contiguous gene syndromes detected, which are 
frequently described in patients with XLI (Maya-Nunez et al., 1999; Langlois et al., 
2009); see 8.1.2). The HDHD1 gene upstream of the STS locus, however, was 
deleted in all patients of this cohort with complete deletions of the STS gene. In fact, 
the absence of HDHD1 has been reported in the majority of patients with STS 
deletions (Hernandez-Martin et al., 1999; Preumont et al., 2010). HDHD1 encodes 
for a pseudouridine-5’-phosphatase involved in RNA metabolism and its molecular 
function has only been described in detail recently (Preumont et al., 2010). It 
dephosphorylates pseudouridine 5’-phosphate, a modified RNA nucleotide present in 
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tRNAs, rRNAs and small nuclear RNAs; pseudouridine is excreted in urine and 
serves as a biomarker for certain cancers (Seidel et al., 2006). The importance of 
HDHD1 in normal physiology is not well understood; an Hdhd1 knock-out mouse has 
not been reported yet. One can speculate that HDHD1 contributes to some extra-
cutaneous manifestations observed in patients with XLI, however detailed genotype-
phenotype studies are lacking and partially due to insufficient genetic 
characterization of XLI patients of earlier cohorts. Preumont and co-workers 
speculate that the absence of pseudouridine 5’-phosphatase activity may contribute 
to the development of testicular cancer and cryptorchidism as this has not been 
observed in patients with missense mutations or partial deletions of the STS gene 
(Preumont et al., 2010). The one patient with an undescended testis from this cohort 
also had a HDHD1 deletion. Most certainly this hypothesis needs to be challenged by 
re-investigating larger XLI cohorts and providing evidence for functional involvement 
of HDHD1 in the testicular descent.  
One patient in this cohort has a partial deletion of exon 7 of the STS gene. 
Although partial STS deletions have been reported in XLI (Nomura et al., 1995; 
Valdes-Flores et al., 2001), the deletion of exon 7 appears to be a novel finding. In 
addition, two brothers of this study carried the known p.R454C missense mutation, 
previously described in a patient with XLI; in vitro functional analysis employing 
radiolabelled 3H-DHEA assays with patient’s leukocytes showed reduced STS 
activity (González-Huerta et al., 2003).  
Pubertal and physical development was not abnormal in this cohort of STSD 
patients: Tanner stages, testicular volumes and height SDS are not different to the 
control group or what is considered to be normal according to standard guidelines 
assessing childhood growth and puberty. The onset of pubertal changes observed in 
this cohort is between 11 and 11.5 years, which is considered to be the normal onset 
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of puberty in males (Raine et al., 2011; Marshall and Tanner, 1970). However, we 
have only assessed five boys who were clinically at the beginning of puberty 
according to their testicular volume and Tanner stages. Of those, three did not 
develop any pubic hair at the age of 13, which is slightly at the late side. Hence, to 
make accurate estimations on the beginning of pubertal development in STSD boys, 
this study is certainly underpowered. 
One patient had an undescended testicle on the left side, which was not 
palpable within the inguinal canal including the groin. The testicle has been 
discovered intra-abdominal, just above the left inner inguinal ring and orchidopexy 
was successfully performed.  
Serum steroid hormone measurements in this cohort of STSD patients indicate 
mild androgen deficiency with increased DHEAS levels, which as been reported as 
well in studies investigating androgen metabolism in adult STSD patients (Delfino et 
al., 1998; Milone et al., 1991; Bergner and Shapiro, 1988; Lykkesfeldt et al., 1985a; 
Muskiet et al., 1983; Ruokonen et al., 1980); however there are contradicting findings 
and DHEAS was not consistently elevated in all studies (Table 27).  
Table 27: Overview of studies investigating androgen and androgen metabolite levels in serum of 
STSD patients. 
Study Subjects Findings Steroid 
quantification 
Delfino et al., 
1998 
33 STSD, 33 
controls, age 3-70 yrs 
DHEAS increases during puberty but not 
significant. Cholesterol-sulfate always 
elevated. 
GC/MS 
Milone et al., 
1991 
15 STSD, 15 
controls; age 22-33 
years 
DHEAS elevated when measured with 
GC/MS (not RIA) 
GC/MS and RIA 
Lykkesfeldt et 
al., 1985a 
20 STSD (age 20-60 
yrs), 100 controls 
(age 20-70 yrs) 
Tendency of higher DHEAS in STSD 
(n.s.), no decline with age; d4dione, E2 
were lower in STSD; higher LH in STSD 
RIA 
Muskiet et al., 
1983 
7 STSD, 20 controls 
(adult age range) 
DHEAS was normal apart from one 
STSD patient 
GC/MS 
Ruokonen et 
al., 1980 
5 STSD, 10 controls All steroid sulfates not significantly 
higher in STSD 
RIA 
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The most comprehensive study was done in an adult Danish cohort of 20 XLI 
patients and 40 age-matched male controls (Lykkesfeldt et al., 1985a). Although, 
there were no detailed information available on the physical development of the 
patients, the investigators found biochemical evidence of mild androgen deficiency 
with increased levels of DHEAS, illustrating for the first time an effect of STS on 
peripheral sex steroid activation. In addition, LH was higher in STSD, suggesting 
(compensatory) activation of the HPG axis. My study focused on a paediatric cohort 
of STSD patients with detailed clinical information and a full genetic characterization. 
My findings concur with those of (Lykkesfeldt et al., 1985a) and the consequences of 
STS deficiency on sex steroid metabolism are only marginal.  
Serum DHEA levels were not measured in neither of these previous studies, 
possibly due to previous technical challenges with non-specifity/ cross-reactivity of 
the antibodies employed for the radio-immuno assays (Lykkesfeldt et al., 1985a). 
However, with both DHEA and DHEAS measurements the contribution of STS to 
androgen re-activation from DHEAS can be more accurately estimated. In this 
context, my data suggest novel insights regarding the activity/role of the STS enzyme 
during childhood. As it appears that the contribution of STS on DHEA metabolism is 
low in adult patients (Hammer, 2005) and a dissociation of DHEA and DHEAS is 
rarely observed (Arlt et al., 2006), this study suggests that the activity of the STS 
enzyme based on the ratio of DHEA/DHEAS is higher before puberty (during 
adrenarche) and decreases when puberty starts (Figure 51). As this observation 
comes from the healthy controls, the STSD cohort serves here as a ‘control’ to 
substantiate that the dissociation of DHEA and DHEAS is due to increased STS 
activity and not due to an inhibition of SULT2A1. 
Little is known about the regulation of STS in normal physiology. Certain 
cytokines (Il-6, TNFa) and growth factors (FGFs, IGF1) have been reported to 
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increase STS activity in vitro, independently of promotor activation, rather via post-
translational modification (Reed and Purohit, 1997). A few rodent and in vitro studies 
employing breast-cancer cell lines examined the effect of steroid hormones 
modulating STS activity, in particular androgens and progesterone (Moutaouakkil et 
al., 1984; Lam and Polani, 1985; Schneider et al., 1971). In this context, the raise of 
gonadal sex steroids during puberty would likely to have an inhibitory effect on STS 
activity.  
We have found from urinary steroid metabolite analysis an increase of 5α-
reductase activity based on substrate-product ratios. Increased global 5α-reductase 
activity would result in increased conversion of testosterone to DHT, i.e. enhanced 
(peripheral) androgen activation, and could therefore mechanistically compensate for 
the mild androgen deficiency observed in XLI/STSD. However, I have not found a 
statistically significant difference between the 5α- and 5β-reduced urinary androgen 
metabolites androsterone and etiocholoanolone; differences were only apparent 
between urinary the 5α- and 5β-reduced GC (and to a lesser extend MC) 
metabolites.  
Increased 5α-reductase activity is frequently observed in androgen excess 
conditions like adult PCOS (Stewart et al., 1990; Vassiliadi et al., 2009; Rodin et al., 
1994), but not in children with premature adrenarche (Silfen et al., 2002). Stewart et 
al. proposed the hypothesis that increased 5α-reduction in PCOS comes first in a 
pathophysiological chain of events leading to enhanced hepatic cortisol clearance 
with compensatory HPA axis activation and adrenal androgen secretion (Stewart et 
al., 1990). The underlying cause for the increase of 5α-reductase activity, either a 
priori or as a secondary event, is still unknown. Obesity affects 5α-reductase activity 
and can be an explanation for its dyregulation in PCOS, which is strongly associated 
with metabolic risk. However, in a recent study it is not only confined to the 
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overweight PCOS subgroup (Vassiliadi et al., 2009). All subgroups from this study 
are non-obese and BMI-matched, making an obesity-related 5α-reductase 
dysregulation unlikely. Androgens themselves may play a role in 5α-reductase 
expression, and the expression of SRD5A2 mRNA in dermal paplillae of hirsute 
women are positively correlated with circulating androgen levels (Skałba et al., 2006). 
A regulatory effect of androgens on the SRD5A promotor can be hypothesized in this 
context, however functional studies are not available. 
 In summary, we have found based on steroid metabolome analysis minimal 
impact of STS on androgen metabolism during childhood, suggesting that the 
sulfotransferase reaction inactivating DHEA to DHEAS is the predominating reaction 
within the context of DHEA pre-receptor metabolism with potentially more severe 
clinical implications (Noordam et al., 2009). However, DHEA and DHEAS dissociate 
before puberty, suggesting that STS is more active during early 
childhood/adrenarche and shuts down during adolescence and increased gonadal 
androgen production. Lastly, we have observed increased global 5α-reductase 
activity, most likely a compensatory mechanism for mild androgen deficiency. The 
results from this study do not suggest that patients with STSD require a routine 
endocrine follow-up as they seem to progress through puberty without significant 
abnormalities.  
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9.  CHAPTER 9: FINAL CONCLUSIONS AND FUTURE 
DIRECTIONS 
9.1. FINAL CONCLUSIONS 
Disturbed androgen biosynthesis can result in a broad variety of phenotypes 
presenting with androgen deficiency or androgen excess. In this work we have 
investigated the impact of mutations of androgenic and androgen metabolizing 
enzymes, with particular emphasis on steroidogenic co-factors aiming towards a 
deeper understanding of the regulation of adrenal androgen biosynthesis. 
9.1.1. Androgen deficiency – CYP17A1 and its co-factors POR and CYB5A 
We have demonstrated that urinary steroid profiling underpinned by a detailed 
phenotypic work up of patients affected by androgen deficiency invariably leads to 
the correct underlying diagnosis. Hence, GC/MS analysis represents a powerful 
diagnostic tool for unraveling androgen deficiency conditions presenting as 46,XY 
DSD or absent/lack of pubertal development. Therefore we suggest that urinary 
steroid profiling should be a first-line investigation in patients with suspected 
disorders of androgen biosynthesis.  
P450 oxidoreductase deficiency (PORD) is a well-described condition since its 
molecular basis has been discovered about a decade ago (Flück et al., 2004; Arlt et 
al., 2004). Since then, a large number of studies have further illuminated this frequent 
cause of CAH with a large variety of mutations being described in patients presenting 
with DSD, (partial) adrenal insufficiency and skeletal malformations occurring from 
birth. Here, we have investigated selected cases of children with PORD presenting 
later in childhood and characterized their phenotypes with regards to their pubertal 
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development. We have found that testicular function might be preserved in boys and 
their progression during puberty is only marginally affected by the condition. In 
contrast, girls tend to develop large ovarian cysts, which are difficult to treat and 
severe complications may occur, providing important information for clinicians on the 
management of children with PORD. In addition we have shown that late-onset (or 
‘non-classical’) presentations can occur in PORD with none or mild phenotypes from 
birth. Importantly, these cases have a typical urinary steroid fingerprint demonstrating 
concomitant inhibition of 17a-hydroxylase/17,20 lyase and 21-hydroxylase activities, 
invariably leading to the correct diagnosis. 
In addition, the value of urinary GC/MS analysis is in particular exemplified in 
those patients presenting with ‘isolated 17,20 lyase deficiency’, a condition previously 
reported in children harboring mutations in CYP17A1, POR and CYB5A genes 
(Geller et al., 1997; 1999; Van Den Akker et al., 2002; Sherbet et al., 2003; 
Hershkovitz et al., 2008; Kok et al., 2010). We could show based on analysis of the 
steroid metabolome of published case reports and the cases analyzed in this thesis 
that the urinary metabolome of the three different genetic disorders are distinct and 
unique for each condition. Of note, true isolated 17,20 lyase deficiency, i.e. without 
impairment of CYP17A1 17α-hydroxylase activity, can only be found in patients with 
mutant CYB5A. The in vivo and in vitro investigations from the family harboring the 
first CYB5A missense mutation (p.H44L) therefore conclusively strengthens previous 
in vitro findings (Auchus et al., 1998) that CYB5A exclusively supports the 17,20 
lyase activity of CYP17A1, i.e. the principal androgen producing step in human 
steroidogenesis. 
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9.1.2. Androgen excess and DHEA/DHEAS inter-conversion 
Previous work from our group has identified genetic abnormalities in the 
PAPSS2 gene in a girl with androgen excess, a co-factor supporting DHEA 
sulfotransferase (SULT2A1) activity and thus revealing DHEA sulfation as a 
gatekeeper of downstream androgen activation (Noordam et al., 2009). In this work 
we have further explored DHEA/DHEAS inter-conversion both on the molecular level 
as well as in a clinical study investigating patients with steroid sulfatase (STS) 
deficiency. 
For the in vitro work we further explored the interplay of the two PAPSS 
isoforms PAPSS1 and PAPSS2 in the context of DHEA sulfation. Firstly, we could 
show by in vitro knock-down and overexpression experiments, that indeed PAPSS2, 
but not PAPSS1, supports SULT2A1 activity. This confirms previous findings from 
the prismatic case report (Noordam et al., 2009) underpinning that only the PAPSS2 
isoform supports DHEA sulfation. Secondly, based on in vitro expression studies, we 
have shown that PAPSS1, PAPSS2 and SULT2A1 are tightly co-regulated and the 
expression levels change upon siRNA mediated knock-down; in particular, SULT2A1 
expression increases when PAPSS2 mRNA is low, which suggests compensatory 
mechanisms. To further elucidate a mechanism for their differential role, we have 
attempted to investigate the effect of different subcellular localization of PAPSS 
proteins but found surprisingly that the PAPSS variants decrease SULT2A1 activity 
apart from the exclusively expressed PAPSS2 variant. Importantly, PAPSS isoforms 
are dynamically regulated proteins being expressed both in the nucleus and in the 
cytoplasm, confirming recently published data (Schröder et al., 2012).  
To further investigate DHEA/DHEAS inter-conversion we have examined boys 
and young men with STS deficiency and could confirm the finding from a previous 
study (Hammer, 2005) suggesting that DHEA sulfation, i.e. DHEA inactivation, is the 
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predominant direction under physiological conditions. However, in addition our data 
suggest that STS is active in younger boys prior to puberty, amplifying androgen 
generation in peripheral target tissues, until gonadal androgen production starts and 
possibly inhibits STS activity. This finding provides important novel insights into the 
physiological regulation of STS, which is more active prior to puberty. 
9.2. FUTURE DIRECTIONS 
Androgen excess in childhood is a common disorder being clearly recognized 
as a risk factor for metabolic as well as fertility disturbances in later life and of 
unknown (idiopathic) origin in most of the cases (see 1.3.2). To further explore the 
regulation of DHEA sulfation on the molecular level has the potential to discover 
novel players in this network in order to potentially develop drugs that can ameliorate 
androgen excess conditions. 
Previous studies have found low or undetectable DHEAS in 5-10% of children 
presenting with early-onset androgen excess (Ibáñez et al., 2000; Paterson et al., 
2010), suggestive of a potentially significant role of dysregulation of this pathway in 
the pathogenesis of premature adrenarche.  
Some clinical studies have investigated the impact of genetic variants of 
SULT2A1 and PAPSS2 on patients with androgen excess or circulating DHEAS 
levels (Louwers et al., 2013; Haring et al., 2013; Goodarzi et al., 2007; Utriainen et 
al., 2012). However, these studies are either focusing on only a few known or 
common SNPs or were conducted in small patient cohorts. Certainly, a broader 
approach employing dense genotyping in large cohorts of patients with premature 
adrenarche/PCOS is needed for future studies. However, given that only one patient 
with PAPSS2 mutations has been identified with an ‘isolated’ androgen excess 
phenotype (Noordam et al., 2009) and only a few patients are reported, who 
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presented with SEMD, i.e. a severe bone phenotype (Haque et al., 1998; Miyake et 
al., 2012; Tüysüz et al., 2013), suggests that PAPSS2 deficiency is a rare cause of 
(isolated) androgen excess. Certainly, increasing awareness is needed amongst 
(paediatric) endocrinologists to detect those patients with androgen excess who have 
low DHEAS levels. We would therefore suggest to include DHEA measurements into 
the diagnostic work-up of patients, as the DHEA/DHEAS ratio would be a robust 
screening tool to identify impaired DHEA sulfation. Currently, the measurement of 
DHEA is challenging (insensitive and expensive) with conventional RIAs, but 
hopefully this will be overcome in the future with the entry of LC/MSMS technologies 
in clinical routine (Krone et al., 2010). 
With co-factors POR, CYB5A and PAPSS2 being expressed in other tissues, 
including liver, disturbed electron flux or PAPS provision, respectively, in affected 
patients will also affect other metabolic pathways apart from androgen production; 
therefore co-factor deficiencies represent multi-system disorders including hepatic 
detoxification of endogenous substances (steroid hormones) and drug metabolism 
(see Figure 55). An in vivo study from our group in a patient with PORD revealed 
impaired activity of key drug metabolizing enzymes, including CYP3A4, which is 
responsible for detoxification of about 80% of drugs, including steroid hormones 
(Tomalik-Scharte et al., 2010). This finding illustrates the importance of widening the 
horizon above steroidogenesis when consulting patients with co-factor mutations and 
stresses the necessity for further research to clearly delineate the impact on other 
organ systems. To do this, global metabolome analysis employing mass-
spectrometry approaches is a promising tool to discover novel metabolic pathways 
(Suhre, 2014; Prosser et al., 2014). Importantly, these findings are likely to be directly 
translated into patient’s care. 
 
Chapter 9          Final Conclusions and Future Directions 
___________________________________________________________________ 
 
241 
  
Figure 55: Schematic diagram illustrating the known implications of co-factors CYB5A, PAPSS and 
POR beyond androgen biosynthesis on haemoglobin, hepatic and chondrocyte metabolism.  
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